{"data": [{"created_at": "2022-12-09T22:57:00.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 278, "end": 284, "tag": "ASH22"}], "annotations": [{"start": 137, "end": 143, "probability": 0.966, "type": "Place", "normalized_text": "England"}, {"start": 180, "end": 183, "probability": 0.9728, "type": "Place", "normalized_text": "NOLA"}], "mentions": [{"start": 54, "end": 66, "username": "SoniSmithMD", "id": "1134857587348967425"}, {"start": 70, "end": 85, "username": "ASH_hematology", "id": "84072624"}, {"start": 109, "end": 120, "username": "graham74GC", "id": "2239893372"}], "urls": [{"start": 285, "end": 308, "url": "https://t.co/1hETQzqRo1", "expanded_url": "https://twitter.com/i/web/status/1601350227625377792", "display_url": "twitter.com/i/web/status/1\u2026"}, {"start": 309, "end": 332, "url": "https://t.co/ZsCeiOhPlJ", "expanded_url": "https://twitter.com/DrAEvens/status/1601350227625377792/video/1", "display_url": "pic.twitter.com/ZsCeiOhPlJ", "media_key": "3_1601350167474700288"}]}, "source": "Twitter for iPhone", "text": "Great to connect w/ the great friend &amp; colleague, @SoniSmithMD at @ASH_hematology. \n\nAnd who would think @graham74GC would come from England to have tea &amp; crumpets here in NOLA (as well as a lovely hart serenade and a beautiful hotel lobby children\u2019s holiday chorus)!!\n\n#ASH22 https://t.co/1hETQzqRo1 https://t.co/ZsCeiOhPlJ", "id": "1601350227625377792", "lang": "en", "edit_history_tweet_ids": ["1601350227625377792"], "conversation_id": "1601350227625377792"}, {"created_at": "2022-12-09T22:48:36.000Z", "author_id": "719175246050410496", "source": "Twitter for iPhone", "text": "Me too! https://t.co/ETkzSeDvrC", "entities": {"urls": [{"start": 8, "end": 31, "url": "https://t.co/ETkzSeDvrC", "expanded_url": "https://twitter.com/johnpleonardmd/status/1601305890208063491", "display_url": "twitter.com/johnpleonardmd\u2026"}]}, "id": "1601348111409913856", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1601305890208063491"}], "edit_history_tweet_ids": ["1601348111409913856"], "conversation_id": "1601348111409913856"}, {"created_at": "2022-12-09T16:29:33.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 256, "end": 279, "tag": "LetsBeatCancerTogether"}, {"start": 280, "end": 286, "tag": "ASH22"}], "annotations": [{"start": 164, "end": 166, "probability": 0.4753, "type": "Other", "normalized_text": "BMT"}], "urls": [{"start": 287, "end": 310, "url": "https://t.co/8NvC5wmbEJ", "expanded_url": "https://twitter.com/rutgerscancer/status/1601245918753325056", "display_url": "twitter.com/rutgerscancer/\u2026"}]}, "source": "Twitter for iPhone", "text": "We are growing! \ud83d\ude80\n\nWe have several key open faculty positions (clinical hematologists &amp; PhD translational research) in plasma cell, lymphoid malignancies &amp; BMT/cell therapy.\n\n\ud83d\udcf2 Use QR codes below to schedule a meeting right into your calendar! \ud83d\uddd3\ufe0f\n\n#LetsBeatCancerTogether #ASH22 https://t.co/8NvC5wmbEJ", "id": "1601252723382702082", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1601245918753325056"}], "edit_history_tweet_ids": ["1601252723382702082"], "conversation_id": "1601252723382702082"}, {"created_at": "2022-12-09T04:56:45.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 44, "end": 50, "probability": 0.5111, "type": "Person", "normalized_text": "J.Mehta"}, {"start": 52, "end": 60, "probability": 0.5541, "type": "Person", "normalized_text": "S.Singhal"}, {"start": 68, "end": 78, "probability": 0.912, "type": "Person", "normalized_text": "Steve Rosen"}], "mentions": [{"start": 16, "end": 32, "username": "LeonidasPlatan1", "id": "1117857169528033280"}, {"start": 34, "end": 42, "username": "jdlicht", "id": "15266393"}, {"start": 96, "end": 108, "username": "LurieCancer", "id": "1006862749"}], "urls": [{"start": 126, "end": 149, "url": "https://t.co/BXK2qq8gu1", "expanded_url": "https://twitter.com/oreganruth/status/1601032778182668288", "display_url": "twitter.com/oreganruth/sta\u2026"}]}, "source": "Twitter for iPhone", "text": "And I\u2019ll add in @LeonidasPlatan1, @jdlicht, J.Mehta/S.Singhal &amp; Steve Rosen to complete the @LurieCancer heme dream team! https://t.co/BXK2qq8gu1", "id": "1601078373673242624", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1601032778182668288"}], "edit_history_tweet_ids": ["1601078373673242624"], "conversation_id": "1601078373673242624"}, {"created_at": "2022-12-09T01:23:08.000Z", "author_id": "719175246050410496", "in_reply_to_user_id": "2212735524", "source": "Twitter Web App", "text": "@chadinabhan @AaronGoodman33 @AleckAmalia Now that is not where I thought the conversation would head (ie, hair &amp; split ends, etc).  You win!", "entities": {"mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 28, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 29, "end": 41, "username": "AleckAmalia", "id": "1331336294828437504"}]}, "id": "1601024615366942720", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600983045577678848"}], "edit_history_tweet_ids": ["1601024615366942720"], "conversation_id": "1600982180507049984"}, {"created_at": "2022-12-08T23:46:39.000Z", "author_id": "719175246050410496", "in_reply_to_user_id": "854692626015993857", "source": "Twitter for iPhone", "text": "@AaronGoodman33 \ud83d\ude4f\ud83d\ude4f feeling is mutual, Papa!", "entities": {"mentions": [{"start": 0, "end": 15, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "id": "1601000336197459969", "lang": "tl", "referenced_tweets": [{"type": "replied_to", "id": "1600982610347720705"}], "edit_history_tweet_ids": ["1601000336197459969"], "conversation_id": "1600982610347720705"}, {"created_at": "2022-12-08T22:34:31.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 40, "end": 43, "probability": 0.6258, "type": "Other", "normalized_text": "Nola"}], "mentions": [{"start": 54, "end": 66, "username": "chadinabhan", "id": "2212735524"}, {"start": 101, "end": 116, "username": "AaronGoodman33", "id": "854692626015993857"}], "urls": [{"start": 139, "end": 162, "url": "https://t.co/6W6O4ZpSao", "expanded_url": "https://twitter.com/DrAEvens/status/1600982180507049984/photo/1", "display_url": "pic.twitter.com/6W6O4ZpSao", "media_key": "3_1600982173858910224"}, {"start": 163, "end": 186, "url": "https://t.co/3gIH8wMnNa", "expanded_url": "https://twitter.com/aarongoodman33/status/1600900892298907648", "display_url": "twitter.com/aarongoodman33\u2026"}]}, "source": "Twitter for iPhone", "text": "And look who I find in the taxi line in Nola. \n\nSorry @chadinabhan but you have some competition for @AaronGoodman33 Papa\u2019s affection!  \ud83e\udd17\ud83e\udd17 https://t.co/6W6O4ZpSao https://t.co/3gIH8wMnNa", "id": "1600982180507049984", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600900892298907648"}], "edit_history_tweet_ids": ["1600982180507049984"], "conversation_id": "1600982180507049984"}, {"created_at": "2022-12-08T22:28:40.000Z", "author_id": "719175246050410496", "source": "Twitter for iPhone", "text": "Gives new meaning to toe drag swag (badges down to the floor)!! https://t.co/yszApRwB82", "entities": {"urls": [{"start": 64, "end": 87, "url": "https://t.co/yszApRwB82", "expanded_url": "https://twitter.com/mikkaelsekeres/status/1600603559149637650", "display_url": "twitter.com/mikkaelsekeres\u2026"}]}, "id": "1600980710474412032", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600603559149637650"}], "edit_history_tweet_ids": ["1600980710474412032"], "conversation_id": "1600980710474412032"}, {"created_at": "2022-12-08T22:05:50.000Z", "author_id": "719175246050410496", "in_reply_to_user_id": "719175246050410496", "entities": {"annotations": [{"start": 0, "end": 16, "probability": 0.9866, "type": "Place", "normalized_text": "Mississippi River"}], "urls": [{"start": 54, "end": 77, "url": "https://t.co/pkPXK2QGTa", "expanded_url": "https://twitter.com/DrAEvens/status/1600974964475461632/photo/1", "display_url": "pic.twitter.com/pkPXK2QGTa", "media_key": "3_1600974918895783954"}]}, "source": "Twitter for iPhone", "text": "Mississippi River in background, bayou in foreground. https://t.co/pkPXK2QGTa", "id": "1600974964475461632", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600972915096563712"}], "edit_history_tweet_ids": ["1600974964475461632"], "conversation_id": "1600972915096563712"}, {"created_at": "2022-12-08T21:57:42.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 162, "end": 168, "tag": "ASH22"}], "annotations": [{"start": 35, "end": 38, "probability": 0.9741, "type": "Place", "normalized_text": "NOLA"}, {"start": 44, "end": 53, "probability": 0.9694, "type": "Place", "normalized_text": "New Jersey"}, {"start": 163, "end": 167, "probability": 0.4322, "type": "Other", "normalized_text": "ASH22"}], "mentions": [{"start": 55, "end": 66, "username": "EWRairport", "id": "234423098"}], "urls": [{"start": 169, "end": 192, "url": "https://t.co/RyjxBvaP12", "expanded_url": "https://twitter.com/DrAEvens/status/1600972915096563712/photo/1", "display_url": "pic.twitter.com/RyjxBvaP12", "media_key": "3_1600972764797616128"}, {"start": 169, "end": 192, "url": "https://t.co/RyjxBvaP12", "expanded_url": "https://twitter.com/DrAEvens/status/1600972915096563712/photo/1", "display_url": "pic.twitter.com/RyjxBvaP12", "media_key": "3_1600972764810301440"}, {"start": 169, "end": 192, "url": "https://t.co/RyjxBvaP12", "expanded_url": "https://twitter.com/DrAEvens/status/1600972915096563712/photo/1", "display_url": "pic.twitter.com/RyjxBvaP12", "media_key": "3_1600972764814495756"}, {"start": 193, "end": 216, "url": "https://t.co/tyEHT8U5hd", "expanded_url": "https://twitter.com/ash_hematology/status/1600856480026075136", "display_url": "twitter.com/ash_hematology\u2026"}]}, "source": "Twitter for iPhone", "text": "A tad delayed, but landing soon in NOLA via New Jersey @EWRairport. \ud83d\udeeb\ud83d\udeec\n\nAlready connected with 10+ people on the plane I\u2019ve not seen in years.\n\nSee y\u2019all soon!   #ASH22 https://t.co/RyjxBvaP12 https://t.co/tyEHT8U5hd", "id": "1600972915096563712", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600856480026075136"}], "edit_history_tweet_ids": ["1600972915096563712"], "conversation_id": "1600972915096563712"}, {"created_at": "2022-12-08T17:30:15.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 16, "end": 22, "tag": "ASH22"}], "mentions": [{"start": 0, "end": 15, "username": "ASH_hematology", "id": "84072624"}]}, "in_reply_to_user_id": "719175246050410496", "source": "Twitter Web App", "text": "@ASH_hematology #ASH22!", "id": "1600905611319087104", "lang": "und", "referenced_tweets": [{"type": "replied_to", "id": "1600905163576725505"}], "edit_history_tweet_ids": ["1600905611319087104"], "conversation_id": "1600905163576725505"}, {"created_at": "2022-12-08T17:28:29.000Z", "author_id": "719175246050410496", "source": "Twitter Web App", "text": "Important work!\n\nIt is hard research to do, but we need to continue to study the \"lifelong time horizon\" for pts, esp w/ curable diseases or long natural history.\n\nNeed to evaluate associated impact varied therapeutics have via post-acute (1-10 yr post Rx) &amp; late effects lens'.\ud83d\udd2d https://t.co/N9aQUTQCAF", "entities": {"urls": [{"start": 284, "end": 307, "url": "https://t.co/N9aQUTQCAF", "expanded_url": "https://twitter.com/chanyooncheah/status/1600900928961642497", "display_url": "twitter.com/chanyooncheah/\u2026"}]}, "id": "1600905163576725505", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600900928961642497"}], "edit_history_tweet_ids": ["1600905163576725505"], "conversation_id": "1600905163576725505"}, {"created_at": "2022-12-08T17:23:20.000Z", "author_id": "719175246050410496", "source": "Twitter Web App", "text": "https://t.co/hAIh9OD279 https://t.co/MPT4yC2QZJ", "entities": {"urls": [{"start": 0, "end": 23, "url": "https://t.co/hAIh9OD279", "expanded_url": "https://twitter.com/DrAEvens/status/1600903869831139328/photo/1", "display_url": "pic.twitter.com/hAIh9OD279", "media_key": "16_1600903863401418766"}, {"start": 24, "end": 47, "url": "https://t.co/MPT4yC2QZJ", "expanded_url": "https://twitter.com/AaronGoodman33/status/1600900892298907648", "display_url": "twitter.com/AaronGoodman33\u2026"}]}, "id": "1600903869831139328", "lang": "zxx", "referenced_tweets": [{"type": "quoted", "id": "1600900892298907648"}], "edit_history_tweet_ids": ["1600903869831139328"], "conversation_id": "1600903869831139328"}, {"created_at": "2022-12-08T16:44:03.000Z", "author_id": "719175246050410496", "in_reply_to_user_id": "2212735524", "source": "Twitter for iPhone", "text": "@chadinabhan w/ unadulterated man crush on @AaronGoodman33? https://t.co/61MHGTAQRz", "entities": {"mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 43, "end": 58, "username": "AaronGoodman33", "id": "854692626015993857"}], "urls": [{"start": 60, "end": 83, "url": "https://t.co/61MHGTAQRz", "expanded_url": "https://twitter.com/chadinabhan/status/1600865250374361089", "display_url": "twitter.com/chadinabhan/st\u2026"}]}, "id": "1600893983668207617", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600865250374361089"}], "edit_history_tweet_ids": ["1600893983668207617"], "conversation_id": "1600893983668207617"}, {"created_at": "2022-12-08T16:42:17.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 12, "end": 18, "tag": "ASH22"}, {"start": 56, "end": 65, "tag": "RUStrong"}], "annotations": [{"start": 13, "end": 17, "probability": 0.6972, "type": "Other", "normalized_text": "ASH22"}, {"start": 57, "end": 64, "probability": 0.7707, "type": "Other", "normalized_text": "RUStrong"}, {"start": 67, "end": 79, "probability": 0.627, "type": "Other", "normalized_text": "Sol iustitiae"}], "mentions": [{"start": 21, "end": 30, "username": "RutgersU", "id": "19272796"}, {"start": 42, "end": 53, "username": "EWRairport", "id": "234423098"}], "urls": [{"start": 105, "end": 128, "url": "https://t.co/lncQQe1JPE", "expanded_url": "https://twitter.com/DrAEvens/status/1600893540615475200/photo/1", "display_url": "pic.twitter.com/lncQQe1JPE", "media_key": "3_1600893536215437316"}]}, "source": "Twitter for iPhone", "text": "En route to #ASH22.\n\n@RutgersU repping at @EWRairport!\n\n#RUStrong (Sol iustitiae et occidentem illustra) https://t.co/lncQQe1JPE", "id": "1600893540615475200", "lang": "en", "edit_history_tweet_ids": ["1600893540615475200"], "conversation_id": "1600893540615475200"}, {"created_at": "2022-12-08T16:32:53.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 75, "end": 76, "probability": 0.868, "type": "Place", "normalized_text": "US"}, {"start": 115, "end": 120, "probability": 0.9604, "type": "Place", "normalized_text": "Boston"}, {"start": 186, "end": 188, "probability": 0.4822, "type": "Other", "normalized_text": "GZL"}, {"start": 274, "end": 277, "probability": 0.5036, "type": "Other", "normalized_text": "HGBL"}], "urls": [{"start": 123, "end": 146, "url": "https://t.co/w1aVsz0ZT6", "expanded_url": "https://ashpublications.org/bloodadvances/article/1/26/2600/16257/Clinicopathologic-consensus-study-of-gray-zone", "display_url": "ashpublications.org/bloodadvances/\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600891183261044744/BaO2nMHj?format=png&name=orig", "width": 520, "height": 685}, {"url": "https://pbs.twimg.com/news_img/1600891183261044744/BaO2nMHj?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL", "description": "Key Points. Accurate GZL diagnosis remains challenging, with >60% of patients with presumed GZL having the diagnosis reclassified on consensus review.Treatme", "unwound_url": "https://ashpublications.org/bloodadvances/article/1/26/2600/16257/Clinicopathologic-consensus-study-of-gray-zone"}, {"start": 284, "end": 307, "url": "https://t.co/HX2tUhDdrV", "expanded_url": "https://twitter.com/DrAEvens/status/1600891174553669647/photo/1", "display_url": "pic.twitter.com/HX2tUhDdrV", "media_key": "3_1600891162939871233"}, {"start": 284, "end": 307, "url": "https://t.co/HX2tUhDdrV", "expanded_url": "https://twitter.com/DrAEvens/status/1600891174553669647/photo/1", "display_url": "pic.twitter.com/HX2tUhDdrV", "media_key": "3_1600891162923081728"}, {"start": 284, "end": 307, "url": "https://t.co/HX2tUhDdrV", "expanded_url": "https://twitter.com/DrAEvens/status/1600891174553669647/photo/1", "display_url": "pic.twitter.com/HX2tUhDdrV", "media_key": "3_1600891162948210688"}, {"start": 308, "end": 331, "url": "https://t.co/Apad4COCeD", "expanded_url": "https://twitter.com/GuiperiniMD/status/1600884497314381824", "display_url": "twitter.com/GuiperiniMD/st\u2026"}]}, "source": "Twitter for iPhone", "text": "No. \n\nWe did that for gray zone lymphoma\u2014 obtained 68 cases/slides from 15 US sites &amp; held consensus review in Boston: https://t.co/w1aVsz0ZT6 \ud83d\udc47\n\nOn central path, only 38% confirmed GZL (rest reclassified); this entity is overdiagnosed a bit.\n\nNot sure if been done for HGBL-NOS? https://t.co/HX2tUhDdrV https://t.co/Apad4COCeD", "id": "1600891174553669647", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600884497314381824"}], "edit_history_tweet_ids": ["1600891174553669647"], "conversation_id": "1600891174553669647"}, {"created_at": "2022-12-08T14:48:21.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 0, "end": 4, "probability": 0.7111, "type": "Person", "normalized_text": "David"}], "urls": [{"start": 56, "end": 79, "url": "https://t.co/CMviuCTEki", "expanded_url": "https://twitter.com/davidsteensma/status/1600829896346910720", "display_url": "twitter.com/davidsteensma/\u2026"}]}, "source": "Twitter for iPhone", "text": "David, you are a venerable, walking encyclopedia! \ud83d\udcd5\ud83d\udcd7\ud83d\udcd8\ud83d\udcd9\ud83e\udd2f https://t.co/CMviuCTEki", "id": "1600864867430576129", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600829896346910720"}], "edit_history_tweet_ids": ["1600864867430576129"], "conversation_id": "1600864867430576129"}, {"created_at": "2022-12-08T14:46:13.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 52, "end": 64, "tag": "ProBowlVote"}, {"start": 86, "end": 98, "tag": "ProBowlVote"}, {"start": 118, "end": 130, "tag": "ProBowlVote"}], "annotations": [{"start": 36, "end": 43, "probability": 0.5662, "type": "Other", "normalized_text": "Pro Bowl"}, {"start": 53, "end": 63, "probability": 0.6116, "type": "Other", "normalized_text": "ProBowlVote"}, {"start": 87, "end": 97, "probability": 0.5581, "type": "Other", "normalized_text": "ProBowlVote"}, {"start": 119, "end": 129, "probability": 0.5304, "type": "Other", "normalized_text": "ProBowlVote"}], "mentions": [{"start": 3, "end": 16, "username": "BuffaloBills", "id": "25084916"}, {"start": 67, "end": 82, "username": "MatthewMilanoo", "id": "287887835"}, {"start": 101, "end": 116, "username": "maine_savage23", "id": "506679880"}]}, "source": "Twitter for iPhone", "text": "RT @BuffaloBills: 1\ufe0f\u20e3 RETWEET = 1\ufe0f\u20e3 Pro Bowl Vote!\n\n#ProBowlVote | @MatthewMilanoo\n  \n#ProBowlVote | @Maine_Savage23\n\n#ProBowlVote | @J_Poy\u2026", "id": "1600864328345088001", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600857555198128128"}], "edit_history_tweet_ids": ["1600864328345088001"], "conversation_id": "1600864328345088001"}, {"created_at": "2022-12-08T14:46:08.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 95, "end": 107, "tag": "ProBowlVote"}, {"start": 125, "end": 137, "tag": "ProBowlVote"}], "annotations": [{"start": 49, "end": 52, "probability": 0.5571, "type": "Other", "normalized_text": "Bowl"}, {"start": 96, "end": 106, "probability": 0.544, "type": "Other", "normalized_text": "ProBowlVote"}, {"start": 126, "end": 136, "probability": 0.476, "type": "Other", "normalized_text": "ProBowlVote"}], "mentions": [{"start": 3, "end": 16, "username": "BuffaloBills", "id": "25084916"}, {"start": 110, "end": 122, "username": "JoshAllenQB", "id": "197974180"}]}, "source": "Twitter for iPhone", "text": "RT @BuffaloBills: Send our Bills to the 2023 Pro Bowl Games!\n\n1\ufe0f\u20e3 RETWEET = 1\ufe0f\u20e3 Pro Bowl Vote\n\n#ProBowlVote | @JoshAllenQB\n \n#ProBowlVote |\u2026", "id": "1600864310409932800", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1600857438407868417"}], "edit_history_tweet_ids": ["1600864310409932800"], "conversation_id": "1600864310409932800"}, {"created_at": "2022-12-08T14:44:37.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 7, "end": 11, "probability": 0.5025, "type": "Other", "normalized_text": "Chris"}], "urls": [{"start": 27, "end": 50, "url": "https://t.co/m8yB5pHVQa", "expanded_url": "https://twitter.com/mdandersonnews/status/1600548111797174272", "display_url": "twitter.com/mdandersonnews\u2026"}]}, "source": "Twitter for iPhone", "text": "Kudos, Chris. Awesome! \ud83d\udc4f\ud83d\udc4f\ud83d\udc4f https://t.co/m8yB5pHVQa", "id": "1600863925880381440", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600548111797174272"}], "edit_history_tweet_ids": ["1600863925880381440"], "conversation_id": "1600863925880381440"}, {"created_at": "2022-12-08T14:40:26.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 15, "end": 19, "probability": 0.8425, "type": "Organization", "normalized_text": "Bills"}, {"start": 39, "end": 45, "probability": 0.8958, "type": "Organization", "normalized_text": "Bengals"}], "urls": [{"start": 111, "end": 134, "url": "https://t.co/DHPU9XOoIp", "expanded_url": "https://twitter.com/lindemilesphd/status/1600856044204625920", "display_url": "twitter.com/lindemilesphd/\u2026"}]}, "source": "Twitter for iPhone", "text": "Kinda wish the Bills \ud83e\uddacwere playing the Bengals \ud83d\udc05this weekend. \n\nGuess we will see that matchup in a few weeks\u2026 https://t.co/DHPU9XOoIp", "id": "1600862872820752384", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600856044204625920"}], "edit_history_tweet_ids": ["1600862872820752384"], "conversation_id": "1600862872820752384"}, {"created_at": "2022-12-08T14:39:14.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 113, "end": 121, "probability": 0.5787, "type": "Other", "normalized_text": "grey zone"}, {"start": 154, "end": 158, "probability": 0.5358, "type": "Other", "normalized_text": "DLBCL"}, {"start": 166, "end": 168, "probability": 0.4858, "type": "Other", "normalized_text": "cHL"}, {"start": 214, "end": 221, "probability": 0.623, "type": "Other", "normalized_text": "HGBL-NOS"}, {"start": 278, "end": 282, "probability": 0.6839, "type": "Other", "normalized_text": "RCHOP"}], "urls": [{"start": 48, "end": 71, "url": "https://t.co/ItDybSIgt0", "expanded_url": "https://ashpublications.org/blood/article-abstract/140/9/943/476913/Defining-and-treating-high-grade-B-cell-lymphoma?redirectedFrom=fulltext", "display_url": "ashpublications.org/blood/article-\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600681030557790208/bSSmiZpd?format=png&name=orig", "width": 520, "height": 685}, {"url": "https://pbs.twimg.com/news_img/1600681030557790208/bSSmiZpd?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Defining and treating high-grade B-cell lymphoma, NOS", "description": "Edited by Associate Editor Laurie Sehn, this 3-part Review Series covers rare, aggressive B-cell lymphomas. First, Olszewski et al discuss a recently-designated", "unwound_url": "https://ashpublications.org/blood/article-abstract/140/9/943/476913/Defining-and-treating-high-grade-B-cell-lymphoma?redirectedFrom=fulltext"}, {"start": 285, "end": 308, "url": "https://t.co/PClAO9jfuK", "expanded_url": "https://twitter.com/DrAEvens/status/1600862571162394624/photo/1", "display_url": "pic.twitter.com/PClAO9jfuK", "media_key": "3_1600862567634817025"}, {"start": 309, "end": 332, "url": "https://t.co/28dgiesTp9", "expanded_url": "https://twitter.com/guiperinimd/status/1600860652951568384", "display_url": "twitter.com/guiperinimd/st\u2026"}]}, "source": "Twitter for iPhone", "text": "Great question. We analyzed this in our review: https://t.co/ItDybSIgt0\n\nDefinite diagnostic challenges, like w/ grey zone lymphoma (aka intermediate b/t DLBCL &amp; cHL, etc).\n\nAnd even if definitive diagnosis of HGBL-NOS, unclear re: optimal Rx but know most pts do poorly w/ RCHOP. https://t.co/PClAO9jfuK https://t.co/28dgiesTp9", "id": "1600862571162394624", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600860652951568384"}], "edit_history_tweet_ids": ["1600862571162394624"], "conversation_id": "1600862571162394624"}, {"created_at": "2022-12-08T03:52:10.000Z", "author_id": "719175246050410496", "source": "Twitter for iPhone", "text": "\ud83d\udc40 https://t.co/uKHCIFAagz", "entities": {"urls": [{"start": 2, "end": 25, "url": "https://t.co/uKHCIFAagz", "expanded_url": "https://twitter.com/sanamloghavi/status/1600699309455863808", "display_url": "twitter.com/sanamloghavi/s\u2026"}]}, "id": "1600699733009305600", "lang": "art", "referenced_tweets": [{"type": "quoted", "id": "1600699309455863808"}], "edit_history_tweet_ids": ["1600699733009305600"], "conversation_id": "1600699733009305600"}, {"created_at": "2022-12-08T03:50:25.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 276, "end": 282, "tag": "ASH22"}], "annotations": [{"start": 69, "end": 87, "probability": 0.508, "type": "Other", "normalized_text": "HoLISTIC consortium"}, {"start": 269, "end": 272, "probability": 0.5239, "type": "Other", "normalized_text": "HIPI"}], "urls": [{"start": 90, "end": 113, "url": "https://t.co/DgIpQkVl7V", "expanded_url": "https://www.hodgkinconsortium.com", "display_url": "hodgkinconsortium.com", "images": [{"url": "https://pbs.twimg.com/news_img/1600699300614635520/OCCfJpHp?format=jpg&name=orig", "width": 1200, "height": 630}, {"url": "https://pbs.twimg.com/news_img/1600699300614635520/OCCfJpHp?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "HoLISTIC: Hodgkin Lymphoma International Study for Individual Care", "description": "Enhancing evidence-based decision support to optimize care for individual patients.", "unwound_url": "https://www.hodgkinconsortium.com"}, {"start": 131, "end": 154, "url": "https://t.co/MY0EPNeBx8", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper164720.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Development and Validation of the<em> a</Em>dvanced-Stage <em>H</Em>odgkin Lymphoma (HL)<em> I</Em>nternational <em>P</Em>rognostication <em>I</Em>ndex (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Advanced Stage and Relapsed Hodgkin Lymphoma Hematology Disease Topics & Pathways: Research, clinical trials, Hodgkin lymphoma, adult, Clinical Practice (Health Services and Quality), Lymphomas, Clinical Research, health outcomes research, Diseases, real-world evidence, Therapies, registries, Lymphoid Malignancies, Study Population, Human 1 Institute for Clinical Research", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper164720.html"}, {"start": 283, "end": 306, "url": "https://t.co/1ls9eanw3j", "expanded_url": "https://twitter.com/rutgerscancer/status/1600482855443914756", "display_url": "twitter.com/rutgerscancer/\u2026"}]}, "source": "Twitter for iPhone", "text": "\ud83e\udee3Can\u2019t wait to present Saturday the inaugural output from the global HoLISTIC consortium (https://t.co/DgIpQkVl7V) as noted below (https://t.co/MY0EPNeBx8).\n\n\ud83d\udc49And the best part besides the rigorous predictive modeling &amp; global collaboration is the acronym (ie, the HIPI)! #ASH22 https://t.co/1ls9eanw3j", "id": "1600699291588530181", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600482855443914756"}], "edit_history_tweet_ids": ["1600699291588530181"], "conversation_id": "1600699291588530181"}, {"created_at": "2022-12-08T03:24:18.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 141, "end": 145, "probability": 0.8063, "type": "Other", "normalized_text": "RCHOP"}, {"start": 162, "end": 164, "probability": 0.5741, "type": "Other", "normalized_text": "MYC"}, {"start": 166, "end": 170, "probability": 0.4227, "type": "Other", "normalized_text": "DLBCL"}, {"start": 217, "end": 224, "probability": 0.6905, "type": "Other", "normalized_text": "HGBL-NOS"}], "mentions": [{"start": 96, "end": 106, "username": "ASkarbnik", "id": "999010996034338818"}], "urls": [{"start": 279, "end": 302, "url": "https://t.co/ohSyGpOHsL", "expanded_url": "https://twitter.com/DrAEvens/status/1600692717755191296/photo/1", "display_url": "pic.twitter.com/ohSyGpOHsL", "media_key": "3_1600692712583430147"}, {"start": 303, "end": 326, "url": "https://t.co/rU8s69p9fF", "expanded_url": "https://twitter.com/askarbnik/status/1600689149098356737", "display_url": "twitter.com/askarbnik/stat\u2026"}]}, "source": "Twitter for iPhone", "text": "And showed the visual abstract from our Blood review (highlighting entities to left).\n\nAs usual @ASkarbnik, we are in violent agreement (eg, RCHOP etc for single MYC DLBCL but much more nuanced/difficult decision for HGBL-NOS, which this B.Advances study was trying to address). https://t.co/ohSyGpOHsL https://t.co/rU8s69p9fF", "id": "1600692717755191296", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600689149098356737"}], "edit_history_tweet_ids": ["1600692717755191296"], "conversation_id": "1600692717755191296"}, {"created_at": "2022-12-08T03:19:13.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 267, "end": 273, "tag": "lymsm"}], "annotations": [{"start": 33, "end": 35, "probability": 0.4788, "type": "Organization", "normalized_text": "MYC"}, {"start": 41, "end": 45, "probability": 0.686, "type": "Other", "normalized_text": "DLBCL"}, {"start": 62, "end": 77, "probability": 0.5049, "type": "Other", "normalized_text": "Burkitt lymphoma"}, {"start": 128, "end": 132, "probability": 0.7495, "type": "Other", "normalized_text": "HGBCL"}, {"start": 247, "end": 250, "probability": 0.7705, "type": "Other", "normalized_text": "HIV+"}], "mentions": [{"start": 254, "end": 266, "username": "lymphomatic", "id": "2891506288"}], "urls": [{"start": 166, "end": 189, "url": "https://t.co/ItDybSZjv0", "expanded_url": "https://ashpublications.org/blood/article-abstract/140/9/943/476913/Defining-and-treating-high-grade-B-cell-lymphoma?redirectedFrom=fulltext", "display_url": "ashpublications.org/blood/article-\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600681030557790208/bSSmiZpd?format=png&name=orig", "width": 520, "height": 685}, {"url": "https://pbs.twimg.com/news_img/1600681030557790208/bSSmiZpd?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Defining and treating high-grade B-cell lymphoma, NOS", "description": "Edited by Associate Editor Laurie Sehn, this 3-part Review Series covers rare, aggressive B-cell lymphomas. First, Olszewski et al discuss a recently-designated", "unwound_url": "https://ashpublications.org/blood/article-abstract/140/9/943/476913/Defining-and-treating-high-grade-B-cell-lymphoma?redirectedFrom=fulltext"}, {"start": 274, "end": 297, "url": "https://t.co/qfomqK4Cxo", "expanded_url": "https://twitter.com/ASkarbnik/status/1600688080742408192", "display_url": "twitter.com/ASkarbnik/stat\u2026"}]}, "source": "Twitter for iPhone", "text": "Said below:\n\nThis was not single MYC hit DLBCL\u2026pts had either Burkitt lymphoma (68%) or the difficult to dx &amp; treat entity, HGBCL w/ single or double/triple hit (https://t.co/ItDybSZjv0).\n\nRetrospective data, but impressive results (including HIV+). @lymphomatic #lymsm https://t.co/qfomqK4Cxo", "id": "1600691441549725696", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600688080742408192"}], "edit_history_tweet_ids": ["1600691441549725696"], "conversation_id": "1600691441549725696"}, {"created_at": "2022-12-08T02:54:46.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 34, "end": 36, "probability": 0.4676, "type": "Organization", "normalized_text": "MYC"}, {"start": 42, "end": 46, "probability": 0.6692, "type": "Other", "normalized_text": "DLBCL"}, {"start": 76, "end": 82, "probability": 0.4631, "type": "Person", "normalized_text": "Burkitt"}, {"start": 87, "end": 90, "probability": 0.7888, "type": "Other", "normalized_text": "HGBL"}, {"start": 92, "end": 94, "probability": 0.6762, "type": "Other", "normalized_text": "NOS"}], "urls": [{"start": 97, "end": 120, "url": "https://t.co/43Xrw3OA2o", "expanded_url": "https://twitter.com/askarbnik/status/1600476542509142016", "display_url": "twitter.com/askarbnik/stat\u2026"}]}, "source": "Twitter for iPhone", "text": "See my reply; this was NOT single MYC hit DLBCL; pts in analysis had either Burkitt or HGBL-NOS. https://t.co/43Xrw3OA2o", "id": "1600685288430268416", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600476542509142016"}], "edit_history_tweet_ids": ["1600685288430268416"], "conversation_id": "1600685288430268416"}, {"created_at": "2022-12-08T02:50:30.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 75, "end": 104, "tag": "dontusetwocellwallinhibitors"}], "annotations": [{"start": 3, "end": 7, "probability": 0.5032, "type": "Other", "normalized_text": "zosyn"}, {"start": 18, "end": 25, "probability": 0.5597, "type": "Other", "normalized_text": "cefepime"}], "urls": [{"start": 108, "end": 131, "url": "https://t.co/TTiUqP9dVM", "expanded_url": "https://twitter.com/marklewismd/status/1600259570609201152", "display_url": "twitter.com/marklewismd/st\u2026"}]}, "source": "Twitter for iPhone", "text": "Or zosyn added to cefepime w/ intent for \u201cdouble gram negative\u201d coverage.\n\n#dontusetwocellwallinhibitors \ud83e\udd14\ud83e\udd14 https://t.co/TTiUqP9dVM", "id": "1600684213229191168", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600259570609201152"}], "edit_history_tweet_ids": ["1600684213229191168"], "conversation_id": "1600684213229191168"}, {"created_at": "2022-12-08T02:46:32.000Z", "author_id": "719175246050410496", "in_reply_to_user_id": "719175246050410496", "source": "Twitter for iPhone", "text": "2 categories to the left https://t.co/ED6aRTg9en", "entities": {"urls": [{"start": 25, "end": 48, "url": "https://t.co/ED6aRTg9en", "expanded_url": "https://twitter.com/DrAEvens/status/1600683213789155329/photo/1", "display_url": "pic.twitter.com/ED6aRTg9en", "media_key": "3_1600683209888505856"}]}, "id": "1600683213789155329", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600681018570465280"}], "edit_history_tweet_ids": ["1600683213789155329"], "conversation_id": "1600681018570465280"}, {"created_at": "2022-12-08T02:37:48.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 278, "end": 284, "tag": "lymsm"}], "annotations": [{"start": 20, "end": 22, "probability": 0.5273, "type": "Organization", "normalized_text": "MYC"}, {"start": 28, "end": 32, "probability": 0.7215, "type": "Other", "normalized_text": "DLBCL"}, {"start": 73, "end": 88, "probability": 0.5041, "type": "Other", "normalized_text": "Burkitt lymphoma"}, {"start": 139, "end": 143, "probability": 0.7338, "type": "Other", "normalized_text": "HGBCL"}, {"start": 258, "end": 261, "probability": 0.7246, "type": "Other", "normalized_text": "HIV+"}], "mentions": [{"start": 265, "end": 277, "username": "lymphomatic", "id": "2891506288"}], "urls": [{"start": 177, "end": 200, "url": "https://t.co/ItDybSIgt0", "expanded_url": "https://ashpublications.org/blood/article-abstract/140/9/943/476913/Defining-and-treating-high-grade-B-cell-lymphoma?redirectedFrom=fulltext", "display_url": "ashpublications.org/blood/article-\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600681030557790208/bSSmiZpd?format=png&name=orig", "width": 520, "height": 685}, {"url": "https://pbs.twimg.com/news_img/1600681030557790208/bSSmiZpd?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Defining and treating high-grade B-cell lymphoma, NOS", "description": "Edited by Associate Editor Laurie Sehn, this 3-part Review Series covers rare, aggressive B-cell lymphomas. First, Olszewski et al discuss a recently-designated", "unwound_url": "https://ashpublications.org/blood/article-abstract/140/9/943/476913/Defining-and-treating-high-grade-B-cell-lymphoma?redirectedFrom=fulltext"}, {"start": 285, "end": 308, "url": "https://t.co/5JZQO2pxph", "expanded_url": "https://twitter.com/chadinabhan/status/1600467379158294528", "display_url": "twitter.com/chadinabhan/st\u2026"}]}, "source": "Twitter for iPhone", "text": "This was not single MYC hit DLBCL.\n\nIn reading the study, pts had either Burkitt lymphoma (68%) or the difficult to dx &amp; treat entity, HGBCL w/ single or double/triple hit (https://t.co/ItDybSIgt0).\n\nRetrospective data, but impressive results (including HIV+). @lymphomatic #lymsm https://t.co/5JZQO2pxph", "id": "1600681018570465280", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600467379158294528"}], "edit_history_tweet_ids": ["1600681018570465280"], "conversation_id": "1600681018570465280"}, {"created_at": "2022-12-08T01:52:18.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 59, "end": 70, "tag": "BillsMafia"}, {"start": 83, "end": 89, "tag": "ASH22"}], "annotations": [{"start": 19, "end": 26, "probability": 0.4198, "type": "Person", "normalized_text": "Schaefer"}, {"start": 60, "end": 69, "probability": 0.6603, "type": "Organization", "normalized_text": "BillsMafia"}, {"start": 84, "end": 88, "probability": 0.5336, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 91, "end": 114, "url": "https://t.co/4LXVwsET8z", "expanded_url": "https://twitter.com/BevSchaeferMD/status/1600665600711430146", "display_url": "twitter.com/BevSchaeferMD/\u2026"}]}, "source": "Twitter Web App", "text": "We have not met Dr Schaefer, but I look forward to repping #BillsMafia together at #ASH22! https://t.co/4LXVwsET8z", "id": "1600669569009745920", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600665600711430146"}], "edit_history_tweet_ids": ["1600669569009745920"], "conversation_id": "1600669569009745920"}, {"created_at": "2022-12-07T22:08:52.000Z", "author_id": "719175246050410496", "source": "Twitter for iPhone", "text": "\ud83e\uddac\ud83e\uddac\ud83e\uddac https://t.co/6ug4fuLxfV", "entities": {"urls": [{"start": 4, "end": 27, "url": "https://t.co/6ug4fuLxfV", "expanded_url": "https://twitter.com/pallawitorkamd/status/1600535436643942400", "display_url": "twitter.com/pallawitorkamd\u2026"}]}, "id": "1600613338882494464", "lang": "art", "referenced_tweets": [{"type": "quoted", "id": "1600535436643942400"}], "edit_history_tweet_ids": ["1600613338882494464"], "conversation_id": "1600613338882494464"}, {"created_at": "2022-12-06T23:21:50.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 45, "end": 58, "tag": "WorldCup2022"}, {"start": 66, "end": 72, "tag": "ASH22"}, {"start": 222, "end": 233, "tag": "BillsMafia"}], "annotations": [{"start": 46, "end": 57, "probability": 0.5754, "type": "Other", "normalized_text": "WorldCup2022"}, {"start": 67, "end": 71, "probability": 0.5067, "type": "Other", "normalized_text": "ASH22"}, {"start": 130, "end": 136, "probability": 0.4681, "type": "Organization", "normalized_text": "Backers"}, {"start": 141, "end": 151, "probability": 0.9439, "type": "Place", "normalized_text": "New Orleans"}, {"start": 197, "end": 198, "probability": 0.8556, "type": "Place", "normalized_text": "US"}, {"start": 223, "end": 232, "probability": 0.8498, "type": "Organization", "normalized_text": "BillsMafia"}], "mentions": [{"start": 110, "end": 123, "username": "BuffaloBills", "id": "25084916"}, {"start": 153, "end": 163, "username": "DrLizBrem", "id": "4476878772"}], "urls": [{"start": 234, "end": 257, "url": "https://t.co/Fm5cxB5DGM", "expanded_url": "https://twitter.com/DrAEvens/status/1600269314971443200/photo/1", "display_url": "pic.twitter.com/Fm5cxB5DGM", "media_key": "16_1600269306037784591"}]}, "source": "Twitter for iPhone", "text": "I completely understand all of the buzz with #WorldCup2022 during #ASH22. \n\nHowever, curious if there are any @BuffaloBills Bills Backers in New Orleans @DrLizBrem? \n\nThere is a big football game (US style) this weekend!  #BillsMafia https://t.co/Fm5cxB5DGM", "id": "1600269314971443200", "lang": "en", "edit_history_tweet_ids": ["1600269314971443200"], "conversation_id": "1600269314971443200"}, {"created_at": "2022-12-06T01:56:23.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 213, "end": 219, "tag": "ASH22"}], "annotations": [{"start": 190, "end": 194, "probability": 0.523, "type": "Other", "normalized_text": "ctDNA"}, {"start": 214, "end": 218, "probability": 0.4818, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 220, "end": 243, "url": "https://t.co/07cWw6jJ4D", "expanded_url": "https://twitter.com/JohnPLeonardMD/status/1598673683786219522", "display_url": "twitter.com/JohnPLeonardMD\u2026"}]}, "source": "Twitter for iPhone", "text": "Very well done and interesting; however, poor risk group represents only 4% of patients. \n\nNeed continue to identify other factors that estimate risk of PD &amp; death (maybe integration of ctDNA will enhance?).\n\n#ASH22 https://t.co/07cWw6jJ4D", "id": "1599945821083967491", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1598673683786219522"}], "edit_history_tweet_ids": ["1599945821083967491"], "conversation_id": "1599945821083967491"}, {"created_at": "2022-12-03T20:11:15.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 26, "end": 34, "probability": 0.9852, "type": "Place", "normalized_text": "San Diego"}], "urls": [{"start": 44, "end": 67, "url": "https://t.co/LJuObRs9LL", "expanded_url": "https://twitter.com/Dr_AmerZeidan/status/1599034589938601987", "display_url": "twitter.com/Dr_AmerZeidan/\u2026"}]}, "source": "Twitter for iPhone", "text": "Here here; fine to add in San Diego too! \ud83d\ude0e\ud83d\ude0e https://t.co/LJuObRs9LL", "id": "1599134186987667456", "lang": "en", "edit_history_tweet_ids": ["1599134186987667456"], "conversation_id": "1599134186987667456"}, {"created_at": "2022-12-03T02:13:58.000Z", "author_id": "719175246050410496", "in_reply_to_user_id": "719175246050410496", "source": "Twitter for iPhone", "text": "Including no treatment/observation as valid option for some diseases.", "id": "1598863079235678208", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1598862174146830338"}], "edit_history_tweet_ids": ["1598863079235678208"], "conversation_id": "1598862174146830338"}, {"created_at": "2022-12-03T02:10:22.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 90, "end": 95, "probability": 0.5134, "type": "Other", "normalized_text": "cancer"}, {"start": 131, "end": 133, "probability": 0.5194, "type": "Other", "normalized_text": "EBM"}], "urls": [{"start": 293, "end": 316, "url": "https://t.co/bNUlEngvzl", "expanded_url": "https://twitter.com/iHematologo/status/1564284969849016320", "display_url": "twitter.com/iHematologo/st\u2026"}]}, "source": "Twitter for iPhone", "text": "We currently have paucity of decision tools (decision support) for providers &amp; pts in cancer.\n\nNeed rigorous &amp; interactive EBM tools (from large amounts harmonized data, applicable to a diverse population) to identify pros &amp; cons across varied treatment choices for individual pts https://t.co/bNUlEngvzl", "id": "1598862174146830338", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1564284969849016320"}], "edit_history_tweet_ids": ["1598862174146830338"], "conversation_id": "1598862174146830338"}, {"created_at": "2022-12-02T22:06:44.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 152, "end": 158, "tag": "ASH22"}, {"start": 159, "end": 165, "tag": "lymsm"}, {"start": 166, "end": 171, "tag": "mmsm"}, {"start": 172, "end": 179, "tag": "leuksm"}], "mentions": [{"start": 0, "end": 14, "username": "RutgersCancer", "id": "2802993134"}, {"start": 15, "end": 27, "username": "RWJBarnabas", "id": "45596617"}, {"start": 28, "end": 35, "username": "theNCI", "id": "38530021"}, {"start": 36, "end": 46, "username": "DrMatasar", "id": "1307491056"}, {"start": 47, "end": 62, "username": "ASH_hematology", "id": "84072624"}]}, "in_reply_to_user_id": "2802993134", "source": "Twitter Web App", "text": "@RutgersCancer @RWJBarnabas @theNCI @DrMatasar @ASH_hematology You can scan the above QR codes to schedule a meeting directly into your calendar!! \ud83d\uddd3\ufe0f\ud83d\udcc6\n\n#ASH22 #lymsm #mmsm #leuksm", "id": "1598800861307600896", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1598783097306161152"}], "edit_history_tweet_ids": ["1598800861307600896"], "conversation_id": "1598783097306161152"}, {"created_at": "2022-12-02T21:19:00.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 30, "end": 36, "tag": "ASH22"}, {"start": 123, "end": 134, "tag": "hematology"}], "annotations": [{"start": 22, "end": 25, "probability": 0.9137, "type": "Place", "normalized_text": "NOLA"}, {"start": 31, "end": 35, "probability": 0.464, "type": "Other", "normalized_text": "ASH22"}], "mentions": [{"start": 195, "end": 209, "username": "RutgersCancer", "id": "2802993134"}, {"start": 210, "end": 222, "username": "RWJBarnabas", "id": "45596617"}], "urls": [{"start": 287, "end": 310, "url": "https://t.co/y0Vlif5L0H", "expanded_url": "https://twitter.com/RutgersCancer/status/1598783097306161152", "display_url": "twitter.com/RutgersCancer/\u2026"}]}, "source": "Twitter Web App", "text": "Come by to meet us in NOLA at #ASH22.\ud83d\udc47\ud83d\udc47\n\nThere are multiple great opportunities (clinical practice &amp; research, etc) in #hematology for physicians of all experience, APPs &amp; pharmacists at @RutgersCancer @RWJBarnabas across our rapidly expanding 15-hospital oncology service line! https://t.co/y0Vlif5L0H", "id": "1598788849639034891", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1598783097306161152"}], "edit_history_tweet_ids": ["1598788849639034891"], "conversation_id": "1598788849639034891"}, {"created_at": "2022-12-01T17:05:21.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 38, "end": 44, "probability": 0.5807, "type": "Other", "normalized_text": "podcast"}], "mentions": [{"start": 25, "end": 37, "username": "chadinabhan", "id": "2212735524"}], "urls": [{"start": 208, "end": 231, "url": "https://t.co/lzuGyNG1lW", "expanded_url": "https://twitter.com/chadinabhan/status/1598322360335089665", "display_url": "twitter.com/chadinabhan/st\u2026"}]}, "source": "Twitter for iPhone", "text": "One of the best parts of @chadinabhan podcast(s) are the inclusion of younger/junior faculty into the shows as well as the global nature to the content.\n\nSo important to hear the views and insights from all. https://t.co/lzuGyNG1lW", "id": "1598362628530835467", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1598322360335089665"}], "edit_history_tweet_ids": ["1598362628530835467"], "conversation_id": "1598362628530835467"}, {"created_at": "2022-12-01T13:30:49.000Z", "author_id": "719175246050410496", "source": "Twitter for iPhone", "text": "RT @JoyAnnReid: Listen and take this in.", "entities": {"mentions": [{"start": 3, "end": 14, "username": "JoyAnnReid", "id": "49698134"}]}, "id": "1598308639562940418", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1598294291649994752"}], "edit_history_tweet_ids": ["1598308639562940418"], "conversation_id": "1598308639562940418"}, {"created_at": "2022-11-29T03:20:41.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 0, "end": 5, "probability": 0.4814, "type": "Other", "normalized_text": "Biases"}], "urls": [{"start": 7, "end": 30, "url": "https://t.co/acUL3e0xWo", "expanded_url": "https://twitter.com/RiderToast/status/1597235612977106945", "display_url": "twitter.com/RiderToast/sta\u2026"}]}, "source": "Twitter for iPhone", "text": "Biases https://t.co/acUL3e0xWo", "id": "1597430317815848962", "lang": "es", "referenced_tweets": [{"type": "quoted", "id": "1597235612977106945"}], "edit_history_tweet_ids": ["1597430317815848962"], "conversation_id": "1597430317815848962"}, {"created_at": "2022-11-27T14:44:40.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 69, "end": 77, "probability": 0.3807, "type": "Other", "normalized_text": "Cwynarski"}, {"start": 81, "end": 110, "probability": 0.6419, "type": "Other", "normalized_text": "British Journal of Haematology"}, {"start": 114, "end": 133, "probability": 0.5469, "type": "Other", "normalized_text": "Wiley Online Library"}], "mentions": [{"start": 3, "end": 9, "username": "SCTNB", "id": "314498013"}]}, "source": "Twitter for iPhone", "text": "RT @SCTNB: Management of secondary central nervous system lymphoma - Cwynarski - British Journal of Haematology - Wiley Online Library http\u2026", "id": "1596877674449981441", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1596848981853831173"}], "edit_history_tweet_ids": ["1596877674449981441"], "conversation_id": "1596877674449981441"}, {"created_at": "2022-11-26T23:06:18.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 127, "end": 134, "probability": 0.5139, "type": "Other", "normalized_text": "Lymphoma"}], "mentions": [{"start": 3, "end": 14, "username": "smbenlazar", "id": "716743703830900736"}]}, "source": "Twitter for iPhone", "text": "RT @smbenlazar: Favorable Outcomes with R-CHOP Induction and Consolidative Autologous Stem Cell Transplantation for Double-Hit Lymphoma #ly\u2026", "id": "1596641526339223552", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1596619349015793665"}], "edit_history_tweet_ids": ["1596641526339223552"], "conversation_id": "1596641526339223552"}, {"created_at": "2022-11-26T22:33:57.000Z", "author_id": "719175246050410496", "source": "Twitter for iPhone", "text": "RT @Dallas_Holladay: Dear Soon to Be Grads,\n\nLast year I took a 22% pay cut to get out of for profit medicine and back into the not for pro\u2026", "entities": {"mentions": [{"start": 3, "end": 19, "username": "Dallas_Holladay", "id": "727898827739402241"}]}, "id": "1596633384284921856", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1596405589705654273"}], "edit_history_tweet_ids": ["1596633384284921856"], "conversation_id": "1596633384284921856"}, {"created_at": "2022-11-26T19:46:42.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 72, "end": 78, "tag": "ASH22"}], "annotations": [{"start": 73, "end": 77, "probability": 0.6962, "type": "Other", "normalized_text": "ASH22"}], "mentions": [{"start": 3, "end": 14, "username": "Mohty_EBMT", "id": "2626263112"}]}, "source": "Twitter for iPhone", "text": "RT @Mohty_EBMT: Let\u2019s learn from the non-conclusive studies reported at #ASH22 and congratulate all colleagues who took the challenge and d\u2026", "id": "1596591294813720576", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1596447119493066754"}], "edit_history_tweet_ids": ["1596591294813720576"], "conversation_id": "1596591294813720576"}, {"created_at": "2022-11-24T13:45:00.000Z", "author_id": "719175246050410496", "in_reply_to_user_id": "719175246050410496", "source": "Twitter for iPhone", "text": "And 99.9% of the creation &amp; prep credit goes to @DrAKritharis!!", "entities": {"mentions": [{"start": 52, "end": 65, "username": "DrAKritharis", "id": "293812846"}]}, "id": "1595775493978353664", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1595771516112838660"}], "edit_history_tweet_ids": ["1595775493978353664"], "conversation_id": "1595771516112838660"}, {"created_at": "2022-11-24T13:29:12.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 71, "end": 82, "tag": "BillsMafia"}], "urls": [{"start": 138, "end": 161, "url": "https://t.co/0kyw9aCLeG", "expanded_url": "https://twitter.com/DrAEvens/status/1595771516112838660/photo/1", "display_url": "pic.twitter.com/0kyw9aCLeG", "media_key": "3_1595771505903812611"}]}, "source": "Twitter for iPhone", "text": "Kicking it up a notch on this years menu (see upper right in spirit of #BillsMafia\u00a0 ).\n\nHAPPY (and HEALTHY) THANKSGIVING TO ALL!!!!   \ud83e\udd83\ud83e\udd83\ud83e\udd83 https://t.co/0kyw9aCLeG", "id": "1595771516112838660", "lang": "en", "edit_history_tweet_ids": ["1595771516112838660"], "conversation_id": "1595771516112838660"}, {"created_at": "2022-11-24T12:30:26.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 15, "end": 24, "tag": "heforshe"}], "urls": [{"start": 25, "end": 48, "url": "https://t.co/UI7kWV0Pju", "expanded_url": "https://twitter.com/WomenInLymphoma/status/1594863080063864885", "display_url": "twitter.com/WomenInLymphom\u2026"}]}, "source": "Twitter for iPhone", "text": "Done/donated!\n\n#heforshe https://t.co/UI7kWV0Pju", "id": "1595756729974800384", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1594863080063864885"}], "edit_history_tweet_ids": ["1595756729974800384"], "conversation_id": "1595756729974800384"}, {"created_at": "2022-11-24T12:11:54.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 63, "end": 68, "probability": 0.5108, "type": "Other", "normalized_text": "cancer"}], "mentions": [{"start": 3, "end": 13, "username": "n8pennell", "id": "205280101"}, {"start": 107, "end": 112, "username": "ASCO", "id": "20187065"}], "urls": [{"start": 113, "end": 136, "url": "https://t.co/vY0ySrf7Nv", "expanded_url": "https://old-prod.asco.org/news-initiatives/policy-news-analysis/nearly-all-oncology-providers-report-prior-authorization", "display_url": "old-prod.asco.org/news-initiativ\u2026", "status": 200, "title": "Nearly All Oncology Providers Report Prior Authorization Causing", "description": "Prior authorization is harming individuals with cancer according to new survey results from the Association for Clinical Oncology (ASCO). The survey found that prior authorization delays necessary", "unwound_url": "https://old-prod.asco.org/news-initiatives/policy-news-analysis/nearly-all-oncology-providers-report-prior-authorization"}]}, "source": "Twitter for iPhone", "text": "RT @n8pennell: Prior authorization is harming individuals with cancer according to new survey results from @ASCO https://t.co/vY0ySrf7Nv WI\u2026", "id": "1595752063706824706", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1595450873383391232"}], "edit_history_tweet_ids": ["1595752063706824706"], "conversation_id": "1595752063706824706"}, {"created_at": "2022-11-22T14:04:29.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 46, "end": 55, "tag": "lymphoma"}, {"start": 232, "end": 251, "tag": "HockeyFightsCancer"}, {"start": 252, "end": 275, "tag": "LetsBeatCancerTogether"}], "annotations": [{"start": 117, "end": 125, "probability": 0.6387, "type": "Other", "normalized_text": "Jumbotron"}], "mentions": [{"start": 18, "end": 30, "username": "RWJBarnabas", "id": "45596617"}, {"start": 31, "end": 45, "username": "RutgersCancer", "id": "2802993134"}, {"start": 152, "end": 161, "username": "NJDevils", "id": "40878677"}], "urls": [{"start": 276, "end": 299, "url": "https://t.co/fnRPGy8eVF", "expanded_url": "https://twitter.com/DrAEvens/status/1595055622545809408/photo/1", "display_url": "pic.twitter.com/fnRPGy8eVF", "media_key": "3_1595055613586771968"}, {"start": 276, "end": 299, "url": "https://t.co/fnRPGy8eVF", "expanded_url": "https://twitter.com/DrAEvens/status/1595055622545809408/photo/1", "display_url": "pic.twitter.com/fnRPGy8eVF", "media_key": "3_1595055613595201536"}, {"start": 276, "end": 299, "url": "https://t.co/fnRPGy8eVF", "expanded_url": "https://twitter.com/DrAEvens/status/1595055622545809408/photo/1", "display_url": "pic.twitter.com/fnRPGy8eVF", "media_key": "3_1595055613591007233"}, {"start": 276, "end": 299, "url": "https://t.co/fnRPGy8eVF", "expanded_url": "https://twitter.com/DrAEvens/status/1595055622545809408/photo/1", "display_url": "pic.twitter.com/fnRPGy8eVF", "media_key": "3_1595055613595115521"}, {"start": 300, "end": 323, "url": "https://t.co/z3T4t11gkk", "expanded_url": "https://twitter.com/RutgersCancer/status/1594868332397830145", "display_url": "twitter.com/RutgersCancer/\u2026"}]}, "source": "Twitter for iPhone", "text": "\ud83d\ude4c TY for honoring @RWJBarnabas @RutgersCancer #lymphoma patient,\nWill; a rousing cheer of support when he was on the Jumbotron! \ud83c\udf89\n\nAnd great to see the @NJDevils win their 13th consec game w/ our heme malignancy nursing team. \ud83c\udfd2\ud83e\udd45\u26f8\ufe0f\n\n#HockeyFightsCancer\n#LetsBeatCancerTogether https://t.co/fnRPGy8eVF https://t.co/z3T4t11gkk", "id": "1595055622545809408", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1594868332397830145"}], "edit_history_tweet_ids": ["1595055622545809408"], "conversation_id": "1595055622545809408"}, {"created_at": "2022-11-21T21:43:46.000Z", "author_id": "719175246050410496", "source": "Twitter Web App", "text": "And thanks to @DrMatasar for your support; next time we hang out, it has to be w/o a masquerade or the \ud83d\udc27\ud83d\udc27 suits! https://t.co/KACjY59IOX https://t.co/BcHw4KlBY4", "entities": {"mentions": [{"start": 14, "end": 24, "username": "DrMatasar", "id": "1307491056"}], "urls": [{"start": 113, "end": 136, "url": "https://t.co/KACjY59IOX", "expanded_url": "https://twitter.com/DrAEvens/status/1594808816989773825/photo/1", "display_url": "pic.twitter.com/KACjY59IOX", "media_key": "3_1594808731086233612"}, {"start": 137, "end": 160, "url": "https://t.co/BcHw4KlBY4", "expanded_url": "https://twitter.com/DrAEvens/status/1594801877220204554", "display_url": "twitter.com/DrAEvens/statu\u2026"}]}, "id": "1594808816989773825", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1594801877220204554"}], "edit_history_tweet_ids": ["1594808816989773825"], "conversation_id": "1594808816989773825"}, {"created_at": "2022-11-21T21:22:32.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 88, "end": 111, "tag": "LetsBeatCancerTogether"}], "mentions": [{"start": 43, "end": 57, "username": "RutgersCancer", "id": "2802993134"}, {"start": 59, "end": 71, "username": "RWJBarnabas", "id": "45596617"}, {"start": 72, "end": 84, "username": "JCMedCenter", "id": "74781431"}], "urls": [{"start": 18, "end": 41, "url": "https://t.co/kyJfQCUwP7", "expanded_url": "https://www.mflfoundation.com/", "display_url": "mflfoundation.com", "images": [{"url": "https://pbs.twimg.com/news_img/1594803515662147613/Dp8zv4ee?format=jpg&name=orig", "width": 1500, "height": 556}, {"url": "https://pbs.twimg.com/news_img/1594803515662147613/Dp8zv4ee?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "MFL Foundation", "unwound_url": "https://www.mflfoundation.com/"}]}, "in_reply_to_user_id": "719175246050410496", "source": "Twitter Web App", "text": "\ud83d\udc49 MFL Foundation: https://t.co/kyJfQCUwP7\n\n@RutgersCancer \n@RWJBarnabas\n@JCMedCenter\n  \n#LetsBeatCancerTogether", "id": "1594803471802310657", "lang": "ht", "referenced_tweets": [{"type": "replied_to", "id": "1594801877220204554"}], "edit_history_tweet_ids": ["1594803471802310657"], "conversation_id": "1594801877220204554"}, {"created_at": "2022-11-21T21:16:12.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 90, "end": 101, "tag": "JerseyCity"}, {"start": 226, "end": 233, "tag": "cancer"}], "annotations": [{"start": 43, "end": 63, "probability": 0.7619, "type": "Other", "normalized_text": "Madeline Fiadini LoRe"}, {"start": 66, "end": 68, "probability": 0.3665, "type": "Organization", "normalized_text": "MFL"}, {"start": 82, "end": 85, "probability": 0.6262, "type": "Other", "normalized_text": "Gala"}, {"start": 91, "end": 100, "probability": 0.7716, "type": "Place", "normalized_text": "JerseyCity"}, {"start": 102, "end": 114, "probability": 0.9352, "type": "Place", "normalized_text": "Hudson County"}, {"start": 227, "end": 232, "probability": 0.5764, "type": "Other", "normalized_text": "cancer"}], "urls": [{"start": 260, "end": 283, "url": "https://t.co/7tt3A1jtkd", "expanded_url": "https://mediazilla.com/VH8XyMgWmW", "display_url": "mediazilla.com/VH8XyMgWmW", "images": [{"url": "https://pbs.twimg.com/news_img/1594799304065138689/2SlbZ8sq?format=jpg&name=orig", "width": 1920, "height": 1080}, {"url": "https://pbs.twimg.com/news_img/1594799304065138689/2SlbZ8sq?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "MFL V2", "description": "This is \"MFL V2\" by Epic Events on MediaZilla", "unwound_url": "https://mediazilla.com/VH8XyMgWmW"}]}, "source": "Twitter Web App", "text": "A privilege to be an honoree at this years Madeline Fiadini LoRe (MFL) Foundation Gala in #JerseyCity Hudson County (below video includes part of tribute at this fantastic event).\n\n\ud83d\ude4f A big THANK YOU for everything MFL does in #cancer prevention &amp; beyond!\n\nhttps://t.co/7tt3A1jtkd", "id": "1594801877220204554", "lang": "en", "edit_history_tweet_ids": ["1594801877220204554"], "conversation_id": "1594801877220204554"}, {"created_at": "2022-11-21T20:00:46.000Z", "author_id": "719175246050410496", "source": "Twitter for iPhone", "text": "Hmmm. https://t.co/J9yRHrfI86", "entities": {"urls": [{"start": 6, "end": 29, "url": "https://t.co/J9yRHrfI86", "expanded_url": "https://twitter.com/jaltucher/status/1594771339553882114", "display_url": "twitter.com/jaltucher/stat\u2026"}]}, "id": "1594782893217353734", "lang": "qst", "referenced_tweets": [{"type": "quoted", "id": "1594771339553882114"}], "edit_history_tweet_ids": ["1594782893217353734"], "conversation_id": "1594782893217353734"}, {"created_at": "2022-11-19T21:23:08.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 195, "end": 202, "tag": "Cancer"}, {"start": 215, "end": 224, "tag": "lymphoma"}, {"start": 254, "end": 262, "tag": "myeloma"}], "annotations": [{"start": 170, "end": 173, "probability": 0.5152, "type": "Other", "normalized_text": "Jack"}, {"start": 181, "end": 193, "probability": 0.7083, "type": "Other", "normalized_text": "Sheryl Morris"}, {"start": 196, "end": 208, "probability": 0.5413, "type": "Other", "normalized_text": "Cancer Center"}, {"start": 255, "end": 261, "probability": 0.6006, "type": "Other", "normalized_text": "myeloma"}], "mentions": [{"start": 106, "end": 116, "username": "DrMatasar", "id": "1307491056"}, {"start": 120, "end": 134, "username": "RutgersCancer", "id": "2802993134"}], "urls": [{"start": 226, "end": 249, "url": "https://t.co/d02Eb32b5J", "expanded_url": "https://jobs.rutgers.edu/postings/182627", "display_url": "jobs.rutgers.edu/postings/182627", "status": 200, "title": "Hematologic Malignancies (Assistant/Associate Professor)", "description": "Rutgers Cancer Institute of New Jersey seeks candidates to join the Division of Blood Disorders within the Department of Medicine. Specifically, we seek candidates with clinical interests in lymphoid, plasma cell, and myeloid malignancies. Candidates with experience and expertise in conducting and leading clinical research are highly encouraged to apply. Directorship opportunities exist for qualified candidates to lead a well-established clinical and research program with a portfolio of first in human to phase 3 clinical trials (industry, cooperative group and investigator-initiated trials). Candidates will have the exciting opportunity to build comprehensive academic programs in their area of focus across the state-wide RWJ Barnabas Health system. Academic appointment will be in the Department of Medicine, Rutgers Robert Wood Johnson Medical School. Academic rank (Assistant/Associate Professor) and clinical research support commensurate with experience.Rutgers Cancer Institute of New ", "unwound_url": "https://jobs.rutgers.edu/postings/182627"}, {"start": 264, "end": 287, "url": "https://t.co/aZUZJs8rIF", "expanded_url": "https://jobs.rutgers.edu/postings/185017", "display_url": "jobs.rutgers.edu/postings/185017", "status": 200, "title": "Chief, Hematologic Malignancies (Associate/Professor)", "description": "Rutgers Cancer Institute seeks a nationally recognized clinical researcher focused in lymphoid, plasma cell,\u00a0 or myeloid malignancies, with proven leadership experience and a distinguished record of original clinical research, exceptional clinical and educational skills, and a commitment to the Institute's mission, to serve as the Chief of Hematologic Malignancies at Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School. The Chief will have oversight of the clinical practice, clinical research activities, and faculty mentorship and development, with the opportunity to build on a solid foundation of excellence, including preeminent research, outstanding clinical services, and prominent educational programs. The Chief will have the unique opportunity to develop the hematologic malignancies clinical program in alignment with Rutgers Cancer Institute of New Jersey and the RWJBarnabas Health partner strategy.\u00a0The Chief will join the leadership team of the Division of Blood", "unwound_url": "https://jobs.rutgers.edu/postings/185017"}, {"start": 288, "end": 311, "url": "https://t.co/w97AKCunrO", "expanded_url": "https://twitter.com/DrAEvens/status/1594078847217139715/photo/1", "display_url": "pic.twitter.com/w97AKCunrO", "media_key": "3_1594078347998466049"}]}, "source": "Twitter Web App", "text": "\ud83d\udea8 SEE BELOW for 2 new leadership positions within the Division of Blood Disorders under the leadership of @DrMatasar at @RutgersCancer &amp; the soon-to-be free-standing Jack &amp; Sheryl Morris #Cancer Center.\n\n1\u20e3 #lymphoma: https://t.co/d02Eb32b5J\n\n2\u20e3 #myeloma: https://t.co/aZUZJs8rIF https://t.co/w97AKCunrO", "id": "1594078847217139715", "lang": "en", "edit_history_tweet_ids": ["1594078847217139715"], "conversation_id": "1594078847217139715"}, {"created_at": "2022-11-17T18:12:23.000Z", "author_id": "719175246050410496", "in_reply_to_user_id": "244846617", "source": "Twitter Web App", "text": "@SamiaHanna \ud83d\udcaf", "entities": {"mentions": [{"start": 0, "end": 11, "username": "SamiaHanna", "id": "244846617"}]}, "id": "1593306067223691267", "lang": "und", "referenced_tweets": [{"type": "replied_to", "id": "1593257526325547009"}], "edit_history_tweet_ids": ["1593306067223691267"], "conversation_id": "1593257526325547009"}, {"created_at": "2022-11-15T20:06:55.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 89, "end": 100, "tag": "BillsMafia"}], "annotations": [{"start": 90, "end": 99, "probability": 0.7684, "type": "Organization", "normalized_text": "BillsMafia"}], "mentions": [{"start": 103, "end": 115, "username": "JoshAllenQB", "id": "197974180"}, {"start": 116, "end": 129, "username": "gabedavis13_", "id": "2190505048"}], "urls": [{"start": 130, "end": 153, "url": "https://t.co/jOwh8PPG9W", "expanded_url": "https://twitter.com/ATCoveredPod/status/1592553545215008768", "display_url": "twitter.com/ATCoveredPod/s\u2026"}]}, "source": "Twitter for iPhone", "text": "Amazing insight. Live and learn. \n\nWill course correct and rebound even stronger/better. #BillsMafia \n\n@JoshAllenQB @gabedavis13_ https://t.co/jOwh8PPG9W", "id": "1592610117727707137", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1592553545215008768"}], "edit_history_tweet_ids": ["1592610117727707137"], "conversation_id": "1592610117727707137"}, {"created_at": "2022-11-15T18:55:35.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 59, "end": 69, "probability": 0.8736, "type": "Person", "normalized_text": "Erica Marsh"}, {"start": 87, "end": 93, "probability": 0.9598, "type": "Other", "normalized_text": "Twitter"}], "mentions": [{"start": 3, "end": 17, "username": "disjoint_4est", "id": "1270567127569883139"}]}, "source": "Twitter for iPhone", "text": "RT @disjoint_4est: WARNING: Do NOT follow or interact with Erica Marsh, a popular Blue Twitter account. She's very likely a bot probably de\u2026", "id": "1592592162960867328", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1592458931158552578"}], "edit_history_tweet_ids": ["1592592162960867328"], "conversation_id": "1592592162960867328"}, {"created_at": "2022-11-13T14:57:07.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 220, "end": 226, "tag": "ASH22"}, {"start": 277, "end": 283, "tag": "lymsm"}], "annotations": [{"start": 221, "end": 225, "probability": 0.4335, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 228, "end": 251, "url": "https://t.co/MY0EPNeBx8", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper164720.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Development and Validation of the<em> a</Em>dvanced-Stage <em>H</Em>odgkin Lymphoma (HL)<em> I</Em>nternational <em>P</Em>rognostication <em>I</Em>ndex (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Advanced Stage and Relapsed Hodgkin Lymphoma Hematology Disease Topics & Pathways: Research, clinical trials, Hodgkin lymphoma, adult, Clinical Practice (Health Services and Quality), Lymphomas, Clinical Research, health outcomes research, Diseases, real-world evidence, Therapies, registries, Lymphoid Malignancies, Study Population, Human 1 Institute for Clinical Research", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper164720.html"}, {"start": 253, "end": 276, "url": "https://t.co/OgzZO189xi", "expanded_url": "https://www.hodgkinconsortium.com/", "display_url": "hodgkinconsortium.com", "images": [{"url": "https://pbs.twimg.com/news_img/1600699300614635520/OCCfJpHp?format=jpg&name=orig", "width": 1200, "height": 630}, {"url": "https://pbs.twimg.com/news_img/1600699300614635520/OCCfJpHp?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "HoLISTIC: Hodgkin Lymphoma International Study for Individual Care", "description": "Enhancing evidence-based decision support to optimize care for individual patients.", "unwound_url": "https://www.hodgkinconsortium.com/"}, {"start": 284, "end": 307, "url": "https://t.co/V2IWYT6OcU", "expanded_url": "https://twitter.com/DrAEvens/status/1591807375631331329/photo/1", "display_url": "pic.twitter.com/V2IWYT6OcU", "media_key": "3_1591806424417435650"}, {"start": 308, "end": 331, "url": "https://t.co/kndJbWiAjx", "expanded_url": "https://twitter.com/VJHemOnc/status/1591717826511110144", "display_url": "twitter.com/VJHemOnc/statu\u2026"}]}, "source": "Twitter Web App", "text": "\ud83d\ude4c After ~5 yrs of negotiating DUAs w/ global groups &amp; countries, harmonizing ~15K detailed patient data, and performing rigorous data analysis/modeling, we GREATLY look forward to our 1st output (of many to come) at #ASH22: https://t.co/MY0EPNeBx8\n\nhttps://t.co/OgzZO189xi #lymsm https://t.co/V2IWYT6OcU https://t.co/kndJbWiAjx", "id": "1591807375631331329", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1591717826511110144"}], "edit_history_tweet_ids": ["1591807375631331329"], "conversation_id": "1591807375631331329"}, {"created_at": "2022-11-07T11:30:46.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 88, "end": 94, "tag": "ash22"}], "annotations": [{"start": 89, "end": 93, "probability": 0.5681, "type": "Other", "normalized_text": "ash22"}], "mentions": [{"start": 3, "end": 14, "username": "Mohty_EBMT", "id": "2626263112"}]}, "source": "Twitter for iPhone", "text": "RT @Mohty_EBMT: Almost 50 abstracts dealing with microbiota/microbiome in hematology at #ash22 This is quite impressive increase compared t\u2026", "id": "1589581118772490241", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1589507409453662209"}], "edit_history_tweet_ids": ["1589581118772490241"], "conversation_id": "1589581118772490241"}, {"created_at": "2022-11-05T20:04:49.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 25, "end": 38, "tag": "healthequity"}, {"start": 108, "end": 115, "tag": "cancer"}, {"start": 243, "end": 256, "tag": "CANCERNJ2022"}, {"start": 257, "end": 280, "tag": "LetsBeatCancerTogether"}], "annotations": [{"start": 244, "end": 255, "probability": 0.4827, "type": "Other", "normalized_text": "CANCERNJ2022"}], "mentions": [{"start": 42, "end": 56, "username": "RutgersCancer", "id": "2802993134"}, {"start": 57, "end": 69, "username": "RWJBarnabas", "id": "45596617"}], "urls": [{"start": 281, "end": 304, "url": "https://t.co/QZKBcLk0pK", "expanded_url": "https://twitter.com/birensaraiya/status/1588871880286474240", "display_url": "twitter.com/birensaraiya/s\u2026"}]}, "source": "Twitter for iPhone", "text": "Incredible commitment to #healthequity at @RutgersCancer @RWJBarnabas.\n\nHigher accrual rates to therapeutic #cancer clinical trials than state averages for Asian/PIs, Blacks, and Hispanic/Latinos.\n\nIt is critical to continue to address this.\n\n#CANCERNJ2022\n#LetsBeatCancerTogether https://t.co/QZKBcLk0pK", "id": "1588985707691134976", "lang": "en", "edit_history_tweet_ids": ["1588985707691134976"], "conversation_id": "1588985707691134976"}, {"created_at": "2022-11-05T19:12:16.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 61, "end": 70, "tag": "oncology"}, {"start": 114, "end": 119, "tag": "CART"}, {"start": 122, "end": 135, "tag": "CANCERNJ2022"}], "annotations": [{"start": 62, "end": 69, "probability": 0.3763, "type": "Organization", "normalized_text": "oncology"}, {"start": 115, "end": 118, "probability": 0.347, "type": "Place", "normalized_text": "CART"}, {"start": 123, "end": 134, "probability": 0.6421, "type": "Other", "normalized_text": "CANCERNJ2022"}], "mentions": [{"start": 33, "end": 47, "username": "RutgersCancer", "id": "2802993134"}, {"start": 48, "end": 60, "username": "RWJBarnabas", "id": "45596617"}], "urls": [{"start": 136, "end": 159, "url": "https://t.co/tMuEIMajwh", "expanded_url": "https://twitter.com/DrAEvens/status/1588972482736029697/photo/1", "display_url": "pic.twitter.com/tMuEIMajwh", "media_key": "3_1588972478545776640"}, {"start": 136, "end": 159, "url": "https://t.co/tMuEIMajwh", "expanded_url": "https://twitter.com/DrAEvens/status/1588972482736029697/photo/1", "display_url": "pic.twitter.com/tMuEIMajwh", "media_key": "3_1588972478524801025"}, {"start": 160, "end": 183, "url": "https://t.co/zY9yemaBYS", "expanded_url": "https://twitter.com/RutgersCancer/status/1588868318819409922", "display_url": "twitter.com/RutgersCancer/\u2026"}]}, "source": "Twitter for iPhone", "text": "Thrilled to highlight our expert @RutgersCancer @RWJBarnabas #oncology nurses vis-a-vis this interactive panel on #CART.\n\n#CANCERNJ2022 https://t.co/tMuEIMajwh https://t.co/zY9yemaBYS", "id": "1588972482736029697", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1588868318819409922"}], "edit_history_tweet_ids": ["1588972482736029697"], "conversation_id": "1588972482736029697"}, {"created_at": "2022-11-05T17:12:01.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 176, "end": 183, "tag": "cancer"}, {"start": 191, "end": 204, "tag": "CANCERNJ2022"}, {"start": 205, "end": 228, "tag": "LetsBeatCancerTogether"}], "annotations": [{"start": 192, "end": 203, "probability": 0.6316, "type": "Other", "normalized_text": "CANCERNJ2022"}], "mentions": [{"start": 255, "end": 269, "username": "RutgersCancer", "id": "2802993134"}, {"start": 270, "end": 282, "username": "RWJBarnabas", "id": "45596617"}], "urls": [{"start": 230, "end": 253, "url": "https://t.co/JcglWAojgw", "expanded_url": "https://cinj.org/?utm_source=AdWords&utm_medium=cpc&utm_campaign=Brand&utm_term=cinj&gclid=EAIaIQobChMIgcfeo8OX-wIVD43ICh1H1QVIEAAYASAAEgLcs_D_BwE", "display_url": "cinj.org/?utm_source=Ad\u2026", "status": 200, "title": "Homepage | Rutgers Cancer Institute of New Jersey", "description": "Rutgers Cancer Institute of New Jersey is dedicated to the prevention, treatment, and care of patients with cancer, transforming science into clinical practice.", "unwound_url": "https://cinj.org/?utm_source=AdWords&utm_medium=cpc&utm_campaign=Brand&utm_term=cinj&gclid=EAIaIQobChMIgcfeo8OX-wIVD43ICh1H1QVIEAAYASAAEgLcs_D_BwE"}, {"start": 283, "end": 306, "url": "https://t.co/7Z6PSb9wlF", "expanded_url": "https://twitter.com/DrAEvens/status/1588942222040641536/photo/1", "display_url": "pic.twitter.com/7Z6PSb9wlF", "media_key": "3_1588942205498032129"}, {"start": 283, "end": 306, "url": "https://t.co/7Z6PSb9wlF", "expanded_url": "https://twitter.com/DrAEvens/status/1588942222040641536/photo/1", "display_url": "pic.twitter.com/7Z6PSb9wlF", "media_key": "3_1588942205502226439"}, {"start": 283, "end": 306, "url": "https://t.co/7Z6PSb9wlF", "expanded_url": "https://twitter.com/DrAEvens/status/1588942222040641536/photo/1", "display_url": "pic.twitter.com/7Z6PSb9wlF", "media_key": "3_1588942205493862402"}, {"start": 307, "end": 330, "url": "https://t.co/zY9yemaBYS", "expanded_url": "https://twitter.com/RutgersCancer/status/1588868318819409922", "display_url": "twitter.com/RutgersCancer/\u2026"}]}, "source": "Twitter for iPhone", "text": "\ud83d\udcda Jammed packed agenda covering the full cancer/disease spectrum via multi-specialty &amp; trans-discipline lens.\n\nGreat to betogether to learn from each other on state-of-art #cancer care.\n\n#CANCERNJ2022\n#LetsBeatCancerTogether\n\nhttps://t.co/JcglWAojgw\n\n@RutgersCancer @RWJBarnabas https://t.co/7Z6PSb9wlF https://t.co/zY9yemaBYS", "id": "1588942222040641536", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1588868318819409922"}], "edit_history_tweet_ids": ["1588942222040641536"], "conversation_id": "1588942222040641536"}, {"created_at": "2022-11-05T15:09:07.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 13, "end": 22, "tag": "oncology"}, {"start": 91, "end": 104, "tag": "CANCERNJ2022"}, {"start": 105, "end": 128, "tag": "LetsBeatCancerTogether"}], "annotations": [{"start": 92, "end": 103, "probability": 0.4828, "type": "Other", "normalized_text": "CANCERNJ2022"}], "mentions": [{"start": 42, "end": 56, "username": "RutgersCancer", "id": "2802993134"}, {"start": 57, "end": 69, "username": "RWJBarnabas", "id": "45596617"}, {"start": 74, "end": 88, "username": "RichardalexMD", "id": "1471291082071842816"}], "urls": [{"start": 129, "end": 152, "url": "https://t.co/HeuIf4rNEM", "expanded_url": "https://twitter.com/RutgersCancer/status/1588903885191917568", "display_url": "twitter.com/RutgersCancer/\u2026"}]}, "source": "Twitter for iPhone", "text": "\ud83d\udcaa A surgical #oncology powerhouse, led by @RutgersCancer @RWJBarnabas CSO @RichardalexMD!\n\n#CANCERNJ2022\n#LetsBeatCancerTogether https://t.co/HeuIf4rNEM", "id": "1588911295201366016", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1588903885191917568"}], "edit_history_tweet_ids": ["1588911295201366016"], "conversation_id": "1588911295201366016"}, {"created_at": "2022-11-05T15:03:39.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 38, "end": 49, "tag": "JeseyShore"}, {"start": 120, "end": 127, "tag": "cancer"}, {"start": 250, "end": 259, "tag": "lymphoma"}, {"start": 267, "end": 280, "tag": "CANCERNJ2022"}], "annotations": [{"start": 25, "end": 28, "probability": 0.5033, "type": "Other", "normalized_text": "Taff"}, {"start": 39, "end": 48, "probability": 0.7461, "type": "Other", "normalized_text": "JeseyShore"}, {"start": 121, "end": 126, "probability": 0.5646, "type": "Other", "normalized_text": "cancer"}, {"start": 251, "end": 258, "probability": 0.4483, "type": "Other", "normalized_text": "lymphoma"}, {"start": 268, "end": 279, "probability": 0.6253, "type": "Other", "normalized_text": "CANCERNJ2022"}], "mentions": [{"start": 10, "end": 18, "username": "JtaffMD", "id": "1095390146"}, {"start": 64, "end": 76, "username": "RWJBarnabas", "id": "45596617"}], "urls": [{"start": 281, "end": 304, "url": "https://t.co/rObqdh32zC", "expanded_url": "https://twitter.com/JtaffMD/status/1588901579889213441", "display_url": "twitter.com/JtaffMD/status\u2026"}]}, "source": "Twitter for iPhone", "text": "Thank you @JtaffMD! \n\nDr Taff (in the #JeseyShore) is 1 of many @RWJBarnabas outstanding community oncologists.\n\nWe say #cancer does not travel well w/ overarching goal to \u201ckeep cancer care close to home\u201d.\n\nGreat to collaborate on many \u2018shared care\u2019 #lymphoma cases\n\n#CANCERNJ2022 https://t.co/rObqdh32zC", "id": "1588909919281229825", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1588901579889213441"}], "edit_history_tweet_ids": ["1588909919281229825"], "conversation_id": "1588909919281229825"}, {"created_at": "2022-11-05T14:25:05.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 213, "end": 220, "tag": "cancer"}, {"start": 233, "end": 246, "tag": "CANCERNJ2022"}], "annotations": [{"start": 101, "end": 108, "probability": 0.4793, "type": "Other", "normalized_text": "Beninato"}, {"start": 234, "end": 245, "probability": 0.694, "type": "Other", "normalized_text": "CANCERNJ2022"}], "mentions": [{"start": 15, "end": 28, "username": "BeninatoToni", "id": "1054725513632190465"}, {"start": 52, "end": 66, "username": "RutgersCancer", "id": "2802993134"}, {"start": 67, "end": 79, "username": "RWJBarnabas", "id": "45596617"}], "urls": [{"start": 247, "end": 270, "url": "https://t.co/sgww167zJi", "expanded_url": "https://twitter.com/HH_Oncodr/status/1588897691186102272", "display_url": "twitter.com/HH_Oncodr/stat\u2026"}]}, "source": "Twitter for iPhone", "text": "Super kudos to @BeninatoToni on a great talk at the @RutgersCancer @RWJBarnabas oncology summit.\n\nDr Beninato is an expertly skilled endocrine surgeon who is also passionate about enhancing access to care for our #cancer patients. \n\n#CANCERNJ2022 https://t.co/sgww167zJi", "id": "1588900213250744322", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1588897691186102272"}], "edit_history_tweet_ids": ["1588900213250744322"], "conversation_id": "1588900213250744322"}, {"created_at": "2022-11-05T14:21:42.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 270, "end": 283, "tag": "CANCERNJ2022"}], "annotations": [{"start": 134, "end": 139, "probability": 0.5947, "type": "Other", "normalized_text": "Lazaro"}, {"start": 142, "end": 149, "probability": 0.3897, "type": "Other", "normalized_text": "Thoracic"}, {"start": 156, "end": 163, "probability": 0.521, "type": "Other", "normalized_text": "Beninato"}, {"start": 166, "end": 174, "probability": 0.3305, "type": "Other", "normalized_text": "Endocrine"}, {"start": 181, "end": 185, "probability": 0.4644, "type": "Other", "normalized_text": "Akins"}, {"start": 188, "end": 195, "probability": 0.5999, "type": "Other", "normalized_text": "Gyne Onc"}, {"start": 202, "end": 210, "probability": 0.6079, "type": "Other", "normalized_text": "Benevenia"}, {"start": 229, "end": 233, "probability": 0.617, "type": "Other", "normalized_text": "Kholi"}, {"start": 271, "end": 282, "probability": 0.5421, "type": "Other", "normalized_text": "CANCERNJ2022"}], "mentions": [{"start": 39, "end": 53, "username": "RutgersCancer", "id": "2802993134"}, {"start": 54, "end": 66, "username": "RWJBarnabas", "id": "45596617"}, {"start": 113, "end": 127, "username": "RichardalexMD", "id": "1471291082071842816"}], "urls": [{"start": 284, "end": 307, "url": "https://t.co/415PaStkLB", "expanded_url": "https://twitter.com/DrAEvens/status/1588899360753844224/photo/1", "display_url": "pic.twitter.com/415PaStkLB", "media_key": "3_1588899349748137987"}]}, "source": "Twitter for iPhone", "text": "\ud83d\udc4f Wow, great surgical oncology panel @ @RutgersCancer @RWJBarnabas: all star panel led by Chief Surgical Officer @RichardalexMD w/ Dr Lazaro (Thoracic), Dr Beninato (Endocrine), Dr Akins (Gyne Onc), Dr Benevenia (Ortho) &amp; Dr Kholi (Breast).\n\nIncredible innovation!\n\n#CANCERNJ2022 https://t.co/415PaStkLB", "id": "1588899360753844224", "lang": "en", "edit_history_tweet_ids": ["1588899360753844224"], "conversation_id": "1588899360753844224"}, {"created_at": "2022-11-05T14:12:16.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 124, "end": 131, "tag": "cancer"}, {"start": 273, "end": 286, "tag": "CANCERNJ2022"}], "annotations": [{"start": 125, "end": 130, "probability": 0.5376, "type": "Other", "normalized_text": "cancer"}, {"start": 166, "end": 170, "probability": 0.4923, "type": "Other", "normalized_text": "Girda"}, {"start": 274, "end": 285, "probability": 0.7352, "type": "Other", "normalized_text": "CANCERNJ2022"}], "mentions": [{"start": 25, "end": 38, "username": "EugeniaGirda", "id": "1328788604630478853"}, {"start": 230, "end": 244, "username": "RutgersCancer", "id": "2802993134"}, {"start": 245, "end": 257, "username": "RWJBarnabas", "id": "45596617"}], "urls": [{"start": 287, "end": 310, "url": "https://t.co/pFsPukJEGZ", "expanded_url": "https://twitter.com/EugeniaGirda/status/1588870720897318913", "display_url": "twitter.com/EugeniaGirda/s\u2026"}]}, "source": "Twitter for iPhone", "text": "And a big GOLD star \ud83c\udf1f to @EugeniaGirda, our current top oncologist in enrolling to clinical trials this year to therapeutic #cancer trials (&gt;30 accruals YTD).\n\nDr Girda is a bright &amp; compassionate gynecologic oncologist at @RutgersCancer @RWJBarnabas.\n\nGreat work!\n\n#CANCERNJ2022 https://t.co/pFsPukJEGZ", "id": "1588896988468514818", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1588870720897318913"}], "edit_history_tweet_ids": ["1588896988468514818"], "conversation_id": "1588896988468514818"}, {"created_at": "2022-11-05T13:12:22.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 62, "end": 68, "tag": "DLBCL"}, {"start": 194, "end": 203, "tag": "lymphoma"}, {"start": 246, "end": 259, "tag": "CANCERNJ2022"}, {"start": 261, "end": 284, "tag": "LetsBeatCancerTogether"}], "annotations": [{"start": 63, "end": 67, "probability": 0.6121, "type": "Other", "normalized_text": "DLBCL"}, {"start": 118, "end": 132, "probability": 0.4817, "type": "Other", "normalized_text": "Blood Disorders"}, {"start": 195, "end": 202, "probability": 0.4778, "type": "Other", "normalized_text": "lymphoma"}, {"start": 239, "end": 242, "probability": 0.5087, "type": "Other", "normalized_text": "CINJ"}, {"start": 247, "end": 258, "probability": 0.606, "type": "Other", "normalized_text": "CANCERNJ2022"}], "mentions": [{"start": 81, "end": 95, "username": "RutgersCancer", "id": "2802993134"}, {"start": 96, "end": 108, "username": "RWJBarnabas", "id": "45596617"}, {"start": 137, "end": 147, "username": "DrMatasar", "id": "1307491056"}], "urls": [{"start": 285, "end": 308, "url": "https://t.co/mSwU1eoLTB", "expanded_url": "https://twitter.com/DrAEvens/status/1588881912612892673/photo/1", "display_url": "pic.twitter.com/mSwU1eoLTB", "media_key": "3_1588881899505721344"}, {"start": 285, "end": 308, "url": "https://t.co/mSwU1eoLTB", "expanded_url": "https://twitter.com/DrAEvens/status/1588881912612892673/photo/1", "display_url": "pic.twitter.com/mSwU1eoLTB", "media_key": "3_1588881899510013953"}, {"start": 285, "end": 308, "url": "https://t.co/mSwU1eoLTB", "expanded_url": "https://twitter.com/DrAEvens/status/1588881912612892673/photo/1", "display_url": "pic.twitter.com/mSwU1eoLTB", "media_key": "3_1588881899514200064"}, {"start": 309, "end": 332, "url": "https://t.co/Ynlu6FijBy", "expanded_url": "https://twitter.com/HH_Oncodr/status/1588879611831767041", "display_url": "twitter.com/HH_Oncodr/stat\u2026"}]}, "source": "Twitter for iPhone", "text": "Awesome tour de force overview of outcomes &amp; treatment of #DLBCL by incoming @RutgersCancer @RWJBarnabas Chief of Blood Disorders Dr @DrMatasar at annual oncology service line summit.\n\nMany #lymphoma clinical trials ongoing/planned at CINJ!\n\n#CANCERNJ2022\n\n#LetsBeatCancerTogether https://t.co/mSwU1eoLTB https://t.co/Ynlu6FijBy", "id": "1588881912612892673", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1588879611831767041"}], "edit_history_tweet_ids": ["1588881912612892673"], "conversation_id": "1588881912612892673"}, {"created_at": "2022-11-05T13:02:15.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 45, "end": 52, "tag": "cancer"}, {"start": 106, "end": 119, "tag": "CANCERNJ2022"}, {"start": 121, "end": 134, "tag": "HealthEquity"}, {"start": 136, "end": 159, "tag": "LetsBeatCancerTogether"}], "annotations": [{"start": 46, "end": 51, "probability": 0.5401, "type": "Other", "normalized_text": "cancer"}], "mentions": [{"start": 161, "end": 175, "username": "RutgersCancer", "id": "2802993134"}, {"start": 176, "end": 188, "username": "RWJBarnabas", "id": "45596617"}, {"start": 189, "end": 195, "username": "RWJUH", "id": "31198269"}, {"start": 196, "end": 206, "username": "HH_Oncodr", "id": "3129806495"}, {"start": 207, "end": 220, "username": "birensaraiya", "id": "91774296"}, {"start": 221, "end": 232, "username": "DrHaigentz", "id": "885933288619167744"}, {"start": 233, "end": 246, "username": "EugeniaGirda", "id": "1328788604630478853"}]}, "in_reply_to_user_id": "719175246050410496", "source": "Twitter for iPhone", "text": "\ud83d\udea8\ud83d\udea8 Nearly 44% of all accruals to therapeutic #cancer clinical trials this calendar year were minorities!\n\n#CANCERNJ2022\n\n#HealthEquity\n\n#LetsBeatCancerTogether\n\n@RutgersCancer @RWJBarnabas @RWJUH @HH_Oncodr @birensaraiya @DrHaigentz @EugeniaGirda", "id": "1588879367177789440", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1588875571484065792"}], "edit_history_tweet_ids": ["1588879367177789440"], "conversation_id": "1588875571484065792"}, {"created_at": "2022-11-05T12:47:10.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 275, "end": 288, "tag": "CANCERNJ2022"}], "mentions": [{"start": 89, "end": 99, "username": "HH_Oncodr", "id": "3129806495"}], "urls": [{"start": 289, "end": 312, "url": "https://t.co/80vhvXW7e8", "expanded_url": "https://twitter.com/DrAEvens/status/1588875571484065792/photo/1", "display_url": "pic.twitter.com/80vhvXW7e8", "media_key": "3_1588875565423108096"}, {"start": 313, "end": 336, "url": "https://t.co/QZKBcLk0pK", "expanded_url": "https://twitter.com/birensaraiya/status/1588871880286474240", "display_url": "twitter.com/birensaraiya/s\u2026"}]}, "source": "Twitter for iPhone", "text": "Incredible commitment to health equity &amp; enrollment of minorities to clinical trials @HH_Oncodr.\n\nOutreach has been critical w/ the FORCE MULTIPLIER of having single IRB &amp; master contracts (and unified employment of clinical research office) across all 15 hospitals\n\n#CANCERNJ2022 https://t.co/80vhvXW7e8 https://t.co/QZKBcLk0pK", "id": "1588875571484065792", "lang": "en", "edit_history_tweet_ids": ["1588875571484065792"], "conversation_id": "1588875571484065792"}, {"created_at": "2022-11-05T12:41:28.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 119, "end": 126, "tag": "cancer"}, {"start": 148, "end": 157, "tag": "oncology"}, {"start": 251, "end": 274, "tag": "LetsBeatCancerTogether"}]}, "in_reply_to_user_id": "719175246050410496", "source": "Twitter for iPhone", "text": "\u261d\ufe0f Clarification: ~300 in attendance today!\n\n\ud83d\ude4f We are fortunate to have &gt;230 employed oncologists and 300+ employed #cancer nurse experts in our #oncology service line (including one of the largest oncology nurse navigation programs nationally!).\n\n#LetsBeatCancerTogether", "id": "1588874137459908608", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1588870442672336896"}], "edit_history_tweet_ids": ["1588874137459908608"], "conversation_id": "1588870442672336896"}, {"created_at": "2022-11-05T12:26:47.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 161, "end": 168, "tag": "cancer"}, {"start": 268, "end": 281, "tag": "CANCERNJ2022"}], "annotations": [{"start": 269, "end": 280, "probability": 0.5942, "type": "Other", "normalized_text": "CANCERNJ2022"}], "mentions": [{"start": 182, "end": 192, "username": "HH_Oncodr", "id": "3129806495"}], "urls": [{"start": 282, "end": 305, "url": "https://t.co/XHu57kf8Jy", "expanded_url": "https://twitter.com/DrAEvens/status/1588870442672336896/photo/1", "display_url": "pic.twitter.com/XHu57kf8Jy", "media_key": "3_1588870434627493892"}, {"start": 306, "end": 329, "url": "https://t.co/zY9yemaBYS", "expanded_url": "https://twitter.com/RutgersCancer/status/1588868318819409922", "display_url": "twitter.com/RutgersCancer/\u2026"}]}, "source": "Twitter for iPhone", "text": "\ud83d\ude4c Thanks; v. excited about our annual oncology service line summit.\n\n\ud83d\udc49 ~300 oncology physician, nursing, admin experts (across our 15 hospitals &amp; associated #cancer practices).\n\n@HH_Oncodr taking the stage to highlight the clinical research machine he\u2019s built! \ud83d\udcaa\n\n#CANCERNJ2022 https://t.co/XHu57kf8Jy https://t.co/zY9yemaBYS", "id": "1588870442672336896", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1588868318819409922"}], "edit_history_tweet_ids": ["1588870442672336896"], "conversation_id": "1588870442672336896"}, {"created_at": "2022-11-04T16:12:33.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 125, "end": 137, "probability": 0.4777, "type": "Other", "normalized_text": "Morris center"}], "mentions": [{"start": 110, "end": 124, "username": "RutgersCancer", "id": "2802993134"}], "urls": [{"start": 284, "end": 307, "url": "https://t.co/brPU1suupd", "expanded_url": "https://twitter.com/DrAEvens/status/1588564869930168324/photo/1", "display_url": "pic.twitter.com/brPU1suupd", "media_key": "3_1588564865991548928"}, {"start": 308, "end": 331, "url": "https://t.co/N7M95YRaXA", "expanded_url": "https://twitter.com/RutgersCancer/status/1587933059831111680", "display_url": "twitter.com/RutgersCancer/\u2026"}]}, "source": "Twitter for iPhone", "text": "That\u2019s my right arm in the white coat (ran over from clinic); honored to sign this \u201ctopping off\u201d beam for the @RutgersCancer Morris center &amp; thrilled to see the progress as it is rapidly built.\n\nIt will be an amazing free standing cancer complex for our patients/the community! \ud83c\udfe5 https://t.co/brPU1suupd https://t.co/N7M95YRaXA", "id": "1588564869930168324", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1587933059831111680"}], "edit_history_tweet_ids": ["1588564869930168324"], "conversation_id": "1588564869930168324"}, {"created_at": "2022-11-03T15:07:26.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 282, "end": 288, "tag": "ASH22"}], "urls": [{"start": 289, "end": 312, "url": "https://t.co/xwVoaUNMqv", "expanded_url": "https://twitter.com/graham74GC/status/1588172256428969984", "display_url": "twitter.com/graham74GC/sta\u2026"}]}, "source": "Twitter Web App", "text": "This work (w/ online calculator) delineates an individualized risk of 5-yr PFS &amp; OS via modern HL data for point-of-care decision-making.\n\nOF NOTE, the model is constructed to allow for dynamic incorporation of new studies &amp; data as they emerge.\n\nMuch more details to come! #ASH22 https://t.co/xwVoaUNMqv", "id": "1588186094834966528", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1588172256428969984"}], "edit_history_tweet_ids": ["1588186094834966528"], "conversation_id": "1588186094834966528"}, {"created_at": "2022-10-31T18:25:45.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 94, "end": 103, "tag": "lymphoma"}, {"start": 140, "end": 147, "tag": "ISHL12"}], "annotations": [{"start": 86, "end": 92, "probability": 0.3436, "type": "Other", "normalized_text": "Hodgkin"}, {"start": 95, "end": 102, "probability": 0.4394, "type": "Other", "normalized_text": "lymphoma"}, {"start": 141, "end": 146, "probability": 0.5548, "type": "Other", "normalized_text": "ISHL12"}], "urls": [{"start": 289, "end": 312, "url": "https://t.co/jsNBIHqkFv", "expanded_url": "https://twitter.com/VJHemOnc/status/1587113637440806917", "display_url": "twitter.com/VJHemOnc/statu\u2026"}]}, "source": "Twitter for iPhone", "text": "Was exciting &amp; frankly inspiring to see how \u201cfront and center\u201d the topic of older Hodgkin #lymphoma pts was at the recent international #ISHL12 meeting &amp; the global efforts to improve outcomes for this heterogenous pt population.\n\nSeveral important advances to date; more to come! https://t.co/jsNBIHqkFv", "id": "1587148837260517376", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1587113637440806917"}], "edit_history_tweet_ids": ["1587148837260517376"], "conversation_id": "1587148837260517376"}, {"created_at": "2022-10-31T01:45:37.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 20, "end": 31, "tag": "BillsMafia"}], "annotations": [{"start": 15, "end": 17, "probability": 0.9103, "type": "Person", "normalized_text": "Tim"}, {"start": 21, "end": 30, "probability": 0.6662, "type": "Organization", "normalized_text": "BillsMafia"}], "urls": [{"start": 32, "end": 55, "url": "https://t.co/kAmKlD56il", "expanded_url": "https://twitter.com/timfenske/status/1586896324137476096", "display_url": "twitter.com/timfenske/stat\u2026"}]}, "source": "Twitter for iPhone", "text": "That about it, Tim. #BillsMafia https://t.co/kAmKlD56il", "id": "1586897148188172289", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1586896324137476096"}], "edit_history_tweet_ids": ["1586897148188172289"], "conversation_id": "1586897148188172289"}, {"created_at": "2022-10-30T01:20:13.000Z", "author_id": "719175246050410496", "source": "Twitter for iPhone", "text": "Syncharit\u00edria @LeonidasPlatan1! \ud83c\udf8a\ud83c\udf89 https://t.co/0YF0m7U5kf", "entities": {"mentions": [{"start": 14, "end": 30, "username": "LeonidasPlatan1", "id": "1117857169528033280"}], "urls": [{"start": 35, "end": 58, "url": "https://t.co/0YF0m7U5kf", "expanded_url": "https://twitter.com/clplatani/status/1586513389719015424", "display_url": "twitter.com/clplatani/stat\u2026"}]}, "id": "1586528364562878464", "lang": "und", "edit_history_tweet_ids": ["1586528364562878464"], "conversation_id": "1586528364562878464"}, {"created_at": "2022-10-29T20:13:41.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 231, "end": 240, "tag": "lymphoma"}, {"start": 268, "end": 286, "tag": "EradicateLymphoma"}], "mentions": [{"start": 243, "end": 252, "username": "lymphoma", "id": "43348496"}, {"start": 253, "end": 267, "username": "RutgersCancer", "id": "2802993134"}], "urls": [{"start": 91, "end": 114, "url": "https://t.co/fWoAmmNIjA", "expanded_url": "https://lymphoma.org/resources/educationresources/programs/edforum/", "display_url": "lymphoma.org/resources/educ\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1585675159574298625/-VHRZbRM?format=png&name=orig", "width": 524, "height": 287}, {"url": "https://pbs.twimg.com/news_img/1585675159574298625/-VHRZbRM?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "North American Educational Forum on Lymphoma", "description": "The North American Educational Forum on Lymphoma is the most comprehensive lymphoma-specific educational conference in North America.", "unwound_url": "https://lymphoma.org/resources/educationresources/programs/edforum/"}]}, "in_reply_to_user_id": "719175246050410496", "source": "Twitter Web App", "text": "\u261d\ufe0f And there is still plenty of time to register &amp; attend this FREE virtual symposium: https://t.co/fWoAmmNIjA.\n\n\ud83d\udc49 Program runs thru Sunday PM; hear (and see!) via interactive Q&amp;A format world's experts across all types of #lymphoma.\n\n@lymphoma @RutgersCancer #EradicateLymphoma", "id": "1586451224643018752", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1586448828466544640"}], "edit_history_tweet_ids": ["1586451224643018752"], "conversation_id": "1586448828466544640"}, {"created_at": "2022-10-29T20:04:10.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 74, "end": 79, "tag": "CART"}, {"start": 165, "end": 174, "tag": "lymphoma"}], "annotations": [{"start": 135, "end": 160, "probability": 0.5846, "type": "Other", "normalized_text": "American Educational Forum"}, {"start": 166, "end": 173, "probability": 0.4806, "type": "Other", "normalized_text": "lymphoma"}, {"start": 210, "end": 215, "probability": 0.7204, "type": "Other", "normalized_text": "Laurie"}, {"start": 223, "end": 230, "probability": 0.8237, "type": "Other", "normalized_text": "Kathleen"}], "mentions": [{"start": 35, "end": 45, "username": "DrLizBrem", "id": "4476878772"}, {"start": 52, "end": 65, "username": "LNastoupilMD", "id": "1491871658876944402"}, {"start": 123, "end": 132, "username": "lymphoma", "id": "43348496"}], "urls": [{"start": 291, "end": 314, "url": "https://t.co/dlbkLNGXFU", "expanded_url": "https://twitter.com/DrAEvens/status/1586448828466544640/photo/1", "display_url": "pic.twitter.com/dlbkLNGXFU", "media_key": "3_1586447978834837506"}]}, "source": "Twitter Web App", "text": "\ud83d\ude4c Great session today w/ co-chairs @DrLizBrem &amp; @LNastoupilMD for our #CART patient &amp; caregiver session @ the 2022 @lymphoma N.American Educational Forum on #lymphoma. \n\n\ud83d\ude4f V. inspiring stories from pts Laurie &amp; Kathleen (w/ her daughter) on their cancer journeys including CART. https://t.co/dlbkLNGXFU", "id": "1586448828466544640", "lang": "en", "edit_history_tweet_ids": ["1586448828466544640"], "conversation_id": "1586448828466544640"}, {"created_at": "2022-10-24T14:20:17.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 14, "end": 22, "tag": "Hodgkin"}, {"start": 23, "end": 32, "tag": "Lymphoma"}, {"start": 277, "end": 284, "tag": "ISHL12"}], "annotations": [{"start": 15, "end": 21, "probability": 0.334, "type": "Other", "normalized_text": "Hodgkin"}, {"start": 24, "end": 31, "probability": 0.4439, "type": "Other", "normalized_text": "Lymphoma"}, {"start": 50, "end": 53, "probability": 0.4451, "type": "Organization", "normalized_text": "GHSG"}, {"start": 112, "end": 115, "probability": 0.9515, "type": "Place", "normalized_text": "K\u00f6ln"}], "mentions": [{"start": 261, "end": 276, "username": "BroeckelmannPJ", "id": "1209011263"}], "urls": [{"start": 285, "end": 308, "url": "https://t.co/u75lVvfoBl", "expanded_url": "https://twitter.com/DrAEvens/status/1584550350886883333/photo/1", "display_url": "pic.twitter.com/u75lVvfoBl", "media_key": "3_1584550311846453249"}, {"start": 285, "end": 308, "url": "https://t.co/u75lVvfoBl", "expanded_url": "https://twitter.com/DrAEvens/status/1584550350886883333/photo/1", "display_url": "pic.twitter.com/u75lVvfoBl", "media_key": "3_1584550311863238656"}, {"start": 285, "end": 308, "url": "https://t.co/u75lVvfoBl", "expanded_url": "https://twitter.com/DrAEvens/status/1584550350886883333/photo/1", "display_url": "pic.twitter.com/u75lVvfoBl", "media_key": "3_1584550311838060544"}, {"start": 285, "end": 308, "url": "https://t.co/u75lVvfoBl", "expanded_url": "https://twitter.com/DrAEvens/status/1584550350886883333/photo/1", "display_url": "pic.twitter.com/u75lVvfoBl", "media_key": "3_1584550311842267139"}]}, "source": "Twitter for iPhone", "text": "Another great #Hodgkin #Lymphoma symposium by the GHSG. Data &amp; presentations were fantastic (as was city of K\u00f6ln).\n\nIt was great to see colleagues from around the \ud83c\udf0f\ud83c\udf0d\ud83c\udf0e. The collegiality &amp; collaboration is inspiring w/ much more to come!\n\n\ud83d\ude4cDanke sch\u00f6n! \n\n@BroeckelmannPJ #ISHL12 https://t.co/u75lVvfoBl", "id": "1584550350886883333", "lang": "en", "edit_history_tweet_ids": ["1584550350886883333"], "conversation_id": "1584550350886883333"}, {"created_at": "2022-10-24T11:48:44.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 0, "end": 32, "tag": "LetsBeatHodgkinLymphomaTogether"}], "mentions": [{"start": 34, "end": 48, "username": "RutgersCancer", "id": "2802993134"}, {"start": 49, "end": 61, "username": "RWJBarnabas", "id": "45596617"}], "urls": [{"start": 62, "end": 85, "url": "https://t.co/PLDAwpxYSW", "expanded_url": "https://twitter.com/DrRaulCordoba/status/1584236348596457472", "display_url": "twitter.com/DrRaulCordoba/\u2026"}]}, "source": "Twitter for iPhone", "text": "#LetsBeatHodgkinLymphomaTogether\n\n@RutgersCancer @RWJBarnabas https://t.co/PLDAwpxYSW", "id": "1584512209258180608", "lang": "qme", "referenced_tweets": [{"type": "quoted", "id": "1584236348596457472"}], "edit_history_tweet_ids": ["1584512209258180608"], "conversation_id": "1584512209258180608"}, {"created_at": "2022-10-24T11:16:30.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 32, "end": 33, "probability": 0.7415, "type": "Place", "normalized_text": "US"}, {"start": 93, "end": 96, "probability": 0.3598, "type": "Organization", "normalized_text": "TARC"}, {"start": 124, "end": 130, "probability": 0.2977, "type": "Other", "normalized_text": "Hodgkin"}], "mentions": [{"start": 3, "end": 14, "username": "graham74GC", "id": "2239893372"}]}, "source": "Twitter for iPhone", "text": "RT @graham74GC: Diepstra et al: US dept of defence serum biobank\n- 101 Hodgkin cases\n- Serum TARC raised several yrs before Hodgkin diagnos\u2026", "id": "1584504097247760384", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1584484745660223488"}], "edit_history_tweet_ids": ["1584504097247760384"], "conversation_id": "1584504097247760384"}, {"created_at": "2022-10-23T20:22:54.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 11, "end": 18, "tag": "ISHL22"}], "annotations": [{"start": 12, "end": 17, "probability": 0.5722, "type": "Other", "normalized_text": "ISHL22"}, {"start": 95, "end": 104, "probability": 0.4618, "type": "Other", "normalized_text": "Dr Portell"}], "mentions": [{"start": 37, "end": 53, "username": "UVACancerCenter", "id": "4901583437"}], "urls": [{"start": 55, "end": 78, "url": "https://t.co/HTJaSPE4Qi", "expanded_url": "https://pubmed.ncbi.nlm.nih.gov/34448831/", "display_url": "pubmed.ncbi.nlm.nih.gov/34448831/", "images": [{"url": "https://pbs.twimg.com/news_img/1587368254984622081/riVL1AZR?format=jpg&name=orig", "width": 1200, "height": 1200}, {"url": "https://pbs.twimg.com/news_img/1587368254984622081/riVL1AZR?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma - PubMed", "description": "We performed a multicenter retrospective analysis across 10 US academic medical centers to evaluate treatment patterns and outcomes in patients age \u226560 years with classic Hodgkin lymphoma (cHL) from 2010-2018. Among 244 eligible patients, median age was 68, 63% had advanced stage (III/IV), 96% had E \u2026", "unwound_url": "https://pubmed.ncbi.nlm.nih.gov/34448831/"}, {"start": 128, "end": 151, "url": "https://t.co/ElkfR0FNJN", "expanded_url": "https://clinicaltrials.gov/ct2/show/NCT05404945", "display_url": "clinicaltrials.gov/ct2/show/NCT05\u2026", "unwound_url": "https://clinicaltrials.gov/ct2/show/NCT05404945"}, {"start": 212, "end": 235, "url": "https://t.co/hY0Hk5Y7f4", "expanded_url": "https://ascopubs.org/doi/abs/10.1200/JCO.2018.79.0139", "display_url": "ascopubs.org/doi/abs/10.120\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1584279217348694016/43mxo07o?format=png&name=orig", "width": 269, "height": 269}, {"url": "https://pbs.twimg.com/news_img/1584279217348694016/43mxo07o?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma", "description": "Purpose To improve the curability of older patients with newly diagnosed Hodgkin lymphoma. Patients and Methods We conducted a multicenter phase II study that administered brentuximab vedotin (Bv) sequentially before and after standard doxorubicin, vinblastine, and dacarbazine (AVD) for untreated patients with Hodgkin lymphoma age 60 years or older. After two lead-in doses of single-agent Bv (1.8 mg/kg once every 3 weeks), patients received six cycles of AVD chemotherapy followed by four consolidative doses of Bv in responding patients. Results Patient characteristics included median age of 69 years (range, 60 to 88 years), 63% male, median Eastern Cooperative Oncology Group performance status 1, 81% stage III to IV disease, 60% International Prognostic Score 3 to 7, median Cumulative Illness Rating Scale-Geriatric comorbidity score of 7 (52% grade 3 to 4); and 12% had loss of instrumental activities of daily living at diagnosis. Thirty-seven (77%) of 48 patients completed six cycles o", "unwound_url": "https://ascopubs.org/doi/abs/10.1200/JCO.2018.79.0139"}, {"start": 281, "end": 304, "url": "https://t.co/pXDg2cSiuA", "expanded_url": "https://twitter.com/DrAEvens/status/1584279215993950208/photo/1", "display_url": "pic.twitter.com/pXDg2cSiuA", "media_key": "3_1584279207542235136"}, {"start": 305, "end": 328, "url": "https://t.co/FxD9HElSco", "expanded_url": "https://twitter.com/DrRaulCordoba/status/1584163647664058370", "display_url": "twitter.com/DrRaulCordoba/\u2026"}]}, "source": "Twitter for iPhone", "text": "Below from #ISHL22 summarizes RWE by @UVACancerCenter (https://t.co/HTJaSPE4Qi); led to IST by Dr Portell for older HL pts (NCT https://t.co/ElkfR0FNJN).\n\nDesign builds off prior study of sequential targeted Rx (https://t.co/hY0Hk5Y7f4); intent now to decrease # AVD chemo cycles. https://t.co/pXDg2cSiuA https://t.co/FxD9HElSco", "id": "1584279215993950208", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1584163647664058370"}], "edit_history_tweet_ids": ["1584279215993950208"], "conversation_id": "1584279215993950208"}, {"created_at": "2022-10-23T17:13:05.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 158, "end": 161, "tag": "HL"}, {"start": 168, "end": 175, "tag": "ISHL22"}], "annotations": [{"start": 61, "end": 66, "probability": 0.9353, "type": "Place", "normalized_text": "Brazil"}, {"start": 69, "end": 73, "probability": 0.9342, "type": "Place", "normalized_text": "Spain"}, {"start": 76, "end": 77, "probability": 0.9465, "type": "Place", "normalized_text": "US"}, {"start": 80, "end": 85, "probability": 0.9556, "type": "Place", "normalized_text": "Norway"}, {"start": 88, "end": 93, "probability": 0.9522, "type": "Place", "normalized_text": "Sweden"}, {"start": 100, "end": 106, "probability": 0.9418, "type": "Place", "normalized_text": "Germany"}, {"start": 159, "end": 160, "probability": 0.5138, "type": "Other", "normalized_text": "HL"}, {"start": 169, "end": 174, "probability": 0.4754, "type": "Other", "normalized_text": "ISHL22"}], "mentions": [{"start": 176, "end": 190, "username": "RutgersCancer", "id": "2802993134"}], "urls": [{"start": 191, "end": 214, "url": "https://t.co/hO1RuYiJfR", "expanded_url": "https://twitter.com/DrRaulCordoba/status/1584184005993250818", "display_url": "twitter.com/DrRaulCordoba/\u2026"}]}, "source": "Twitter for iPhone", "text": "Great presentations w/ representation from around the globe (Brazil, Spain, US, Norway, Sweden, and Germany) all on the topic of improving outcomes for older #HL pts!\n\n#ISHL22 @RutgersCancer https://t.co/hO1RuYiJfR", "id": "1584231450236182529", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1584184005993250818"}], "edit_history_tweet_ids": ["1584231450236182529"], "conversation_id": "1584231450236182529"}, {"created_at": "2022-10-23T17:03:20.000Z", "author_id": "719175246050410496", "in_reply_to_user_id": "1582593798", "source": "Twitter for iPhone", "text": "@lymphomahub @draevans @RutgersCancer @DrAEvens\n\nWeird spelling of the last name (Evens with an \u201ce\u201d)!", "entities": {"mentions": [{"start": 0, "end": 12, "username": "lymphomahub", "id": "1582593798"}, {"start": 13, "end": 22, "username": "draevans", "id": "18993076"}, {"start": 23, "end": 37, "username": "RutgersCancer", "id": "2802993134"}, {"start": 38, "end": 47, "username": "DrAEvens", "id": "719175246050410496"}]}, "id": "1584228996283125761", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1584166776967168005"}], "edit_history_tweet_ids": ["1584228996283125761"], "conversation_id": "1584166776967168005"}, {"created_at": "2022-10-23T14:55:01.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 88, "end": 95, "tag": "ISHL22"}, {"start": 198, "end": 201, "tag": "HL"}, {"start": 212, "end": 221, "tag": "geriheme"}, {"start": 222, "end": 230, "tag": "gerionc"}], "annotations": [{"start": 89, "end": 94, "probability": 0.6242, "type": "Other", "normalized_text": "ISHL22"}, {"start": 96, "end": 99, "probability": 0.6558, "type": "Other", "normalized_text": "GHSG"}, {"start": 199, "end": 200, "probability": 0.6027, "type": "Other", "normalized_text": "HL"}, {"start": 213, "end": 220, "probability": 0.753, "type": "Other", "normalized_text": "geriheme"}, {"start": 223, "end": 229, "probability": 0.6906, "type": "Other", "normalized_text": "gerionc"}], "mentions": [{"start": 9, "end": 23, "username": "DrRaulCordoba", "id": "1697360292"}, {"start": 232, "end": 246, "username": "RutgersCancer", "id": "2802993134"}, {"start": 247, "end": 259, "username": "RWJBarnabas", "id": "45596617"}], "urls": [{"start": 260, "end": 283, "url": "https://t.co/hO1RuYiJfR", "expanded_url": "https://twitter.com/DrRaulCordoba/status/1584184005993250818", "display_url": "twitter.com/DrRaulCordoba/\u2026"}]}, "source": "Twitter for iPhone", "text": "\ud83d\ude4c Thanks @DrRaulCordoba; it was great to co-chair the session with you!\n \nAnd thanks to #ISHL22 GHSG for highlighting the improving (outcomes) yet continued heterogeneity &amp; unmet need for older #HL patients. #geriheme #gerionc\n\n@RutgersCancer @RWJBarnabas https://t.co/hO1RuYiJfR", "id": "1584196702168227845", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1584184005993250818"}], "edit_history_tweet_ids": ["1584196702168227845"], "conversation_id": "1584196702168227845"}, {"created_at": "2022-10-23T08:57:03.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 47, "end": 58, "probability": 0.6752, "type": "Place", "normalized_text": "Chicago city"}], "mentions": [{"start": 18, "end": 30, "username": "SoniSmithMD", "id": "1134857587348967425"}], "urls": [{"start": 80, "end": 103, "url": "https://t.co/rEV2rEMnE2", "expanded_url": "https://twitter.com/SoniSmithMD/status/1584027942807478273", "display_url": "twitter.com/SoniSmithMD/st\u2026"}]}, "source": "Twitter for iPhone", "text": "And senior author @SoniSmithMD; it was a great Chicago city-wide collaboration! https://t.co/rEV2rEMnE2", "id": "1584106616919842816", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1584027942807478273"}], "edit_history_tweet_ids": ["1584106616919842816"], "conversation_id": "1584106616919842816"}, {"created_at": "2022-10-22T18:18:09.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 0, "end": 21, "tag": "SharedDecisionMaking"}], "urls": [{"start": 22, "end": 45, "url": "https://t.co/3HGkjwcaC1", "expanded_url": "https://twitter.com/graham74GC/status/1583818319781834754", "display_url": "twitter.com/graham74GC/sta\u2026"}]}, "source": "Twitter for iPhone", "text": "#SharedDecisionMaking https://t.co/3HGkjwcaC1", "id": "1583885436245536768", "lang": "qht", "referenced_tweets": [{"type": "quoted", "id": "1583818319781834754"}], "edit_history_tweet_ids": ["1583885436245536768"], "conversation_id": "1583885436245536768"}, {"created_at": "2022-10-22T18:12:42.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 124, "end": 131, "tag": "ISHL12"}], "annotations": [{"start": 125, "end": 130, "probability": 0.6385, "type": "Other", "normalized_text": "ISHL12"}], "mentions": [{"start": 92, "end": 103, "username": "graham74GC", "id": "2239893372"}], "urls": [{"start": 132, "end": 155, "url": "https://t.co/yWgdRGpJhj", "expanded_url": "https://twitter.com/Dr_Daniel_Molin/status/1583777853975384064", "display_url": "twitter.com/Dr_Daniel_Moli\u2026"}]}, "source": "Twitter for iPhone", "text": "That basically summarizes all of my key points for the talk planned tomorrow. \n\nSounds like @graham74GC did a bang up job.  #ISHL12 https://t.co/yWgdRGpJhj", "id": "1583884061633748992", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1583777853975384064"}], "edit_history_tweet_ids": ["1583884061633748992"], "conversation_id": "1583884061633748992"}, {"created_at": "2022-10-22T17:00:18.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 26, "end": 30, "probability": 0.4112, "type": "Other", "normalized_text": "RAPID"}], "mentions": [{"start": 3, "end": 14, "username": "graham74GC", "id": "2239893372"}, {"start": 115, "end": 128, "username": "DavidJCutter", "id": "382175232"}]}, "source": "Twitter for iPhone", "text": "RT @graham74GC: Hoppe: in RAPID, 54% pts predicted to have gtr heart disease risk from anthracycline than from RT (@DavidJCutter  et al). B\u2026", "id": "1583865843229675520", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1583804739501760512"}], "edit_history_tweet_ids": ["1583865843229675520"], "conversation_id": "1583865843229675520"}, {"created_at": "2022-10-22T12:43:01.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 21, "end": 27, "probability": 0.4397, "type": "Person", "normalized_text": "Radford"}, {"start": 65, "end": 69, "probability": 0.4007, "type": "Organization", "normalized_text": "RADAR"}, {"start": 87, "end": 90, "probability": 0.406, "type": "Other", "normalized_text": "ABVD"}, {"start": 103, "end": 105, "probability": 0.3385, "type": "Organization", "normalized_text": "AVD"}], "mentions": [{"start": 3, "end": 14, "username": "graham74GC", "id": "2239893372"}]}, "source": "Twitter for iPhone", "text": "RT @graham74GC: Prof Radford presenting the currently recruiting RADAR study comparing ABVD based with AVD-BV based therapy in 1L early sta\u2026", "id": "1583801096341884928", "lang": "en", "referenced_tweets": [{"type": "retweeted", "id": "1583800544736337920"}], "edit_history_tweet_ids": ["1583801096341884928"], "conversation_id": "1583801096341884928"}, {"created_at": "2022-10-22T12:22:27.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 65, "end": 68, "tag": "HL"}, {"start": 148, "end": 155, "tag": "ISHL12"}], "annotations": [{"start": 30, "end": 37, "probability": 0.6948, "type": "Other", "normalized_text": "Dr Fossa"}, {"start": 66, "end": 67, "probability": 0.4356, "type": "Other", "normalized_text": "HL"}], "mentions": [{"start": 43, "end": 58, "username": "BroeckelmannPJ", "id": "1209011263"}], "urls": [{"start": 156, "end": 179, "url": "https://t.co/zmg1v1gllx", "expanded_url": "https://twitter.com/DrRaulCordoba/status/1583732811877744640", "display_url": "twitter.com/DrRaulCordoba/\u2026"}]}, "source": "Twitter for iPhone", "text": "Great session/workshop led by Dr Fossa and @BroeckelmannPJ older #HL.\n\nGood progress made on this topic in last 5-10 years; much more work to do! \n\n#ISHL12 https://t.co/zmg1v1gllx", "id": "1583795918608162817", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1583732811877744640"}], "edit_history_tweet_ids": ["1583795918608162817"], "conversation_id": "1583795918608162817"}, {"created_at": "2022-10-21T20:28:40.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 13, "end": 20, "tag": "ISHL12"}], "mentions": [{"start": 0, "end": 12, "username": "GuiperiniMD", "id": "1294745239656202240"}], "urls": [{"start": 21, "end": 44, "url": "https://t.co/d0a9pXIsd5", "expanded_url": "https://twitter.com/DrAEvens/status/1583555891797708800/photo/1", "display_url": "pic.twitter.com/d0a9pXIsd5", "media_key": "3_1583555882243203083"}]}, "in_reply_to_user_id": "1294745239656202240", "source": "Twitter for iPhone", "text": "@GuiperiniMD #ISHL12 https://t.co/d0a9pXIsd5", "id": "1583555891797708800", "lang": "qme", "referenced_tweets": [{"type": "replied_to", "id": "1583541143492386817"}], "edit_history_tweet_ids": ["1583555891797708800"], "conversation_id": "1583541143492386817"}, {"created_at": "2022-10-21T06:55:07.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 23, "end": 30, "tag": "ISHL22"}], "annotations": [{"start": 24, "end": 29, "probability": 0.8406, "type": "Other", "normalized_text": "ISHL22"}], "mentions": [{"start": 0, "end": 11, "username": "graham74GC", "id": "2239893372"}], "urls": [{"start": 38, "end": 61, "url": "https://t.co/diIOLRZpQR", "expanded_url": "https://twitter.com/IDdocAdi/status/1583191523805446144", "display_url": "twitter.com/IDdocAdi/statu\u2026"}]}, "in_reply_to_user_id": "2239893372", "source": "Twitter for iPhone", "text": "@graham74GC working on #ISHL22 talk?! https://t.co/diIOLRZpQR", "id": "1583351157543432192", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1583191523805446144"}], "edit_history_tweet_ids": ["1583351157543432192"], "conversation_id": "1583351157543432192"}, {"created_at": "2022-10-20T21:39:32.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 0, "end": 9, "tag": "CantWait"}], "urls": [{"start": 10, "end": 33, "url": "https://t.co/wCMB787QtM", "expanded_url": "https://twitter.com/BroeckelmannPJ/status/1583188799592747008", "display_url": "twitter.com/BroeckelmannPJ\u2026"}]}, "source": "Twitter for iPhone", "text": "#CantWait https://t.co/wCMB787QtM", "id": "1583211340444811270", "lang": "qht", "referenced_tweets": [{"type": "quoted", "id": "1583188799592747008"}], "edit_history_tweet_ids": ["1583211340444811270"], "conversation_id": "1583211340444811270"}, {"created_at": "2022-10-20T16:30:54.000Z", "author_id": "719175246050410496", "in_reply_to_user_id": "719175246050410496", "source": "Twitter for iPhone", "text": "*Nastoupil!\n\nhttps://t.co/fWoAmmNIjA", "entities": {"urls": [{"start": 13, "end": 36, "url": "https://t.co/fWoAmmNIjA", "expanded_url": "https://lymphoma.org/resources/educationresources/programs/edforum/", "display_url": "lymphoma.org/resources/educ\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1585675159574298625/-VHRZbRM?format=png&name=orig", "width": 524, "height": 287}, {"url": "https://pbs.twimg.com/news_img/1585675159574298625/-VHRZbRM?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "North American Educational Forum on Lymphoma", "description": "The North American Educational Forum on Lymphoma is the most comprehensive lymphoma-specific educational conference in North America.", "unwound_url": "https://lymphoma.org/resources/educationresources/programs/edforum/"}]}, "id": "1583133666946842632", "lang": "cs", "referenced_tweets": [{"type": "replied_to", "id": "1583133023092215809"}], "edit_history_tweet_ids": ["1583133666946842632"], "conversation_id": "1583133023092215809"}, {"created_at": "2022-10-20T16:28:20.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 167, "end": 176, "tag": "Lymphoma"}], "annotations": [{"start": 86, "end": 89, "probability": 0.3853, "type": "Other", "normalized_text": "Brem"}, {"start": 98, "end": 105, "probability": 0.382, "type": "Other", "normalized_text": "Nasoupil"}, {"start": 131, "end": 162, "probability": 0.7244, "type": "Other", "normalized_text": "North American Educational Forum"}, {"start": 168, "end": 175, "probability": 0.6034, "type": "Other", "normalized_text": "Lymphoma"}, {"start": 246, "end": 247, "probability": 0.7778, "type": "Place", "normalized_text": "US"}], "mentions": [{"start": 251, "end": 265, "username": "RutgersCancer", "id": "2802993134"}, {"start": 266, "end": 278, "username": "RWJBarnabas", "id": "45596617"}], "urls": [{"start": 279, "end": 302, "url": "https://t.co/bboC1bkUmI", "expanded_url": "https://twitter.com/DrLizBrem/status/1583120198789656577", "display_url": "twitter.com/DrLizBrem/stat\u2026"}]}, "source": "Twitter for iPhone", "text": "Very much looking to co-chairing this meeting/educational forum w/ 2 rising stars, Dr Brem and Dr Nasoupil.\ud83c\udf1f\ud83c\udf1f\n\nThis 2022 (virtual) North American Educational Forum on #Lymphoma will feature other top experts in the field.\n\nIt will be great; JOIN US!\n\n@RutgersCancer @RWJBarnabas https://t.co/bboC1bkUmI", "id": "1583133023092215809", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1583120198789656577"}], "edit_history_tweet_ids": ["1583133023092215809"], "conversation_id": "1583133023092215809"}, {"created_at": "2022-10-20T12:49:49.000Z", "author_id": "719175246050410496", "source": "Twitter for iPhone", "text": "Even more impressive given that @JoshAllenQB mid-play was pointing to @dawson_knox to take an in breaking route (as revealed on @KBBasement) as @gabedavis13_ in last year\u2018s playoff game. \n\nAmazing split second throw to the out and over the safety\u2019s fingertips. \u270b\ud83e\udd2f https://t.co/9YuXdpUCIl", "entities": {"mentions": [{"start": 32, "end": 44, "username": "JoshAllenQB", "id": "197974180"}, {"start": 70, "end": 82, "username": "dawson_knox", "id": "3042083863"}, {"start": 128, "end": 139, "username": "KBBasement", "id": "1544356128431247362"}, {"start": 144, "end": 157, "username": "gabedavis13_", "id": "2190505048"}], "urls": [{"start": 264, "end": 287, "url": "https://t.co/9YuXdpUCIl", "expanded_url": "https://twitter.com/insidetheNFL/status/1582822782672416769", "display_url": "twitter.com/insidetheNFL/s\u2026"}]}, "id": "1583078029391441925", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1582822782672416769"}], "edit_history_tweet_ids": ["1583078029391441925"], "conversation_id": "1583078029391441925"}], "includes": {"users": [{"id": "719175246050410496", "name": "Andrew M. Evens, DO, MBA, MSc", "username": "DrAEvens"}, {"id": "2212735524", "name": "chadi nabhan MD, MBA, FACP", "username": "chadinabhan"}, {"id": "854692626015993857", "name": "Aaron Goodman - \u201cPapa Heme\u201d", "username": "AaronGoodman33"}, {"id": "2802993134", "name": "RutgersCancerInstNJ", "username": "RutgersCancer"}, {"id": "244846617", "name": "Samia", "username": "SamiaHanna"}, {"id": "1582593798", "name": "Lymphoma Hub", "username": "lymphomahub"}, {"id": "1294745239656202240", "name": "Guilherme Perini, MD", "username": "GuiperiniMD"}, {"id": "2239893372", "name": "Graham Collins", "username": "graham74GC"}], "tweets": [{"created_at": "2022-12-09T20:00:49.000Z", "author_id": "2891662867", "entities": {"hashtags": [{"start": 17, "end": 23, "tag": "ASH22"}], "annotations": [{"start": 18, "end": 22, "probability": 0.6991, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 24, "end": 47, "url": "https://t.co/n0aInK50dO", "expanded_url": "https://twitter.com/JohnPLeonardMD/status/1601305890208063491/photo/1", "display_url": "pic.twitter.com/n0aInK50dO", "media_key": "3_1601305885355266049"}]}, "source": "Twitter for iPhone", "text": "Going unribboned #ASH22 https://t.co/n0aInK50dO", "id": "1601305890208063491", "lang": "en", "edit_history_tweet_ids": ["1601305890208063491"], "conversation_id": "1601305890208063491"}, {"created_at": "2022-12-09T16:02:31.000Z", "author_id": "2802993134", "entities": {"hashtags": [{"start": 47, "end": 53, "tag": "ASH22"}], "annotations": [{"start": 165, "end": 166, "probability": 0.723, "type": "Place", "normalized_text": "NJ"}, {"start": 194, "end": 220, "probability": 0.5331, "type": "Other", "normalized_text": "Comprehensive Cancer Center"}], "mentions": [{"start": 6, "end": 20, "username": "RutgersCancer", "id": "2802993134"}, {"start": 27, "end": 39, "username": "RWJBarnabas", "id": "45596617"}, {"start": 175, "end": 182, "username": "theNCI", "id": "38530021"}, {"start": 223, "end": 238, "username": "ASH_hematology", "id": "84072624"}, {"start": 239, "end": 249, "username": "DrMatasar", "id": "1307491056"}, {"start": 250, "end": 259, "username": "DrAEvens", "id": "719175246050410496"}], "urls": [{"start": 260, "end": 283, "url": "https://t.co/o4SUefBxbw", "expanded_url": "https://twitter.com/RutgersCancer/status/1601245918753325056/photo/1", "display_url": "pic.twitter.com/o4SUefBxbw", "media_key": "3_1601245916563922945"}]}, "source": "Hootsuite Inc.", "text": "Visit @RutgersCancer &amp; @RWJBarnabas during #ASH22 at booth 311 to meet our leaders and learn about the latest research advancements and current opportunities at NJ\u2019s only @theNCI-designated Comprehensive Cancer Center! @ASH_hematology @DrMatasar @DrAEvens https://t.co/o4SUefBxbw", "id": "1601245918753325056", "lang": "en", "edit_history_tweet_ids": ["1601245918753325056"], "conversation_id": "1601245918753325056"}, {"created_at": "2022-12-09T01:55:34.000Z", "author_id": "712479641504579584", "source": "Twitter for iPhone", "text": "Learnt all my malignant hem from this dream team and @ligordon @LurieCancer https://t.co/MYagQTWYCt", "entities": {"mentions": [{"start": 53, "end": 62, "username": "ligordon", "id": "30854886"}, {"start": 63, "end": 75, "username": "LurieCancer", "id": "1006862749"}], "urls": [{"start": 76, "end": 99, "url": "https://t.co/MYagQTWYCt", "expanded_url": "https://twitter.com/martintallman/status/1600579740351479828", "display_url": "twitter.com/martintallman/\u2026"}]}, "id": "1601032778182668288", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600579740351479828"}], "edit_history_tweet_ids": ["1601032778182668288"], "conversation_id": "1601032778182668288"}, {"created_at": "2022-12-08T22:37:57.000Z", "author_id": "2212735524", "in_reply_to_user_id": "719175246050410496", "source": "Twitter for iPhone", "text": "@DrAEvens @AaronGoodman33 Looks like he cut his hair short @AleckAmalia", "entities": {"mentions": [{"start": 0, "end": 9, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 10, "end": 25, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 59, "end": 71, "username": "AleckAmalia", "id": "1331336294828437504"}]}, "id": "1600983045577678848", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600982180507049984"}], "edit_history_tweet_ids": ["1600983045577678848"], "conversation_id": "1600982180507049984"}, {"created_at": "2022-12-08T22:36:13.000Z", "author_id": "854692626015993857", "entities": {"annotations": [{"start": 39, "end": 46, "probability": 0.435, "type": "Other", "normalized_text": "Dr Evens"}], "urls": [{"start": 59, "end": 82, "url": "https://t.co/376FQxGYSb", "expanded_url": "https://twitter.com/draevens/status/1600982180507049984", "display_url": "twitter.com/draevens/statu\u2026"}]}, "source": "Twitter for iPhone", "text": "I\u2019m here!  Great to meet the legendary Dr Evens in person. https://t.co/376FQxGYSb", "id": "1600982610347720705", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600982180507049984"}], "edit_history_tweet_ids": ["1600982610347720705"], "conversation_id": "1600982610347720705"}, {"created_at": "2022-12-08T17:11:30.000Z", "author_id": "854692626015993857", "in_reply_to_user_id": "719175246050410496", "source": "Twitter for iPhone", "text": "@DrAEvens @chadinabhan Jealous?", "entities": {"mentions": [{"start": 0, "end": 9, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 10, "end": 22, "username": "chadinabhan", "id": "2212735524"}]}, "id": "1600900892298907648", "lang": "fr", "referenced_tweets": [{"type": "replied_to", "id": "1600893983668207617"}], "edit_history_tweet_ids": ["1600900892298907648"], "conversation_id": "1600893983668207617"}, {"created_at": "2022-12-07T21:30:00.000Z", "author_id": "390846254", "entities": {"hashtags": [{"start": 32, "end": 38, "tag": "ASH22"}], "annotations": [{"start": 21, "end": 26, "probability": 0.5138, "type": "Other", "normalized_text": "RehASH"}, {"start": 33, "end": 37, "probability": 0.5251, "type": "Other", "normalized_text": "ASH22"}], "mentions": [{"start": 136, "end": 147, "username": "jmikhaelmd", "id": "2377190652"}, {"start": 248, "end": 263, "username": "ASH_hematology", "id": "84072624"}], "urls": [{"start": 265, "end": 288, "url": "https://t.co/6u2yqcHwl8", "expanded_url": "https://twitter.com/MikkaelSekeres/status/1600603559149637650/photo/1", "display_url": "pic.twitter.com/6u2yqcHwl8", "media_key": "3_1600594274210365440"}]}, "source": "Twitter Web App", "text": "Time for a brief ASH RehASH for #ASH22...One of my favorite memories has to be the annual ribbon competition with the always victorious @jmikhaelmd, here modeling his famous ASH sash! Here's to our incoming Treasurer and the lengths he will go for @ASH_hematology! https://t.co/6u2yqcHwl8", "id": "1600603559149637650", "lang": "en", "edit_history_tweet_ids": ["1600603559149637650"], "conversation_id": "1600603559149637650"}, {"created_at": "2022-12-08T21:57:42.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 162, "end": 168, "tag": "ASH22"}], "annotations": [{"start": 35, "end": 38, "probability": 0.9741, "type": "Place", "normalized_text": "NOLA"}, {"start": 44, "end": 53, "probability": 0.9694, "type": "Place", "normalized_text": "New Jersey"}, {"start": 163, "end": 167, "probability": 0.4322, "type": "Other", "normalized_text": "ASH22"}], "mentions": [{"start": 55, "end": 66, "username": "EWRairport", "id": "234423098"}], "urls": [{"start": 169, "end": 192, "url": "https://t.co/RyjxBvaP12", "expanded_url": "https://twitter.com/DrAEvens/status/1600972915096563712/photo/1", "display_url": "pic.twitter.com/RyjxBvaP12", "media_key": "3_1600972764797616128"}, {"start": 169, "end": 192, "url": "https://t.co/RyjxBvaP12", "expanded_url": "https://twitter.com/DrAEvens/status/1600972915096563712/photo/1", "display_url": "pic.twitter.com/RyjxBvaP12", "media_key": "3_1600972764810301440"}, {"start": 169, "end": 192, "url": "https://t.co/RyjxBvaP12", "expanded_url": "https://twitter.com/DrAEvens/status/1600972915096563712/photo/1", "display_url": "pic.twitter.com/RyjxBvaP12", "media_key": "3_1600972764814495756"}, {"start": 193, "end": 216, "url": "https://t.co/tyEHT8U5hd", "expanded_url": "https://twitter.com/ash_hematology/status/1600856480026075136", "display_url": "twitter.com/ash_hematology\u2026"}]}, "source": "Twitter for iPhone", "text": "A tad delayed, but landing soon in NOLA via New Jersey @EWRairport. \ud83d\udeeb\ud83d\udeec\n\nAlready connected with 10+ people on the plane I\u2019ve not seen in years.\n\nSee y\u2019all soon!   #ASH22 https://t.co/RyjxBvaP12 https://t.co/tyEHT8U5hd", "id": "1600972915096563712", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600856480026075136"}], "edit_history_tweet_ids": ["1600972915096563712"], "conversation_id": "1600972915096563712"}, {"created_at": "2022-12-08T14:15:01.000Z", "author_id": "84072624", "entities": {"hashtags": [{"start": 63, "end": 69, "tag": "ASH22"}], "annotations": [{"start": 0, "end": 10, "probability": 0.9784, "type": "Place", "normalized_text": "New Orleans"}, {"start": 64, "end": 68, "probability": 0.3733, "type": "Other", "normalized_text": "ASH22"}, {"start": 183, "end": 188, "probability": 0.9827, "type": "Place", "normalized_text": "Denver"}, {"start": 202, "end": 205, "probability": 0.9775, "type": "Place", "normalized_text": "NOLA"}, {"start": 223, "end": 228, "probability": 0.6175, "type": "Place", "normalized_text": "Foshan"}], "urls": [{"start": 277, "end": 300, "url": "https://t.co/onkjS3hLVE", "expanded_url": "https://twitter.com/ASH_hematology/status/1600856480026075136/photo/1", "display_url": "pic.twitter.com/onkjS3hLVE", "media_key": "3_1600856477333422081"}]}, "source": "Loomly", "text": "New Orleans, here we come\u2026 \ud83d\udeeb \ud83e\uddf3 Show us how you\u2019re traveling to #ASH22 &amp; reply with a photo of your journey \ud83d\udcf8 Whether you\u2019re commuting from your kitchen to the couch, driving from Denver to downtown NOLA, or flying from Foshan to the French Quarter \u2013 we want to see it all! https://t.co/onkjS3hLVE", "id": "1600856480026075136", "lang": "en", "edit_history_tweet_ids": ["1600856480026075136"], "conversation_id": "1600856480026075136"}, {"created_at": "2022-12-08T17:28:29.000Z", "author_id": "719175246050410496", "source": "Twitter Web App", "text": "Important work!\n\nIt is hard research to do, but we need to continue to study the \"lifelong time horizon\" for pts, esp w/ curable diseases or long natural history.\n\nNeed to evaluate associated impact varied therapeutics have via post-acute (1-10 yr post Rx) &amp; late effects lens'.\ud83d\udd2d https://t.co/N9aQUTQCAF", "entities": {"urls": [{"start": 284, "end": 307, "url": "https://t.co/N9aQUTQCAF", "expanded_url": "https://twitter.com/chanyooncheah/status/1600900928961642497", "display_url": "twitter.com/chanyooncheah/\u2026"}]}, "id": "1600905163576725505", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600900928961642497"}], "edit_history_tweet_ids": ["1600905163576725505"], "conversation_id": "1600905163576725505"}, {"created_at": "2022-12-08T17:11:39.000Z", "author_id": "245607411", "entities": {"hashtags": [{"start": 233, "end": 239, "tag": "ASH22"}, {"start": 240, "end": 246, "tag": "lymSM"}], "annotations": [{"start": 0, "end": 4, "probability": 0.3609, "type": "Place", "normalized_text": "Desai"}, {"start": 21, "end": 26, "probability": 0.3953, "type": "Other", "normalized_text": "Cerhan"}], "mentions": [{"start": 7, "end": 19, "username": "MaurerStats", "id": "2233351410"}], "urls": [{"start": 247, "end": 270, "url": "https://t.co/NsXof8MitD", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper165207.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 905. Outcomes Research\u2014Lymphoid Malignancie s: Outcomes in Lymphoma Hematology Disease Topics & Pathways: Research, Clinical Research, survivorship 1 University of Minnesota, Division of Hematology Oncology Transplantation, Minneapolis, MN 2 Division of Hematology, Mayo Clinic, Rochester, MN 3 Department of Quantitative Health Sciences Research, Mayo Clinic, Rochester, MN 4 Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 5", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper165207.html"}, {"start": 271, "end": 294, "url": "https://t.co/lMLCroAddN", "expanded_url": "https://twitter.com/chanyooncheah/status/1600900928961642497/photo/1", "display_url": "pic.twitter.com/lMLCroAddN", "media_key": "3_1600899570992545792"}]}, "source": "Twitter Web App", "text": "Desai, @MaurerStats (Cerhan): MER dataset on second primary malignancies in lymphoma survivors\n - cum incidence SPM at 10y 12% (half skin cancer)\n - 5 fold \u2b06\ufe0f MDS/AML (absolute risk low 0.7%)\nencourage sun safe behavior, skin checks\n#ASH22 #lymSM\nhttps://t.co/NsXof8MitD https://t.co/lMLCroAddN", "id": "1600900928961642497", "lang": "en", "edit_history_tweet_ids": ["1600900928961642497"], "conversation_id": "1600900928961642497"}, {"created_at": "2022-12-08T14:49:52.000Z", "author_id": "2212735524", "entities": {"hashtags": [{"start": 4, "end": 25, "tag": "HealthcareUnfiltered"}, {"start": 123, "end": 129, "tag": "ASH22"}], "annotations": [{"start": 5, "end": 24, "probability": 0.6204, "type": "Other", "normalized_text": "HealthcareUnfiltered"}, {"start": 55, "end": 58, "probability": 0.4415, "type": "Organization", "normalized_text": "PAPA"}, {"start": 124, "end": 128, "probability": 0.6857, "type": "Other", "normalized_text": "ASH22"}], "mentions": [{"start": 60, "end": 75, "username": "AaronGoodman33", "id": "854692626015993857"}, {"start": 100, "end": 108, "username": "Nirvana", "id": "68412310"}], "urls": [{"start": 281, "end": 304, "url": "https://t.co/EhTVwqiTG4", "expanded_url": "https://twitter.com/chadinabhan/status/1600865250374361089/video/1", "display_url": "pic.twitter.com/EhTVwqiTG4", "media_key": "7_1600865073060356097"}]}, "source": "Twitter for iPhone", "text": "The #HealthcareUnfiltered podcast crashed the party at PAPA @AaronGoodman33 house 2 talk guitar and @Nirvana \nThere was NO #ASH22 talk in this 7 mins video, but it\u2019s the one U must watch on your way 2 the meeting.\n\nUnedited, unfiltered, watch as things evolved.\n\nAnd yes: he sings https://t.co/EhTVwqiTG4", "id": "1600865250374361089", "lang": "en", "edit_history_tweet_ids": ["1600865250374361089"], "conversation_id": "1600865250374361089"}, {"created_at": "2022-12-08T16:06:21.000Z", "author_id": "1294745239656202240", "in_reply_to_user_id": "719175246050410496", "entities": {"annotations": [{"start": 184, "end": 187, "probability": 0.8799, "type": "Other", "normalized_text": "HGBL"}, {"start": 197, "end": 208, "probability": 0.4862, "type": "Other", "normalized_text": "pathologists"}], "mentions": [{"start": 0, "end": 9, "username": "DrAEvens", "id": "719175246050410496"}]}, "source": "Twitter for Android", "text": "@DrAEvens Great review BTW.\n\nBut I dont believe we can base our decisions solely if the pathologist thinks this is a large x intermediate cells.\n\nDo you have data on % of agreement on HGBL between pathologists?", "id": "1600884497314381824", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600862571162394624"}], "edit_history_tweet_ids": ["1600884497314381824"], "conversation_id": "1600862571162394624"}, {"created_at": "2022-12-08T12:29:23.000Z", "author_id": "2739065578", "entities": {"hashtags": [{"start": 52, "end": 58, "tag": "ASH22"}], "annotations": [{"start": 20, "end": 30, "probability": 0.9909, "type": "Place", "normalized_text": "New Orleans"}, {"start": 101, "end": 103, "probability": 0.3377, "type": "Other", "normalized_text": "MSY"}, {"start": 164, "end": 167, "probability": 0.9675, "type": "Place", "normalized_text": "NOLA"}, {"start": 187, "end": 198, "probability": 0.6485, "type": "Person", "normalized_text": "John Moisant"}, {"start": 214, "end": 223, "probability": 0.3933, "type": "Place", "normalized_text": "Bl\u00e9riot XI"}, {"start": 264, "end": 282, "probability": 0.5901, "type": "Other", "normalized_text": "Moisant Stock Yards"}], "mentions": [{"start": 36, "end": 51, "username": "ASH_hematology", "id": "84072624"}], "urls": [{"start": 285, "end": 308, "url": "https://t.co/jBRKoxVGGS", "expanded_url": "https://twitter.com/DavidSteensma/status/1600829896346910720/photo/1", "display_url": "pic.twitter.com/jBRKoxVGGS", "media_key": "3_1600829865212665860"}, {"start": 285, "end": 308, "url": "https://t.co/jBRKoxVGGS", "expanded_url": "https://twitter.com/DavidSteensma/status/1600829896346910720/photo/1", "display_url": "pic.twitter.com/jBRKoxVGGS", "media_key": "3_1600829865204277249"}]}, "source": "Twitter for iPhone", "text": "If you\u2019re flying to New Orleans for @ASH_hematology #ASH22 and wondering why your plane ticket says \u201cMSY\u201d, it\u2019s because in 1910 long before there was an airport in NOLA, this daredevil - John Moisant - crashed his Bl\u00e9riot XI plane nearby &amp; the site was named \u201cMoisant Stock Yards\u201d https://t.co/jBRKoxVGGS", "id": "1600829896346910720", "lang": "en", "edit_history_tweet_ids": ["1600829896346910720"], "conversation_id": "1600829896346910720"}, {"created_at": "2022-12-08T14:19:18.000Z", "author_id": "25084916", "entities": {"hashtags": [{"start": 34, "end": 46, "tag": "ProBowlVote"}, {"start": 68, "end": 80, "tag": "ProBowlVote"}, {"start": 100, "end": 112, "tag": "ProBowlVote"}, {"start": 127, "end": 139, "tag": "ProBowlVote"}, {"start": 156, "end": 168, "tag": "ProBowlVote"}, {"start": 186, "end": 198, "tag": "ProBowlVote"}], "annotations": [{"start": 22, "end": 25, "probability": 0.5479, "type": "Other", "normalized_text": "Bowl"}, {"start": 35, "end": 45, "probability": 0.5783, "type": "Other", "normalized_text": "ProBowlVote"}, {"start": 69, "end": 79, "probability": 0.4823, "type": "Other", "normalized_text": "ProBowlVote"}, {"start": 101, "end": 111, "probability": 0.5064, "type": "Other", "normalized_text": "ProBowlVote"}, {"start": 128, "end": 138, "probability": 0.5048, "type": "Other", "normalized_text": "ProBowlVote"}, {"start": 157, "end": 167, "probability": 0.4635, "type": "Other", "normalized_text": "ProBowlVote"}, {"start": 187, "end": 197, "probability": 0.5622, "type": "Other", "normalized_text": "ProBowlVote"}], "mentions": [{"start": 49, "end": 64, "username": "MatthewMilanoo", "id": "287887835"}, {"start": 83, "end": 98, "username": "maine_savage23", "id": "506679880"}, {"start": 115, "end": 125, "username": "J_poyer21", "id": "155682067"}, {"start": 142, "end": 154, "username": "Edoliver_11", "id": "3266389416"}, {"start": 171, "end": 184, "username": "gregrousseau", "id": "2924676692"}, {"start": 201, "end": 210, "username": "Taronj11", "id": "349388767"}], "urls": [{"start": 211, "end": 234, "url": "https://t.co/vOT8ihiyV5", "expanded_url": "https://twitter.com/BuffaloBills/status/1600857555198128128/photo/1", "display_url": "pic.twitter.com/vOT8ihiyV5", "media_key": "3_1600857549649092608"}]}, "in_reply_to_user_id": "25084916", "source": "Twitter for iPhone", "text": "1\ufe0f\u20e3 RETWEET = 1\ufe0f\u20e3 Pro Bowl Vote!\n\n#ProBowlVote | @MatthewMilanoo\n  \n#ProBowlVote | @Maine_Savage23\n\n#ProBowlVote | @J_Poyer21\n\n#ProBowlVote | @EdOliver_11\n\n#ProBowlVote | @GregRousseau\n\n#ProBowlVote | @Taronj11 https://t.co/vOT8ihiyV5", "id": "1600857555198128128", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600857438407868417"}], "edit_history_tweet_ids": ["1600857555198128128"], "conversation_id": "1600857438407868417"}, {"created_at": "2022-12-08T14:18:50.000Z", "author_id": "25084916", "entities": {"hashtags": [{"start": 77, "end": 89, "tag": "ProBowlVote"}, {"start": 107, "end": 119, "tag": "ProBowlVote"}, {"start": 138, "end": 150, "tag": "ProBowlVote"}, {"start": 168, "end": 180, "tag": "ProBowlVote"}, {"start": 197, "end": 209, "tag": "ProBowlVote"}, {"start": 225, "end": 237, "tag": "ProBowlVote"}], "annotations": [{"start": 139, "end": 149, "probability": 0.4695, "type": "Other", "normalized_text": "ProBowlVote"}, {"start": 198, "end": 208, "probability": 0.5123, "type": "Other", "normalized_text": "ProBowlVote"}], "mentions": [{"start": 92, "end": 104, "username": "JoshAllenQB", "id": "197974180"}, {"start": 122, "end": 134, "username": "stefondiggs", "id": "2545680959"}, {"start": 153, "end": 166, "username": "gabedavis13_", "id": "2190505048"}, {"start": 183, "end": 195, "username": "dawson_knox", "id": "3042083863"}, {"start": 212, "end": 223, "username": "DDawkins66", "id": "2178328028"}, {"start": 240, "end": 252, "username": "mithenmor60", "id": "1491442587131125767"}], "urls": [{"start": 253, "end": 276, "url": "https://t.co/6Z0UVD9eNw", "expanded_url": "https://twitter.com/BuffaloBills/status/1600857438407868417/photo/1", "display_url": "pic.twitter.com/6Z0UVD9eNw", "media_key": "3_1600857431885635586"}]}, "source": "Twitter for iPhone", "text": "Send our Bills to the 2023 Pro Bowl Games!\n\n1\ufe0f\u20e3 RETWEET = 1\ufe0f\u20e3 Pro Bowl Vote\n\n#ProBowlVote | @JoshAllenQB\n \n#ProBowlVote | @StefonDiggs\n  \n#ProBowlVote | @GabeDavis13_\n\n#ProBowlVote | @Dawson_Knox\n\n#ProBowlVote | @DDawkins66\n\n#ProBowlVote | @MithenMor60 https://t.co/6Z0UVD9eNw", "id": "1600857438407868417", "lang": "en", "edit_history_tweet_ids": ["1600857438407868417"], "conversation_id": "1600857438407868417"}, {"created_at": "2022-12-07T17:49:41.000Z", "author_id": "14062554", "entities": {"hashtags": [{"start": 261, "end": 267, "tag": "ASH22"}, {"start": 268, "end": 278, "tag": "EndCancer"}], "annotations": [{"start": 1, "end": 5, "probability": 0.5894, "type": "Person", "normalized_text": "Chris"}, {"start": 146, "end": 153, "probability": 0.3829, "type": "Other", "normalized_text": "Anderson"}, {"start": 169, "end": 173, "probability": 0.4323, "type": "Person", "normalized_text": "Peter"}], "mentions": [{"start": 193, "end": 209, "username": "ChrisRFlowersMD", "id": "3401391461"}, {"start": 235, "end": 244, "username": "ppisters", "id": "217997153"}, {"start": 245, "end": 260, "username": "ASH_hematology", "id": "84072624"}], "urls": [{"start": 211, "end": 234, "url": "https://t.co/kmGmKRuaiG", "expanded_url": "https://fal.cn/3uflX", "display_url": "fal.cn/3uflX", "images": [{"url": "https://pbs.twimg.com/news_img/1600548122035462146/fym0Teyd?format=jpg&name=orig", "width": 1376, "height": 774}, {"url": "https://pbs.twimg.com/news_img/1600548122035462146/fym0Teyd?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "MD Anderson\u2019s Christopher Flowers, M.D., receives ASH Mentor Award", "description": "Christopher Flowers, M.D., division head ad interim of Cancer Medicine and chair of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, has received a 2022 ASH Mentor Award from the American Society of Hematology in acknowledgement of his career-long commitment to mentoring.", "unwound_url": "https://www.mdanderson.org/newsroom/christopher-flowers-m-d-receives-ash-mentor-award.h00-159545268.html?cmpid=twitter"}]}, "source": "Brandwatch", "text": "\u201cChris\u2019 dedication to guiding the next generation of health care leaders is a testament to his generosity and passion for ending cancer,\u201d says MD Anderson President Dr. Peter WT Pisters of our @ChrisRFlowersMD: https://t.co/kmGmKRuaiG @PPisters @ASH_Hematology #ASH22 #EndCancer", "id": "1600548111797174272", "lang": "en", "edit_history_tweet_ids": ["1600548111797174272"], "conversation_id": "1600548111797174272"}, {"created_at": "2022-12-08T14:13:18.000Z", "author_id": "1255157925447860224", "in_reply_to_user_id": "1227696127216095232", "source": "Twitter for Android", "text": "@emmauible @dstarczynowski @TheDoctorIsVin @calliecoombsmd @DrLizBrem @PallawiTorkaMD @KaraKellyMD @DrAEvens @BuffaloBills @RoswellPark @OCHBuffalo @shengfcai @DrCraigSauter @KlcoLab @CourtneeClough @DrLMJonesDO @tchlon @jenniyeu May have to take you or @calliecoombsmd up on your offers... Not sure I can fit another shirt in my suitcase \ud83d\ude2c haha", "entities": {"mentions": [{"start": 0, "end": 10, "username": "emmauible", "id": "1227696127216095232"}, {"start": 11, "end": 26, "username": "dstarczynowski", "id": "1029649538"}, {"start": 27, "end": 42, "username": "TheDoctorIsVin", "id": "2919951234"}, {"start": 43, "end": 58, "username": "calliecoombsmd", "id": "896161000562536448"}, {"start": 59, "end": 69, "username": "DrLizBrem", "id": "4476878772"}, {"start": 70, "end": 85, "username": "PallawiTorkaMD", "id": "918471705408016384"}, {"start": 86, "end": 98, "username": "KaraKellyMD", "id": "1532109206953906180"}, {"start": 99, "end": 108, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 109, "end": 122, "username": "BuffaloBills", "id": "25084916"}, {"start": 123, "end": 135, "username": "RoswellPark", "id": "16044589"}, {"start": 136, "end": 147, "username": "OCHBuffalo", "id": "245900695"}, {"start": 148, "end": 158, "username": "shengfcai", "id": "2255835829"}, {"start": 159, "end": 173, "username": "DrCraigSauter", "id": "1466406257720446987"}, {"start": 174, "end": 182, "username": "KlcoLab", "id": "1395508263123312642"}, {"start": 183, "end": 198, "username": "CourtneeClough", "id": "1321583662345801728"}, {"start": 199, "end": 211, "username": "DrLMJonesDO", "id": "1406279214056329225"}, {"start": 212, "end": 219, "username": "tchlon", "id": "15342555"}, {"start": 220, "end": 229, "username": "jenniyeu", "id": "1500577711831629829"}, {"start": 254, "end": 269, "username": "calliecoombsmd", "id": "896161000562536448"}]}, "id": "1600856044204625920", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600598769250467840"}], "edit_history_tweet_ids": ["1600856044204625920"], "conversation_id": "1600269314971443200"}, {"created_at": "2022-12-08T14:31:36.000Z", "author_id": "1294745239656202240", "in_reply_to_user_id": "2212735524", "entities": {"annotations": [{"start": 77, "end": 79, "probability": 0.4146, "type": "Other", "normalized_text": "MYC"}, {"start": 82, "end": 86, "probability": 0.6277, "type": "Other", "normalized_text": "DLBCL"}, {"start": 131, "end": 133, "probability": 0.4108, "type": "Organization", "normalized_text": "MYC"}, {"start": 136, "end": 139, "probability": 0.685, "type": "Other", "normalized_text": "HGBL"}, {"start": 174, "end": 178, "probability": 0.7017, "type": "Other", "normalized_text": "DLBCL"}, {"start": 184, "end": 187, "probability": 0.7678, "type": "Other", "normalized_text": "HGBL"}], "mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 23, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 24, "end": 33, "username": "DrAEvens", "id": "719175246050410496"}]}, "source": "Twitter for Android", "text": "@chadinabhan @ASkarbnik @DrAEvens Just to put some \ud83d\udd25\ud83d\udd25\n\nHow come we not treat MYC+ DLBCL with alternative treatments but we do with MYC+ HGBL when the criteria for separating DLBCL and HGBL is sometimes so shaddy?", "id": "1600860652951568384", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600701514871283715"}], "edit_history_tweet_ids": ["1600860652951568384"], "conversation_id": "1600685288430268416"}, {"created_at": "2022-12-08T03:50:29.000Z", "author_id": "3076847052", "entities": {"hashtags": [{"start": 39, "end": 45, "tag": "ASH22"}, {"start": 46, "end": 54, "tag": "pregame"}], "annotations": [{"start": 40, "end": 44, "probability": 0.7077, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 60, "end": 83, "url": "https://t.co/0L7eWzZPTR", "expanded_url": "https://twitter.com/sanamloghavi/status/1600699309455863808/photo/1", "display_url": "pic.twitter.com/0L7eWzZPTR", "media_key": "3_1600699300249583617"}]}, "source": "Twitter for iPhone", "text": "My commitment to this organ is real!!! #ASH22 #pregame  \ud83e\ude78 \ud83e\uddb4 https://t.co/0L7eWzZPTR", "id": "1600699309455863808", "lang": "en", "edit_history_tweet_ids": ["1600699309455863808"], "conversation_id": "1600699309455863808"}, {"created_at": "2022-12-07T13:30:22.000Z", "author_id": "2802993134", "entities": {"hashtags": [{"start": 16, "end": 22, "tag": "ASH22"}, {"start": 150, "end": 158, "tag": "Hodgkin"}, {"start": 254, "end": 260, "tag": "lymsm"}], "annotations": [{"start": 17, "end": 21, "probability": 0.6758, "type": "Other", "normalized_text": "ASH22"}, {"start": 151, "end": 157, "probability": 0.6123, "type": "Other", "normalized_text": "Hodgkin"}, {"start": 159, "end": 196, "probability": 0.7339, "type": "Other", "normalized_text": "Lymphoma International Prognostication"}, {"start": 206, "end": 206, "probability": 0.4847, "type": "Other", "normalized_text": "-"}], "mentions": [{"start": 29, "end": 43, "username": "RutgersCancer", "id": "2802993134"}, {"start": 48, "end": 60, "username": "RWJBarnabas", "id": "45596617"}, {"start": 62, "end": 71, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 238, "end": 253, "username": "ASH_hematology", "id": "84072624"}], "urls": [{"start": 214, "end": 237, "url": "https://t.co/m9gGXw2Vfy", "expanded_url": "http://bit.ly/3TMZcgO", "display_url": "bit.ly/3TMZcgO", "images": [{"url": "https://pbs.twimg.com/news_img/1600124199091281923/qrUMsMVj?format=jpg&name=orig", "width": 500, "height": 333}, {"url": "https://pbs.twimg.com/news_img/1600124199091281923/qrUMsMVj?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Showcase Novel and Expansive Hematology/Oncology Data at the 64th American Society of Hematology Annual Meeting and Exposition | Rutgers Cancer Institute of New Jersey", "description": "Patient Info & Login Search by Cancer Type Bladder Cancer Blood Cancers Bone Marrow Transplant Brain & Spine Tumors Breast Cancer Cancer Genetics Cervical Cancer Childhood Cancers Clinical Trials Colorectal Cancer Endocrine Tumors Endometrial Cancer Esophageal Cancer Gastrointestinal Cancer Genitourinary Cancer Gynecologic/Reproductive Cancer Head & Neck Cancers Hepatobiliary Tumors Hodgkin's Lymphoma Kidney Cancer Leukemia Liver Cancer Lung Cancer Lymphoma, Hodgkin's & Non-Hodgkin's Melanoma Mesotheliomas", "unwound_url": "https://cinj.org/rutgers-cancer-institute-rwjbarnabas-health-showcase-novel-expansive-hematology-data-ash"}, {"start": 261, "end": 284, "url": "https://t.co/arG1NIT3iS", "expanded_url": "https://twitter.com/RutgersCancer/status/1600482855443914756/photo/1", "display_url": "pic.twitter.com/arG1NIT3iS", "media_key": "3_1600482853653028868"}]}, "source": "Hootsuite Inc.", "text": "This weekend at #ASH22, join @RutgersCancer and @RWJBarnabas\u2019 @DrAEvens as he shares insights on the development and validation of the advanced-stage #Hodgkin Lymphoma International Prognostication Index (A-HIPI).\nhttps://t.co/m9gGXw2Vfy\n@ASH_hematology #lymsm https://t.co/arG1NIT3iS", "id": "1600482855443914756", "lang": "en", "edit_history_tweet_ids": ["1600482855443914756"], "conversation_id": "1600482855443914756"}, {"created_at": "2022-12-08T03:10:07.000Z", "author_id": "999010996034338818", "in_reply_to_user_id": "999010996034338818", "entities": {"annotations": [{"start": 98, "end": 102, "probability": 0.4581, "type": "Person", "normalized_text": "Chadi"}, {"start": 182, "end": 184, "probability": 0.4509, "type": "Organization", "normalized_text": "MYC"}, {"start": 197, "end": 200, "probability": 0.5672, "type": "Organization", "normalized_text": "NHLs"}, {"start": 208, "end": 212, "probability": 0.4525, "type": "Other", "normalized_text": "DLBCL"}], "mentions": [{"start": 0, "end": 9, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 10, "end": 22, "username": "chadinabhan", "id": "2212735524"}]}, "source": "Twitter for iPhone", "text": "@DrAEvens @chadinabhan Too much to put in a single tweet! At any rate, that\u2019s my opinion. I blame Chadi for asking a question that early in the morning and my brain didn\u2019t go to ALL MYC-single hit NHLs (just DLBCL). In that case, I think you and I may share a similar view \ud83d\ude0a", "id": "1600689149098356737", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600688080742408192"}], "edit_history_tweet_ids": ["1600689149098356737"], "conversation_id": "1600685288430268416"}, {"created_at": "2022-12-08T03:05:52.000Z", "author_id": "999010996034338818", "in_reply_to_user_id": "719175246050410496", "entities": {"annotations": [{"start": 10, "end": 13, "probability": 0.6966, "type": "Person", "normalized_text": "Andy"}, {"start": 131, "end": 133, "probability": 0.4259, "type": "Organization", "normalized_text": "MYC"}, {"start": 158, "end": 162, "probability": 0.5873, "type": "Other", "normalized_text": "DLBCL"}, {"start": 198, "end": 199, "probability": 0.4076, "type": "Other", "normalized_text": "BL"}, {"start": 241, "end": 243, "probability": 0.448, "type": "Other", "normalized_text": "MYC"}, {"start": 245, "end": 249, "probability": 0.7108, "type": "Other", "normalized_text": "HGBCL"}, {"start": 285, "end": 289, "probability": 0.5291, "type": "Other", "normalized_text": "EPOCH"}], "mentions": [{"start": 0, "end": 9, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 90, "end": 102, "username": "chadinabhan", "id": "2212735524"}]}, "source": "Twitter for iPhone", "text": "@DrAEvens Andy, I couldn\u2019t find your reply on the thread. My response was specifically to @chadinabhan question on how I\u2019d treat a MYC-single hit (I inferred DLBCL) not my opinion on this analysis. BL obviously demands high-intensity chemo. MYC+HGBCL is a more nuanced discussion. DHL=EPOCH", "id": "1600688080742408192", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600685288430268416"}], "edit_history_tweet_ids": ["1600688080742408192"], "conversation_id": "1600685288430268416"}, {"created_at": "2022-12-07T13:05:17.000Z", "author_id": "999010996034338818", "in_reply_to_user_id": "2212735524", "entities": {"annotations": [{"start": 109, "end": 113, "probability": 0.6868, "type": "Other", "normalized_text": "Chadi"}], "mentions": [{"start": 0, "end": 12, "username": "chadinabhan", "id": "2212735524"}, {"start": 13, "end": 27, "username": "BloodAdvances", "id": "732570175162179585"}, {"start": 28, "end": 40, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 41, "end": 56, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "source": "Twitter for iPhone", "text": "@chadinabhan @BloodAdvances @GuiperiniMD @AaronGoodman33 Why do you want to stir the pot so early in the day Chadi \ud83e\udd23? MYC-only I treat with R-CHOP. Double-hit you already know my answer \ud83d\ude09.", "id": "1600476542509142016", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600467379158294528"}], "edit_history_tweet_ids": ["1600476542509142016"], "conversation_id": "1600467379158294528"}, {"created_at": "2022-12-06T22:43:07.000Z", "author_id": "807337182", "entities": {"annotations": [{"start": 0, "end": 3, "probability": 0.4647, "type": "Other", "normalized_text": "Vanc"}], "urls": [{"start": 69, "end": 92, "url": "https://t.co/ygeZZWbqzm", "expanded_url": "https://twitter.com/marklewismd/status/1600259570609201152/photo/1", "display_url": "pic.twitter.com/ygeZZWbqzm", "media_key": "3_1600258567474278404"}]}, "source": "Twitter Web App", "text": "Vanc being added to coverage in already-treated gram-negative sepsis https://t.co/ygeZZWbqzm", "id": "1600259570609201152", "lang": "en", "edit_history_tweet_ids": ["1600259570609201152"], "conversation_id": "1600259570609201152"}, {"created_at": "2022-12-08T02:37:48.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 278, "end": 284, "tag": "lymsm"}], "annotations": [{"start": 20, "end": 22, "probability": 0.5273, "type": "Organization", "normalized_text": "MYC"}, {"start": 28, "end": 32, "probability": 0.7215, "type": "Other", "normalized_text": "DLBCL"}, {"start": 73, "end": 88, "probability": 0.5041, "type": "Other", "normalized_text": "Burkitt lymphoma"}, {"start": 139, "end": 143, "probability": 0.7338, "type": "Other", "normalized_text": "HGBCL"}, {"start": 258, "end": 261, "probability": 0.7246, "type": "Other", "normalized_text": "HIV+"}], "mentions": [{"start": 265, "end": 277, "username": "lymphomatic", "id": "2891506288"}], "urls": [{"start": 177, "end": 200, "url": "https://t.co/ItDybSIgt0", "expanded_url": "https://ashpublications.org/blood/article-abstract/140/9/943/476913/Defining-and-treating-high-grade-B-cell-lymphoma?redirectedFrom=fulltext", "display_url": "ashpublications.org/blood/article-\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1600681030557790208/bSSmiZpd?format=png&name=orig", "width": 520, "height": 685}, {"url": "https://pbs.twimg.com/news_img/1600681030557790208/bSSmiZpd?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Defining and treating high-grade B-cell lymphoma, NOS", "description": "Edited by Associate Editor Laurie Sehn, this 3-part Review Series covers rare, aggressive B-cell lymphomas. First, Olszewski et al discuss a recently-designated", "unwound_url": "https://ashpublications.org/blood/article-abstract/140/9/943/476913/Defining-and-treating-high-grade-B-cell-lymphoma?redirectedFrom=fulltext"}, {"start": 285, "end": 308, "url": "https://t.co/5JZQO2pxph", "expanded_url": "https://twitter.com/chadinabhan/status/1600467379158294528", "display_url": "twitter.com/chadinabhan/st\u2026"}]}, "source": "Twitter for iPhone", "text": "This was not single MYC hit DLBCL.\n\nIn reading the study, pts had either Burkitt lymphoma (68%) or the difficult to dx &amp; treat entity, HGBCL w/ single or double/triple hit (https://t.co/ItDybSIgt0).\n\nRetrospective data, but impressive results (including HIV+). @lymphomatic #lymsm https://t.co/5JZQO2pxph", "id": "1600681018570465280", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1600467379158294528"}], "edit_history_tweet_ids": ["1600681018570465280"], "conversation_id": "1600681018570465280"}, {"created_at": "2022-12-07T12:28:53.000Z", "author_id": "2212735524", "entities": {"annotations": [{"start": 57, "end": 59, "probability": 0.5132, "type": "Organization", "normalized_text": "MYC"}, {"start": 79, "end": 81, "probability": 0.7652, "type": "Organization", "normalized_text": "NHL"}, {"start": 92, "end": 96, "probability": 0.5451, "type": "Other", "normalized_text": "RCHOP"}], "mentions": [{"start": 21, "end": 35, "username": "BloodAdvances", "id": "732570175162179585"}, {"start": 107, "end": 117, "username": "ASkarbnik", "id": "999010996034338818"}, {"start": 118, "end": 130, "username": "GuiperiniMD", "id": "1294745239656202240"}, {"start": 131, "end": 146, "username": "AaronGoodman33", "id": "854692626015993857"}], "urls": [{"start": 149, "end": 172, "url": "https://t.co/5sw3fwWNsx", "expanded_url": "https://ashpublications.org/bloodadvances/article/6/22/5811/485287/Safety-and-efficacy-of-a-dose-dense-short-term?utm_source=&utm_medium=&utm_campaign=highlights_12_6_22&utm_source=sfmc&utm_medium=email&utm_campaign=BA+Highlights_12_6_22&utm_term=Link+Text", "display_url": "ashpublications.org/bloodadvances/\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1599788273773121537/xXGO_tPi?format=png&name=orig", "width": 520, "height": 685}, {"url": "https://pbs.twimg.com/news_img/1599788273773121537/xXGO_tPi?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma", "description": "Key Points. CARMEN regimen includes single doses of drugs delivered in 81 days (median), with good tolerability and lower risk of late toxicity.A 5-year OS of \u223c", "unwound_url": "https://ashpublications.org/bloodadvances/article/6/22/5811/485287/Safety-and-efficacy-of-a-dose-dense-short-term?utm_source=&utm_medium=&utm_campaign=highlights_12_6_22&utm_source=sfmc&utm_medium=email&utm_campaign=BA+Highlights_12_6_22&utm_term=Link+Text"}]}, "source": "Twitter for iPhone", "text": "Interesting study in @BloodAdvances but are you treating MYC-only translocated NHL with non-RCHOP program?\n@ASkarbnik @GuiperiniMD @AaronGoodman33 \n\nhttps://t.co/5sw3fwWNsx+\u00bb&amp;utm_id=212692&amp;sfmc_id=19415589", "id": "1600467379158294528", "lang": "en", "edit_history_tweet_ids": ["1600467379158294528"], "conversation_id": "1600467379158294528"}, {"created_at": "2022-12-08T01:36:32.000Z", "author_id": "1266377656989171713", "entities": {"hashtags": [{"start": 53, "end": 64, "tag": "BillsMafia"}, {"start": 87, "end": 100, "tag": "BillsBackers"}], "annotations": [{"start": 54, "end": 63, "probability": 0.8542, "type": "Organization", "normalized_text": "BillsMafia"}, {"start": 88, "end": 99, "probability": 0.521, "type": "Organization", "normalized_text": "BillsBackers"}], "mentions": [{"start": 0, "end": 9, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 10, "end": 23, "username": "BuffaloBills", "id": "25084916"}, {"start": 24, "end": 34, "username": "DrLizBrem", "id": "4476878772"}, {"start": 65, "end": 73, "username": "ash2022", "id": "39475758"}]}, "in_reply_to_user_id": "719175246050410496", "source": "Twitter for iPhone", "text": "@DrAEvens @BuffaloBills @DrLizBrem I will be repping #BillsMafia @ASH2022. There are 2 #BillsBackers bars within walking distance of convention center. \ud83e\uddac", "id": "1600665600711430146", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600269314971443200"}], "edit_history_tweet_ids": ["1600665600711430146"], "conversation_id": "1600269314971443200"}, {"created_at": "2022-12-07T16:59:19.000Z", "author_id": "918471705408016384", "in_reply_to_user_id": "1532109206953906180", "entities": {"annotations": [{"start": 80, "end": 84, "probability": 0.3865, "type": "Organization", "normalized_text": "o Bil"}], "mentions": [{"start": 0, "end": 12, "username": "KaraKellyMD", "id": "1532109206953906180"}, {"start": 13, "end": 22, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 23, "end": 36, "username": "BuffaloBills", "id": "25084916"}, {"start": 37, "end": 47, "username": "DrLizBrem", "id": "4476878772"}, {"start": 48, "end": 60, "username": "RoswellPark", "id": "16044589"}, {"start": 61, "end": 72, "username": "OCHBuffalo", "id": "245900695"}]}, "source": "Twitter Web App", "text": "@KaraKellyMD @DrAEvens @BuffaloBills @DrLizBrem @RoswellPark @OCHBuffalo \ud83d\ude4b\u200d\u2640\ufe0f. Go Bills!", "id": "1600535436643942400", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1600510861503766529"}], "edit_history_tweet_ids": ["1600535436643942400"], "conversation_id": "1600269314971443200"}, {"created_at": "2022-12-02T13:41:22.000Z", "author_id": "2891662867", "entities": {"hashtags": [{"start": 8, "end": 20, "tag": "LeonardList"}, {"start": 21, "end": 27, "tag": "ASH22"}, {"start": 32, "end": 41, "tag": "lymphoma"}, {"start": 141, "end": 150, "tag": "lymphoma"}], "annotations": [{"start": 9, "end": 19, "probability": 0.5651, "type": "Other", "normalized_text": "LeonardList"}, {"start": 22, "end": 26, "probability": 0.6064, "type": "Other", "normalized_text": "ASH22"}, {"start": 87, "end": 92, "probability": 0.4003, "type": "Other", "normalized_text": "Stuver"}, {"start": 96, "end": 114, "probability": 0.468, "type": "Other", "normalized_text": "Brentuximab vedotin"}, {"start": 133, "end": 139, "probability": 0.3713, "type": "Other", "normalized_text": "Hodgkin"}, {"start": 142, "end": 149, "probability": 0.4003, "type": "Other", "normalized_text": "lymphoma"}, {"start": 203, "end": 205, "probability": 0.5607, "type": "Organization", "normalized_text": "MTV"}], "urls": [{"start": 251, "end": 274, "url": "https://t.co/gE2BCeTCNn", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper156382.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Hodgkin Lymphoma: Retrospective Analyses and Prospective Trials Hematology Disease Topics & Pathways: Antibody Therapy, clinical trials, Hodgkin lymphoma, Biological therapies, Research, Lymphomas, Combination therapy, Clinical Research, Diseases, therapy sequence, Therapies, Lymphoid Malignancies, Monoclonal Antibody Therapy 1 Department of Medicine, Lymphoma Service,", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper156382.html"}, {"start": 275, "end": 298, "url": "https://t.co/Nmb4iEx7GJ", "expanded_url": "https://twitter.com/JohnPLeonardMD/status/1598673683786219522/photo/1", "display_url": "pic.twitter.com/Nmb4iEx7GJ", "media_key": "3_1598672517757018112"}]}, "source": "Twitter Web App", "text": "Now for #LeonardList #ASH22 top #lymphoma abstracts daily countdown - Number 8 - 730 - Stuver - Brentuximab vedotin + chemo in early Hodgkin #lymphoma followup and association of metabolic tumor volume (MTV), PET2 status and outcome in early stage HL https://t.co/gE2BCeTCNn https://t.co/Nmb4iEx7GJ", "id": "1598673683786219522", "lang": "en", "edit_history_tweet_ids": ["1598673683786219522"], "conversation_id": "1598673683786219522"}, {"created_at": "2022-12-03T02:10:22.000Z", "author_id": "719175246050410496", "entities": {"annotations": [{"start": 90, "end": 95, "probability": 0.5134, "type": "Other", "normalized_text": "cancer"}, {"start": 131, "end": 133, "probability": 0.5194, "type": "Other", "normalized_text": "EBM"}], "urls": [{"start": 293, "end": 316, "url": "https://t.co/bNUlEngvzl", "expanded_url": "https://twitter.com/iHematologo/status/1564284969849016320", "display_url": "twitter.com/iHematologo/st\u2026"}]}, "source": "Twitter for iPhone", "text": "We currently have paucity of decision tools (decision support) for providers &amp; pts in cancer.\n\nNeed rigorous &amp; interactive EBM tools (from large amounts harmonized data, applicable to a diverse population) to identify pros &amp; cons across varied treatment choices for individual pts https://t.co/bNUlEngvzl", "id": "1598862174146830338", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1564284969849016320"}], "edit_history_tweet_ids": ["1598862174146830338"], "conversation_id": "1598862174146830338"}, {"created_at": "2022-08-29T16:12:54.000Z", "author_id": "191828708", "in_reply_to_user_id": "1316325128", "source": "Twitter for iPhone", "text": "@MorieGertz @AaronGoodman33 Very interesting interpretation. It is difficult to persuade people, as 20-20-2 has been rapidly adopted in clinical practice. (there was/is need for a decision making tool like this)", "entities": {"mentions": [{"start": 0, "end": 11, "username": "MorieGertz", "id": "1316325128"}, {"start": 12, "end": 27, "username": "AaronGoodman33", "id": "854692626015993857"}]}, "id": "1564284969849016320", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1563315385079738371"}], "edit_history_tweet_ids": ["1564284969849016320"], "conversation_id": "1563315385079738371"}, {"created_at": "2022-12-02T20:56:09.000Z", "author_id": "2802993134", "entities": {"hashtags": [{"start": 43, "end": 49, "tag": "ASH22"}, {"start": 221, "end": 226, "tag": "mmsm"}, {"start": 227, "end": 242, "tag": "cancerresearch"}, {"start": 243, "end": 250, "tag": "hemonc"}, {"start": 251, "end": 262, "tag": "MedTwitter"}], "annotations": [{"start": 44, "end": 48, "probability": 0.4057, "type": "Other", "normalized_text": "ASH22"}, {"start": 161, "end": 162, "probability": 0.8111, "type": "Place", "normalized_text": "NJ"}, {"start": 190, "end": 216, "probability": 0.5914, "type": "Other", "normalized_text": "Comprehensive Cancer Center"}, {"start": 244, "end": 249, "probability": 0.5105, "type": "Place", "normalized_text": "hemonc"}], "mentions": [{"start": 6, "end": 20, "username": "RutgersCancer", "id": "2802993134"}, {"start": 23, "end": 35, "username": "RWJBarnabas", "id": "45596617"}, {"start": 171, "end": 178, "username": "theNCI", "id": "38530021"}], "urls": [{"start": 263, "end": 286, "url": "https://t.co/IFtHOZkEfl", "expanded_url": "https://twitter.com/RutgersCancer/status/1598783097306161152/photo/1", "display_url": "pic.twitter.com/IFtHOZkEfl", "media_key": "3_1598782915764264960"}, {"start": 263, "end": 286, "url": "https://t.co/IFtHOZkEfl", "expanded_url": "https://twitter.com/RutgersCancer/status/1598783097306161152/photo/1", "display_url": "pic.twitter.com/IFtHOZkEfl", "media_key": "3_1598783078956208129"}, {"start": 263, "end": 286, "url": "https://t.co/IFtHOZkEfl", "expanded_url": "https://twitter.com/RutgersCancer/status/1598783097306161152/photo/1", "display_url": "pic.twitter.com/IFtHOZkEfl", "media_key": "3_1598783066029301760"}]}, "source": "Twitter Web App", "text": "Visit @RutgersCancer / @RWJBarnabas during #ASH22 at booth 311 to meet our leaders and learn about the latest research advancements and current opportunities at NJ\u2019s only @theNCI-designated Comprehensive Cancer Center! \n\n#mmsm #cancerresearch #hemonc #MedTwitter https://t.co/IFtHOZkEfl", "id": "1598783097306161152", "lang": "en", "edit_history_tweet_ids": ["1598783097306161152"], "conversation_id": "1598783097306161152"}, {"created_at": "2022-12-01T14:25:20.000Z", "author_id": "2212735524", "entities": {"hashtags": [{"start": 147, "end": 168, "tag": "HealthcareUnfiltered"}, {"start": 178, "end": 190, "tag": "HemOncPulse"}, {"start": 227, "end": 233, "tag": "ASH22"}], "annotations": [{"start": 31, "end": 46, "probability": 0.8118, "type": "Other", "normalized_text": "The HemOnc Pulse"}, {"start": 179, "end": 189, "probability": 0.6387, "type": "Other", "normalized_text": "HemOncPulse"}, {"start": 228, "end": 232, "probability": 0.5532, "type": "Other", "normalized_text": "ASH22"}], "mentions": [{"start": 235, "end": 250, "username": "ASH_hematology", "id": "84072624"}], "urls": [{"start": 270, "end": 293, "url": "https://t.co/ZPh5a0rDUh", "expanded_url": "https://twitter.com/chadinabhan/status/1598322360335089665/video/1", "display_url": "pic.twitter.com/ZPh5a0rDUh", "media_key": "7_1598322258728161283"}]}, "source": "Twitter for iPhone", "text": "COMING SOON.\n\nMy new podcast: \u201cThe HemOnc Pulse\u201d dedicated to all things clinical hematology and hematology only.\n\nA new podcast in addition to my #HealthcareUnfiltered one. The #HemOncPulse.\n\nStarting in two weeks right after #ASH22 \u2066@ASH_hematology\u2069 \n\nMore info soon. https://t.co/ZPh5a0rDUh", "id": "1598322360335089665", "lang": "en", "edit_history_tweet_ids": ["1598322360335089665"], "conversation_id": "1598322360335089665"}, {"created_at": "2022-12-01T12:33:48.000Z", "author_id": "49698134", "source": "Twitter for iPhone", "text": "Listen and take this in. https://t.co/SXy6UrQoo4", "entities": {"urls": [{"start": 25, "end": 48, "url": "https://t.co/SXy6UrQoo4", "expanded_url": "https://twitter.com/colbertlateshow/status/1597825250028306433", "display_url": "twitter.com/colbertlatesho\u2026"}]}, "id": "1598294291649994752", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1597825250028306433"}], "edit_history_tweet_ids": ["1598294291649994752"], "conversation_id": "1598294291649994752"}, {"created_at": "2022-11-28T14:26:59.000Z", "author_id": "1028702407298113537", "entities": {"annotations": [{"start": 273, "end": 277, "probability": 0.9012, "type": "Organization", "normalized_text": "Tesla"}]}, "source": "Twitter for iPhone", "text": "A man and his son are in a car accident. The man is killed instantly. His son is rushed to the hospital. The surgeon says \u201cI can\u2019t operate on this patient, he is my son\u201d. The car then crashes through the wall of the operating room, killing everyone. How is this possible? (Tesla)", "id": "1597235612977106945", "lang": "en", "edit_history_tweet_ids": ["1597235612977106945"], "conversation_id": "1597235612977106945"}, {"created_at": "2022-11-27T12:50:39.000Z", "author_id": "314498013", "entities": {"annotations": [{"start": 58, "end": 66, "probability": 0.2933, "type": "Other", "normalized_text": "Cwynarski"}, {"start": 70, "end": 99, "probability": 0.738, "type": "Other", "normalized_text": "British Journal of Haematology"}, {"start": 103, "end": 122, "probability": 0.6926, "type": "Other", "normalized_text": "Wiley Online Library"}], "urls": [{"start": 124, "end": 147, "url": "https://t.co/NWa81FUEne", "expanded_url": "https://onlinelibrary.wiley.com/doi/10.1111/bjh.18539", "display_url": "onlinelibrary.wiley.com/doi/10.1111/bj\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1594681566864678912/ww7HnJLc?format=jpg&name=orig", "width": 758, "height": 1000}, {"url": "https://pbs.twimg.com/news_img/1594681566864678912/ww7HnJLc?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Management of secondary central nervous system lymphoma", "description": "The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.", "unwound_url": "https://onlinelibrary.wiley.com/doi/10.1111/bjh.18539"}]}, "source": "Twitter for iPhone", "text": "Management of secondary central nervous system lymphoma - Cwynarski - British Journal of Haematology - Wiley Online Library https://t.co/NWa81FUEne", "id": "1596848981853831173", "lang": "en", "edit_history_tweet_ids": ["1596848981853831173"], "conversation_id": "1596848981853831173"}, {"created_at": "2022-11-26T21:38:11.000Z", "author_id": "716743703830900736", "entities": {"hashtags": [{"start": 120, "end": 126, "tag": "lymsm"}], "annotations": [{"start": 25, "end": 25, "probability": 0.4504, "type": "Other", "normalized_text": "-"}, {"start": 111, "end": 118, "probability": 0.5195, "type": "Other", "normalized_text": "Lymphoma"}], "urls": [{"start": 127, "end": 150, "url": "https://t.co/1NxNG4e78q", "expanded_url": "https://www.astctjournal.org/article/S2666-6367(22)01598-6/fulltext#.Y4KHNl0D_xw.twitter", "display_url": "astctjournal.org/article/S2666-\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1596476933206052864/tbMgo5-G?format=jpg&name=orig", "width": 678, "height": 506}, {"url": "https://pbs.twimg.com/news_img/1596476933206052864/tbMgo5-G?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "Favorable Outcomes with R-CHOP Induction and Consolidative Autologous Stem Cell Transplantation for Double-Hit Lymphoma", "description": "High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, known as double-hit lymphoma (DHL), is an aggressive variant of large B cell lymphoma (LBCL) that is found in 5% to 8% of cases and portends a poor prognosis with R-CHOP chemotherapy [1,2]. Although the optimal treatment is unknown, retrospective studies suggest that outcomes might be improved by high-dose chemotherapy and autologous stem cell transplantation (HDT/ASCT) or intensive regimens used for Burkitt lymphoma (BL), such as dose-adjusted (da)-EPOCH-R or R-CODOX-M/R-IVAC [3\u20136].", "unwound_url": "https://www.astctjournal.org/article/S2666-6367(22)01598-6/fulltext#.Y4KHNl0D_xw.twitter"}]}, "source": "Twitter Web App", "text": "Favorable Outcomes with R-CHOP Induction and Consolidative Autologous Stem Cell Transplantation for Double-Hit Lymphoma #lymsm https://t.co/1NxNG4e78q", "id": "1596619349015793665", "lang": "en", "edit_history_tweet_ids": ["1596619349015793665"], "conversation_id": "1596619349015793665"}, {"created_at": "2022-11-26T07:28:47.000Z", "author_id": "727898827739402241", "source": "Twitter for Android", "text": "Dear Soon to Be Grads,\n\nLast year I took a 22% pay cut to get out of for profit medicine and back into the not for profit world. I couldn't be happier about it. When considering your job opportunities, remember that pay isn't everything.\n\nGood luck!", "id": "1596405589705654273", "lang": "en", "edit_history_tweet_ids": ["1596405589705654273"], "conversation_id": "1596405589705654273"}, {"created_at": "2022-11-26T10:13:48.000Z", "author_id": "2626263112", "entities": {"hashtags": [{"start": 56, "end": 62, "tag": "ASH22"}], "annotations": [{"start": 57, "end": 61, "probability": 0.7867, "type": "Other", "normalized_text": "ASH22"}], "urls": [{"start": 281, "end": 304, "url": "https://t.co/FcbW9dYo0x", "expanded_url": "https://twitter.com/Mohty_EBMT/status/1595293396297449472", "display_url": "twitter.com/Mohty_EBMT/sta\u2026"}]}, "source": "Twitter for iPhone", "text": "Let\u2019s learn from the non-conclusive studies reported at #ASH22 and congratulate all colleagues who took the challenge and dedicated time, efforts, ressources and energy to try to advance the field. A negative tweet is easy to write, but spending 5y to run a trial is another story https://t.co/FcbW9dYo0x", "id": "1596447119493066754", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1595293396297449472"}], "edit_history_tweet_ids": ["1596447119493066754"], "conversation_id": "1596447119493066754"}, {"created_at": "2022-11-24T13:29:12.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 71, "end": 82, "tag": "BillsMafia"}], "urls": [{"start": 138, "end": 161, "url": "https://t.co/0kyw9aCLeG", "expanded_url": "https://twitter.com/DrAEvens/status/1595771516112838660/photo/1", "display_url": "pic.twitter.com/0kyw9aCLeG", "media_key": "3_1595771505903812611"}]}, "source": "Twitter for iPhone", "text": "Kicking it up a notch on this years menu (see upper right in spirit of #BillsMafia\u00a0 ).\n\nHAPPY (and HEALTHY) THANKSGIVING TO ALL!!!!   \ud83e\udd83\ud83e\udd83\ud83e\udd83 https://t.co/0kyw9aCLeG", "id": "1595771516112838660", "lang": "en", "edit_history_tweet_ids": ["1595771516112838660"], "conversation_id": "1595771516112838660"}, {"created_at": "2022-11-22T01:19:24.000Z", "author_id": "1217527785616441344", "entities": {"hashtags": [{"start": 19, "end": 41, "tag": "womenwhoconquercancer"}, {"start": 85, "end": 108, "tag": "younginvestigatoraward"}, {"start": 126, "end": 135, "tag": "lymphoma"}, {"start": 246, "end": 258, "tag": "WomenInSTEM"}], "annotations": [{"start": 127, "end": 134, "probability": 0.346, "type": "Other", "normalized_text": "lymphoma"}], "mentions": [{"start": 2, "end": 18, "username": "ConquerCancerFd", "id": "221775604"}, {"start": 138, "end": 150, "username": "DrJulieVose", "id": "2416787444"}, {"start": 151, "end": 162, "username": "lymphomaOz", "id": "213861384"}, {"start": 163, "end": 174, "username": "ALLGtrials", "id": "1214386885784567808"}, {"start": 175, "end": 191, "username": "AustralasianLy1", "id": "1334653558143164422"}, {"start": 192, "end": 206, "username": "knowyournodes", "id": "166624836"}, {"start": 207, "end": 220, "username": "LysaLymphoma", "id": "733637482135355392"}, {"start": 221, "end": 236, "username": "LYM_MM_CONNECT", "id": "1024911754164355072"}, {"start": 237, "end": 245, "username": "Cure_FL", "id": "1184807867532095488"}], "urls": [{"start": 259, "end": 282, "url": "https://t.co/2zuP7Rhdm2", "expanded_url": "https://twitter.com/WomenInLymphoma/status/1594863080063864885/photo/1", "display_url": "pic.twitter.com/2zuP7Rhdm2", "media_key": "3_1594861655082512384"}]}, "source": "Twitter Web App", "text": "\ud83e\udde1 @ConquerCancerFd #womenwhoconquercancer Please join us in helping to fund the 2022 #younginvestigatoraward (YIA) focused on #lymphoma \n\n@DrJulieVose @lymphomaOz @ALLGtrials @AustralasianLy1 @knowyournodes @LysaLymphoma @LYM_MM_CONNECT @Cure_FL #WomenInSTEM https://t.co/2zuP7Rhdm2", "id": "1594863080063864885", "lang": "en", "edit_history_tweet_ids": ["1594863080063864885"], "conversation_id": "1594863080063864885"}, {"created_at": "2022-11-23T16:15:04.000Z", "author_id": "205280101", "entities": {"hashtags": [{"start": 146, "end": 159, "tag": "fixpriorauth"}], "annotations": [{"start": 48, "end": 53, "probability": 0.577, "type": "Other", "normalized_text": "cancer"}, {"start": 147, "end": 158, "probability": 0.6431, "type": "Other", "normalized_text": "fixpriorauth"}], "mentions": [{"start": 92, "end": 97, "username": "ASCO", "id": "20187065"}, {"start": 161, "end": 177, "username": "MedicineForward", "id": "1166431443968385024"}, {"start": 178, "end": 188, "username": "tmprowell", "id": "86970530"}, {"start": 189, "end": 201, "username": "gabrieldane", "id": "27549971"}], "urls": [{"start": 98, "end": 121, "url": "https://t.co/vY0ySrf7Nv", "expanded_url": "https://old-prod.asco.org/news-initiatives/policy-news-analysis/nearly-all-oncology-providers-report-prior-authorization", "display_url": "old-prod.asco.org/news-initiativ\u2026", "status": 200, "title": "Nearly All Oncology Providers Report Prior Authorization Causing", "description": "Prior authorization is harming individuals with cancer according to new survey results from the Association for Clinical Oncology (ASCO). The survey found that prior authorization delays necessary", "unwound_url": "https://old-prod.asco.org/news-initiatives/policy-news-analysis/nearly-all-oncology-providers-report-prior-authorization"}]}, "source": "Twitter Web App", "text": "Prior authorization is harming individuals with cancer according to new survey results from @ASCO https://t.co/vY0ySrf7Nv WITH RECOMMENDATIONS to #fixpriorauth! @MedicineForward @tmprowell @gabrieldane THREAD 1/15", "id": "1595450873383391232", "lang": "en", "edit_history_tweet_ids": ["1595450873383391232"], "conversation_id": "1595450873383391232"}, {"created_at": "2022-11-22T01:40:16.000Z", "author_id": "2802993134", "entities": {"hashtags": [{"start": 81, "end": 100, "tag": "HockeyFightsCancer"}], "annotations": [{"start": 46, "end": 49, "probability": 0.4547, "type": "Other", "normalized_text": "Luke"}, {"start": 59, "end": 66, "probability": 0.5486, "type": "Other", "normalized_text": "Among Us"}, {"start": 129, "end": 138, "probability": 0.7062, "type": "Other", "normalized_text": "Andy Evens"}], "mentions": [{"start": 1, "end": 10, "username": "NJDevils", "id": "40878677"}, {"start": 18, "end": 32, "username": "RutgersCancer", "id": "2802993134"}, {"start": 141, "end": 150, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 192, "end": 206, "username": "RutgersCancer", "id": "2802993134"}, {"start": 208, "end": 220, "username": "RWJBarnabas", "id": "45596617"}], "urls": [{"start": 222, "end": 245, "url": "https://t.co/fnEL862Zea", "expanded_url": "https://twitter.com/RutgersCancer/status/1594868332397830145/photo/1", "display_url": "pic.twitter.com/fnEL862Zea", "media_key": "3_1594868325103927297"}, {"start": 222, "end": 245, "url": "https://t.co/fnEL862Zea", "expanded_url": "https://twitter.com/RutgersCancer/status/1594868332397830145/photo/1", "display_url": "pic.twitter.com/fnEL862Zea", "media_key": "3_1594868325095448578"}]}, "source": "Twitter for iPhone", "text": ".@NJDevils honors @RutgersCancer patient Will Luke as Hero Among Us at tonight\u2019s #HockeyFightsCancer game! Will is joined by Dr. Andy Evens (@DrAEvens) &amp; the Hematology/Oncology team from @RutgersCancer/ @RWJBarnabas! https://t.co/fnEL862Zea", "id": "1594868332397830145", "lang": "en", "edit_history_tweet_ids": ["1594868332397830145"], "conversation_id": "1594868332397830145"}, {"created_at": "2022-11-21T21:16:12.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 90, "end": 101, "tag": "JerseyCity"}, {"start": 226, "end": 233, "tag": "cancer"}], "annotations": [{"start": 43, "end": 63, "probability": 0.7619, "type": "Other", "normalized_text": "Madeline Fiadini LoRe"}, {"start": 66, "end": 68, "probability": 0.3665, "type": "Organization", "normalized_text": "MFL"}, {"start": 82, "end": 85, "probability": 0.6262, "type": "Other", "normalized_text": "Gala"}, {"start": 91, "end": 100, "probability": 0.7716, "type": "Place", "normalized_text": "JerseyCity"}, {"start": 102, "end": 114, "probability": 0.9352, "type": "Place", "normalized_text": "Hudson County"}, {"start": 227, "end": 232, "probability": 0.5764, "type": "Other", "normalized_text": "cancer"}], "urls": [{"start": 260, "end": 283, "url": "https://t.co/7tt3A1jtkd", "expanded_url": "https://mediazilla.com/VH8XyMgWmW", "display_url": "mediazilla.com/VH8XyMgWmW", "images": [{"url": "https://pbs.twimg.com/news_img/1594799304065138689/2SlbZ8sq?format=jpg&name=orig", "width": 1920, "height": 1080}, {"url": "https://pbs.twimg.com/news_img/1594799304065138689/2SlbZ8sq?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "MFL V2", "description": "This is \"MFL V2\" by Epic Events on MediaZilla", "unwound_url": "https://mediazilla.com/VH8XyMgWmW"}]}, "source": "Twitter Web App", "text": "A privilege to be an honoree at this years Madeline Fiadini LoRe (MFL) Foundation Gala in #JerseyCity Hudson County (below video includes part of tribute at this fantastic event).\n\n\ud83d\ude4f A big THANK YOU for everything MFL does in #cancer prevention &amp; beyond!\n\nhttps://t.co/7tt3A1jtkd", "id": "1594801877220204554", "lang": "en", "edit_history_tweet_ids": ["1594801877220204554"], "conversation_id": "1594801877220204554"}, {"created_at": "2022-11-21T19:14:51.000Z", "author_id": "8287602", "entities": {"hashtags": [{"start": 101, "end": 109, "tag": "twitter"}, {"start": 110, "end": 119, "tag": "ElonMusk"}, {"start": 120, "end": 127, "tag": "crypto"}, {"start": 128, "end": 142, "tag": "everythingapp"}, {"start": 143, "end": 152, "tag": "payments"}, {"start": 153, "end": 162, "tag": "platform"}], "annotations": [{"start": 49, "end": 55, "probability": 0.9546, "type": "Other", "normalized_text": "twitter"}, {"start": 102, "end": 108, "probability": 0.969, "type": "Other", "normalized_text": "twitter"}, {"start": 111, "end": 118, "probability": 0.8584, "type": "Person", "normalized_text": "ElonMusk"}, {"start": 121, "end": 126, "probability": 0.6416, "type": "Other", "normalized_text": "crypto"}, {"start": 129, "end": 141, "probability": 0.5228, "type": "Other", "normalized_text": "everythingapp"}], "mentions": [{"start": 39, "end": 48, "username": "elonmusk", "id": "44196397"}], "urls": [{"start": 163, "end": 186, "url": "https://t.co/O1kLzwwna1", "expanded_url": "https://twitter.com/jaltucher/status/1594771339553882114/video/1", "display_url": "pic.twitter.com/O1kLzwwna1", "media_key": "7_1594769229919752201"}]}, "source": "TweetDeck", "text": "Here's my prediction for the future of @elonmusk twitter and everything app. You hear it here first!\n#twitter #ElonMusk #crypto #everythingapp #payments #platform https://t.co/O1kLzwwna1", "id": "1594771339553882114", "lang": "en", "edit_history_tweet_ids": ["1594771339553882114"], "conversation_id": "1594771339553882114"}, {"created_at": "2022-11-17T14:59:30.000Z", "author_id": "244846617", "source": "Twitter for iPhone", "text": "Seeing my dad decline is breaking my heart so much. Whether your loved ones are sick or not; go visit them/call. Life is way too short.", "id": "1593257526325547009", "lang": "en", "edit_history_tweet_ids": ["1593257526325547009"], "conversation_id": "1593257526325547009"}, {"created_at": "2022-11-15T16:22:08.000Z", "author_id": "1323718307841716225", "entities": {"hashtags": [{"start": 162, "end": 167, "tag": "SKOL"}], "annotations": [{"start": 0, "end": 15, "probability": 0.9804, "type": "Person", "normalized_text": "Patrick Peterson"}, {"start": 88, "end": 94, "probability": 0.9573, "type": "Organization", "normalized_text": "Vikings"}, {"start": 105, "end": 109, "probability": 0.6258, "type": "Organization", "normalized_text": "Bills"}], "mentions": [{"start": 141, "end": 144, "username": "P2", "id": "277161300"}, {"start": 145, "end": 161, "username": "BMac_SportsTalk", "id": "2274786446"}], "urls": [{"start": 169, "end": 192, "url": "https://t.co/USVBc24NT2", "expanded_url": "https://www.youtube.com/watch?v=xcJE7NA0q1A", "display_url": "youtube.com/watch?v=xcJE7N\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1592533569888743428/UZopALxT?format=jpg&name=orig", "width": 1280, "height": 720}, {"url": "https://pbs.twimg.com/news_img/1592533569888743428/UZopALxT?format=jpg&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "PATRICK PETERSON REACTS TO GAME-WINNING INTERCEPTION TO PROPEL VIKINGS OVER BILLS", "description": "#allthingscovered #Vikings #PatrickPeterson #Bills #JoshAllen #nfl #football #sports #Cowboys #JustinJefferson #StefonDiggs #CeeDeeLamb #KirkCousins Our very...", "unwound_url": "https://www.youtube.com/watch?v=xcJE7NA0q1A"}, {"start": 193, "end": 216, "url": "https://t.co/8dkRuCP675", "expanded_url": "https://twitter.com/ATCoveredPod/status/1592553545215008768/video/1", "display_url": "pic.twitter.com/8dkRuCP675", "media_key": "7_1592553145510543361"}]}, "source": "Twitter Web App", "text": "Patrick Peterson with an INCREDIBLE breakdown of his walk off interception to boost the Vikings over the Bills in Week 10 \ud83d\udd8a\ufe0f\n\nFull episode \ud83d\udc47 @P2 @BMac_SportsTalk #SKOL \nhttps://t.co/USVBc24NT2 https://t.co/8dkRuCP675", "id": "1592553545215008768", "lang": "en", "edit_history_tweet_ids": ["1592553545215008768"], "conversation_id": "1592553545215008768"}, {"created_at": "2022-11-15T10:06:10.000Z", "author_id": "1270567127569883139", "entities": {"annotations": [{"start": 40, "end": 50, "probability": 0.879, "type": "Person", "normalized_text": "Erica Marsh"}, {"start": 68, "end": 74, "probability": 0.9698, "type": "Other", "normalized_text": "Twitter"}]}, "source": "Twitter for Android", "text": "WARNING: Do NOT follow or interact with Erica Marsh, a popular Blue Twitter account. She's very likely a bot probably designed to collect as much data about Democratic voters as possible for God knows what. Here's why I think so:", "id": "1592458931158552578", "lang": "en", "edit_history_tweet_ids": ["1592458931158552578"], "conversation_id": "1592458931158552578"}, {"created_at": "2022-11-13T09:01:17.000Z", "author_id": "3187500729", "entities": {"hashtags": [{"start": 0, "end": 7, "tag": "ISHL12"}, {"start": 144, "end": 152, "tag": "Hodgkin"}, {"start": 191, "end": 198, "tag": "HemOnc"}, {"start": 199, "end": 205, "tag": "LymSM"}], "annotations": [{"start": 1, "end": 6, "probability": 0.4556, "type": "Other", "normalized_text": "ISHL12"}, {"start": 68, "end": 75, "probability": 0.5389, "type": "Other", "normalized_text": "HoLISTIC"}, {"start": 145, "end": 151, "probability": 0.618, "type": "Other", "normalized_text": "Hodgkin"}], "mentions": [{"start": 10, "end": 19, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 23, "end": 37, "username": "RutgersCancer", "id": "2802993134"}], "urls": [{"start": 165, "end": 188, "url": "https://t.co/sEWqWhfNLt", "expanded_url": "http://ow.ly/gsJt50LyRtI", "display_url": "ow.ly/gsJt50LyRtI", "status": 200, "title": "An insight into the HoLISTIC consortium and the value of international collaborations in HL", "description": "Andrew Evens, DO, MBA, FACP, Rutgers University, New Brunswick, NJ, shares some insights into emerging international collaborations in Hodgkin lymphoma (HL), drawing focus on the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) consortium, which stores and analyzes over 10,000 records concerning HL. Dr Evens discusses the various Phase II and Phase III trials and resources that are offered to both providers and patients, as well as the future goals of the HoLISTIC consortium. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.", "unwound_url": "https://www.vjhemonc.com/video/yipxxjbjt3o-an-insight-into-the-holistic-consortium-and-the-value-of-international-collaborations-in-hl/"}]}, "source": "Hootsuite Inc.", "text": "#ISHL12 | @DrAEvens of @RutgersCancer shares some insights into the HoLISTIC consortium &amp; the importance of international collaborations in #Hodgkin lymphoma:\n\n\ud83d\udc49https://t.co/sEWqWhfNLt\ud83d\udc48\n\n#HemOnc #LymSM", "id": "1591717826511110144", "lang": "en", "edit_history_tweet_ids": ["1591717826511110144"], "conversation_id": "1591717826511110144"}, {"created_at": "2022-11-07T06:37:52.000Z", "author_id": "2626263112", "entities": {"hashtags": [{"start": 72, "end": 78, "tag": "ash22"}], "annotations": [{"start": 73, "end": 77, "probability": 0.5776, "type": "Other", "normalized_text": "ash22"}], "mentions": [{"start": 143, "end": 154, "username": "Mohty_EBMT", "id": "2626263112"}], "urls": [{"start": 157, "end": 180, "url": "https://t.co/Ms8eDErkl8", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/start.html#srch=words%7CMicrobiome%7Cmethod%7Cand%7Cpge%7C1%7CbyDayany%7Cany%7CbySymposiumany%7Cany%7CbyAudienceany%7Cany", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "64th ASH Annual Meeting and Exposition", "description": "You may search for particular presentations by typing key words, an author's name, or the title in the box below. You may specify the type of search, i.e. whether you want to see pages that contain any or all of the words you specify. The Boolean search option requires one of the keywords and, or, and not, as well as parentheses. The search filters will allow you to restrict your search by date, session type, or abstract category and are all optional. Hold down the Ctrl key while selecting to choose more", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/start.html#srch=words%7CMicrobiome%7Cmethod%7Cand%7Cpge%7C1%7CbyDayany%7Cany%7CbySymposiumany%7Cany%7CbyAudienceany%7Cany"}]}, "source": "Twitter for iPad", "text": "Almost 50 abstracts dealing with microbiota/microbiome in hematology at #ash22 This is quite impressive increase compared to previous years. \u2066\u2066@Mohty_EBMT\u2069  https://t.co/Ms8eDErkl8", "id": "1589507409453662209", "lang": "en", "edit_history_tweet_ids": ["1589507409453662209"], "conversation_id": "1589507409453662209"}, {"created_at": "2022-11-05T12:18:21.000Z", "author_id": "2802993134", "entities": {"hashtags": [{"start": 102, "end": 115, "tag": "CancerNJ2022"}], "annotations": [{"start": 4, "end": 13, "probability": 0.5043, "type": "Person", "normalized_text": "Andy Evens"}], "mentions": [{"start": 16, "end": 25, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 116, "end": 128, "username": "RWJBarnabas", "id": "45596617"}], "urls": [{"start": 129, "end": 152, "url": "https://t.co/PxWgwCS0Ju", "expanded_url": "https://twitter.com/RutgersCancer/status/1588868318819409922/photo/1", "display_url": "pic.twitter.com/PxWgwCS0Ju", "media_key": "3_1588868302050304000"}]}, "source": "Twitter for iPhone", "text": "Dr. Andy Evens (@DrAEvens) kicks off the 2nd Annual Oncology Clinical Practice &amp; Research Summit! #CancerNJ2022 @RWJBarnabas https://t.co/PxWgwCS0Ju", "id": "1588868318819409922", "lang": "en", "edit_history_tweet_ids": ["1588868318819409922"], "conversation_id": "1588868318819409922"}, {"created_at": "2022-11-05T14:39:41.000Z", "author_id": "2802993134", "entities": {"hashtags": [{"start": 236, "end": 245, "tag": "oncology"}, {"start": 270, "end": 283, "tag": "CancerNJ2022"}], "annotations": [{"start": 80, "end": 102, "probability": 0.4492, "type": "Organization", "normalized_text": "Monmouth Medical Center"}, {"start": 113, "end": 129, "probability": 0.6134, "type": "Other", "normalized_text": "Richard Alexander"}, {"start": 132, "end": 147, "probability": 0.7654, "type": "Other", "normalized_text": "Joseph Benevenia"}, {"start": 150, "end": 162, "probability": 0.7769, "type": "Other", "normalized_text": "Toni Beninato"}, {"start": 165, "end": 176, "probability": 0.5218, "type": "Other", "normalized_text": "James Aikins"}, {"start": 179, "end": 193, "probability": 0.6586, "type": "Other", "normalized_text": "Richard Lazzaro"}, {"start": 202, "end": 215, "probability": 0.6593, "type": "Other", "normalized_text": "Manpreet Kohli"}, {"start": 271, "end": 282, "probability": 0.4816, "type": "Other", "normalized_text": "CancerNJ2022"}], "mentions": [{"start": 13, "end": 27, "username": "RutgersCancer", "id": "2802993134"}, {"start": 29, "end": 41, "username": "RWJBarnabas", "id": "45596617"}, {"start": 43, "end": 55, "username": "rwjhamilton", "id": "188525431"}, {"start": 57, "end": 72, "username": "UnivHospNewark", "id": "441041430"}], "urls": [{"start": 284, "end": 307, "url": "https://t.co/5VcQmD9IdR", "expanded_url": "https://twitter.com/RutgersCancer/status/1588903885191917568/photo/1", "display_url": "pic.twitter.com/5VcQmD9IdR", "media_key": "3_1588903856515289088"}]}, "source": "Twitter for iPhone", "text": "Representing @RutgersCancer, @RWJBarnabas, @rwjhamilton, @UnivHospNewark, &amp; Monmouth Medical Center, Drs. H. Richard Alexander, Joseph Benevenia, Toni Beninato, James Aikins, Richard Lazzaro, &amp; Manpreet Kohli present the latest #oncology surgical care advances.\n#CancerNJ2022 https://t.co/5VcQmD9IdR", "id": "1588903885191917568", "lang": "en", "edit_history_tweet_ids": ["1588903885191917568"], "conversation_id": "1588903885191917568"}, {"created_at": "2022-11-05T14:30:31.000Z", "author_id": "1095390146", "in_reply_to_user_id": "2802993134", "entities": {"annotations": [{"start": 41, "end": 86, "probability": 0.6492, "type": "Other", "normalized_text": "Oncology Clinical Practice and Research Summit"}], "mentions": [{"start": 0, "end": 14, "username": "RutgersCancer", "id": "2802993134"}, {"start": 147, "end": 156, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 157, "end": 170, "username": "birensaraiya", "id": "91774296"}, {"start": 171, "end": 184, "username": "EugeniaGirda", "id": "1328788604630478853"}], "urls": [{"start": 185, "end": 208, "url": "https://t.co/AdOKusQf1i", "expanded_url": "https://twitter.com/JtaffMD/status/1588901579889213441/photo/1", "display_url": "pic.twitter.com/AdOKusQf1i", "media_key": "3_1588901575145160704"}, {"start": 185, "end": 208, "url": "https://t.co/AdOKusQf1i", "expanded_url": "https://twitter.com/JtaffMD/status/1588901579889213441/photo/1", "display_url": "pic.twitter.com/AdOKusQf1i", "media_key": "3_1588901575153565697"}]}, "source": "Twitter for iPhone", "text": "@RutgersCancer putting on a great Annual Oncology Clinical Practice and Research Summit! Great seeing people I share patients with with from afar! @DrAEvens @birensaraiya @EugeniaGirda https://t.co/AdOKusQf1i", "id": "1588901579889213441", "lang": "en", "edit_history_tweet_ids": ["1588901579889213441"], "conversation_id": "1588901579889213441"}, {"created_at": "2022-11-05T14:15:04.000Z", "author_id": "3129806495", "entities": {"hashtags": [{"start": 90, "end": 104, "tag": "thyroidcancer"}, {"start": 105, "end": 118, "tag": "CANCERNJ2022"}], "annotations": [{"start": 51, "end": 53, "probability": 0.4604, "type": "Organization", "normalized_text": " on"}, {"start": 87, "end": 99, "probability": 0.5124, "type": "Other", "normalized_text": "or #thyroidca"}, {"start": 102, "end": 113, "probability": 0.7401, "type": "Other", "normalized_text": "er #CANCERNJ"}], "mentions": [{"start": 14, "end": 27, "username": "BeninatoToni", "id": "1054725513632190465"}, {"start": 127, "end": 141, "username": "RutgersCancer", "id": "2802993134"}, {"start": 144, "end": 156, "username": "RWJBarnabas", "id": "45596617"}], "urls": [{"start": 158, "end": 181, "url": "https://t.co/1CJQtjffP9", "expanded_url": "https://twitter.com/HH_Oncodr/status/1588897691186102272/photo/1", "display_url": "pic.twitter.com/1CJQtjffP9", "media_key": "3_1588897677084852225"}]}, "source": "Twitter for iPhone", "text": "Thank you Dr \u2066@BeninatoToni\u2069 for your critical work on ACA and patient access to care for #thyroidcancer #CANCERNJ2022 Summit \u2066@RutgersCancer\u2069 \u2066@RWJBarnabas\u2069 https://t.co/1CJQtjffP9", "id": "1588897691186102272", "lang": "en", "edit_history_tweet_ids": ["1588897691186102272"], "conversation_id": "1588897691186102272"}, {"created_at": "2022-11-05T12:27:54.000Z", "author_id": "1328788604630478853", "entities": {"hashtags": [{"start": 59, "end": 72, "tag": "cancernj2022"}], "annotations": [{"start": 16, "end": 57, "probability": 0.7779, "type": "Other", "normalized_text": "Oncology Clinical Practice Research Summit"}, {"start": 60, "end": 71, "probability": 0.6305, "type": "Other", "normalized_text": "cancernj2022"}], "urls": [{"start": 73, "end": 96, "url": "https://t.co/wzLhhIGqc1", "expanded_url": "https://twitter.com/EugeniaGirda/status/1588870720897318913/photo/1", "display_url": "pic.twitter.com/wzLhhIGqc1", "media_key": "3_1588870716669267968"}]}, "source": "Twitter for iPhone", "text": "Starting Annual Oncology Clinical Practice Research Summit #cancernj2022 https://t.co/wzLhhIGqc1", "id": "1588870720897318913", "lang": "en", "edit_history_tweet_ids": ["1588870720897318913"], "conversation_id": "1588870720897318913"}, {"created_at": "2022-11-05T13:03:14.000Z", "author_id": "3129806495", "entities": {"hashtags": [{"start": 129, "end": 138, "tag": "lymphoma"}, {"start": 142, "end": 155, "tag": "CANCERNJ2022"}], "annotations": [{"start": 114, "end": 117, "probability": 0.4533, "type": "Other", "normalized_text": "rova"}, {"start": 120, "end": 127, "probability": 0.3989, "type": "Other", "normalized_text": "for DLCL"}, {"start": 133, "end": 151, "probability": 0.7022, "type": "Other", "normalized_text": "phoma at #CANCERNJ2"}, {"start": 163, "end": 166, "probability": 0.5972, "type": "Person", "normalized_text": "  We"}], "mentions": [{"start": 42, "end": 56, "username": "RutgersCancer", "id": "2802993134"}, {"start": 59, "end": 71, "username": "RWJBarnabas", "id": "45596617"}, {"start": 74, "end": 84, "username": "DrMatasar", "id": "1307491056"}], "urls": [{"start": 180, "end": 203, "url": "https://t.co/hRpcowffxD", "expanded_url": "https://twitter.com/HH_Oncodr/status/1588879611831767041/photo/1", "display_url": "pic.twitter.com/hRpcowffxD", "media_key": "3_1588879590411337728"}]}, "source": "Twitter for iPhone", "text": "New Chief of Hematologic malignancies at \u2066@RutgersCancer\u2069 \u2066@RWJBarnabas, \u2066@DrMatasar\u2069 reporting on latest drug approval for DLCL #lymphoma at #CANCERNJ2022 Summit.  Welcome Matt!! https://t.co/hRpcowffxD", "id": "1588879611831767041", "lang": "en", "edit_history_tweet_ids": ["1588879611831767041"], "conversation_id": "1588879611831767041"}, {"created_at": "2022-11-05T12:47:10.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 275, "end": 288, "tag": "CANCERNJ2022"}], "mentions": [{"start": 89, "end": 99, "username": "HH_Oncodr", "id": "3129806495"}], "urls": [{"start": 289, "end": 312, "url": "https://t.co/80vhvXW7e8", "expanded_url": "https://twitter.com/DrAEvens/status/1588875571484065792/photo/1", "display_url": "pic.twitter.com/80vhvXW7e8", "media_key": "3_1588875565423108096"}, {"start": 313, "end": 336, "url": "https://t.co/QZKBcLk0pK", "expanded_url": "https://twitter.com/birensaraiya/status/1588871880286474240", "display_url": "twitter.com/birensaraiya/s\u2026"}]}, "source": "Twitter for iPhone", "text": "Incredible commitment to health equity &amp; enrollment of minorities to clinical trials @HH_Oncodr.\n\nOutreach has been critical w/ the FORCE MULTIPLIER of having single IRB &amp; master contracts (and unified employment of clinical research office) across all 15 hospitals\n\n#CANCERNJ2022 https://t.co/80vhvXW7e8 https://t.co/QZKBcLk0pK", "id": "1588875571484065792", "lang": "en", "edit_history_tweet_ids": ["1588875571484065792"], "conversation_id": "1588875571484065792"}, {"created_at": "2022-11-05T12:26:47.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 161, "end": 168, "tag": "cancer"}, {"start": 268, "end": 281, "tag": "CANCERNJ2022"}], "annotations": [{"start": 269, "end": 280, "probability": 0.5942, "type": "Other", "normalized_text": "CANCERNJ2022"}], "mentions": [{"start": 182, "end": 192, "username": "HH_Oncodr", "id": "3129806495"}], "urls": [{"start": 282, "end": 305, "url": "https://t.co/XHu57kf8Jy", "expanded_url": "https://twitter.com/DrAEvens/status/1588870442672336896/photo/1", "display_url": "pic.twitter.com/XHu57kf8Jy", "media_key": "3_1588870434627493892"}, {"start": 306, "end": 329, "url": "https://t.co/zY9yemaBYS", "expanded_url": "https://twitter.com/RutgersCancer/status/1588868318819409922", "display_url": "twitter.com/RutgersCancer/\u2026"}]}, "source": "Twitter for iPhone", "text": "\ud83d\ude4c Thanks; v. excited about our annual oncology service line summit.\n\n\ud83d\udc49 ~300 oncology physician, nursing, admin experts (across our 15 hospitals &amp; associated #cancer practices).\n\n@HH_Oncodr taking the stage to highlight the clinical research machine he\u2019s built! \ud83d\udcaa\n\n#CANCERNJ2022 https://t.co/XHu57kf8Jy https://t.co/zY9yemaBYS", "id": "1588870442672336896", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1588868318819409922"}], "edit_history_tweet_ids": ["1588870442672336896"], "conversation_id": "1588870442672336896"}, {"created_at": "2022-11-02T22:21:58.000Z", "author_id": "2802993134", "entities": {"hashtags": [{"start": 0, "end": 23, "tag": "LetsBeatCancerTogether"}], "urls": [{"start": 48, "end": 71, "url": "https://t.co/bBEaUOIgT6", "expanded_url": "https://twitter.com/RutgersCancer/status/1587933059831111680/photo/1", "display_url": "pic.twitter.com/bBEaUOIgT6", "media_key": "3_1587930791325081607"}, {"start": 48, "end": 71, "url": "https://t.co/bBEaUOIgT6", "expanded_url": "https://twitter.com/RutgersCancer/status/1587933059831111680/photo/1", "display_url": "pic.twitter.com/bBEaUOIgT6", "media_key": "3_1587930791719354368"}, {"start": 48, "end": 71, "url": "https://t.co/bBEaUOIgT6", "expanded_url": "https://twitter.com/RutgersCancer/status/1587933059831111680/photo/1", "display_url": "pic.twitter.com/bBEaUOIgT6", "media_key": "3_1587930792084344835"}, {"start": 48, "end": 71, "url": "https://t.co/bBEaUOIgT6", "expanded_url": "https://twitter.com/RutgersCancer/status/1587933059831111680/photo/1", "display_url": "pic.twitter.com/bBEaUOIgT6", "media_key": "3_1587930792512180224"}]}, "in_reply_to_user_id": "2802993134", "source": "Twitter Web App", "text": "#LetsBeatCancerTogether\n\n\ud83d\udcf8: Daniel Della Piazza https://t.co/bBEaUOIgT6", "id": "1587933059831111680", "lang": "it", "referenced_tweets": [{"type": "replied_to", "id": "1587933051337994240"}], "edit_history_tweet_ids": ["1587933059831111680"], "conversation_id": "1587933051337994240"}, {"created_at": "2022-11-03T14:12:27.000Z", "author_id": "2239893372", "entities": {"hashtags": [{"start": 42, "end": 48, "tag": "ASH22"}], "annotations": [{"start": 30, "end": 37, "probability": 0.5111, "type": "Other", "normalized_text": "HoLISTIC"}, {"start": 43, "end": 47, "probability": 0.7171, "type": "Other", "normalized_text": "ASH22"}, {"start": 75, "end": 81, "probability": 0.514, "type": "Other", "normalized_text": "Hodgkin"}], "urls": [{"start": 265, "end": 288, "url": "https://t.co/hhHZZb4cSL", "expanded_url": "https://ash.confex.com/ash/2022/webprogram/Paper164720.html", "display_url": "ash.confex.com/ash/2022/webpr\u2026", "status": 200, "title": "Paper: Development and Validation of the<em> a</Em>dvanced-Stage <em>H</Em>odgkin Lymphoma (HL)<em> I</Em>nternational <em>P</Em>rognostication <em>I</Em>ndex (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium", "description": "Program: Oral and Poster Abstracts Type: Oral Session: 624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological: Advanced Stage and Relapsed Hodgkin Lymphoma Hematology Disease Topics & Pathways: Research, clinical trials, Hodgkin lymphoma, adult, Clinical Practice (Health Services and Quality), Lymphomas, Clinical Research, health outcomes research, Diseases, real-world evidence, Therapies, registries, Lymphoid Malignancies, Study Population, Human 1 Institute for Clinical Research", "unwound_url": "https://ash.confex.com/ash/2022/webprogram/Paper164720.html"}, {"start": 289, "end": 312, "url": "https://t.co/8e2773jlkA", "expanded_url": "https://twitter.com/graham74GC/status/1588172256428969984/photo/1", "display_url": "pic.twitter.com/8e2773jlkA", "media_key": "3_1588172174803836930"}]}, "source": "Twitter for iPhone", "text": "Can\u2019t wait to see output from HoLISTIC at #ASH22. \nPrognostic model in adv Hodgkin for PFS &amp; OS developed &amp; validated. Web based calculator being presented. \n\nQ: prognostic but will it be predictive?\nQ: will this hold for escBEACOPP or BV-AVD treated pts? \nhttps://t.co/hhHZZb4cSL https://t.co/8e2773jlkA", "id": "1588172256428969984", "lang": "en", "edit_history_tweet_ids": ["1588172256428969984"], "conversation_id": "1588172256428969984"}, {"created_at": "2022-10-31T16:05:52.000Z", "author_id": "3187500729", "entities": {"hashtags": [{"start": 80, "end": 88, "tag": "Hodgkin"}, {"start": 203, "end": 210, "tag": "ISHL12"}, {"start": 211, "end": 218, "tag": "HemOnc"}, {"start": 219, "end": 225, "tag": "LymSM"}, {"start": 226, "end": 236, "tag": "ImmunoOnc"}], "annotations": [{"start": 81, "end": 87, "probability": 0.6903, "type": "Other", "normalized_text": "Hodgkin"}, {"start": 130, "end": 141, "probability": 0.8964, "type": "Person", "normalized_text": "Andrew Evens"}], "mentions": [{"start": 144, "end": 153, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 158, "end": 172, "username": "RutgersCancer", "id": "2802993134"}], "urls": [{"start": 178, "end": 201, "url": "https://t.co/XMTjx53hdR", "expanded_url": "http://ow.ly/Y25250LlbM3", "display_url": "ow.ly/Y25250LlbM3", "status": 200, "title": "Current treatment strategies for older and frail patients with HL and future outlooks", "description": "Andrew Evens, DO, MBA, FACP, Rutgers University, New Brunswick, NJ, shares some insights into treatment strategies for older and frail patients with Hodgkin lymphoma (HL), and challenges in this space. Dr Evens first explain factors that influence patient response to therapy, and why older patients may not respond as well as younger patients. Following this, Dr Evens comments on how the incorporation of geriatric assessments may improve outcomes for patients, and concludes by discussing the benefits observed with the use of novel targeted agents, such as brentuximab vedotin. This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.", "unwound_url": "https://www.vjhemonc.com/video/grxqh749izm-current-treatment-strategies-for-older-and-frail-patients-with-hl-and-future-outlooks/"}]}, "source": "Hootsuite Inc.", "text": "Learn more about current treatment strategies for older and frail patients with #Hodgkin lymphoma in our exclusive interview with Andrew Evens (@DrAEvens) of @RutgersCancer:\n\n\ud83c\udfa5: https://t.co/XMTjx53hdR\n\n#ISHL12 #HemOnc #LymSM #ImmunoOnc", "id": "1587113637440806917", "lang": "en", "edit_history_tweet_ids": ["1587113637440806917"], "conversation_id": "1587113637440806917"}, {"created_at": "2022-10-31T01:42:21.000Z", "author_id": "1036403696", "entities": {"annotations": [{"start": 20, "end": 26, "probability": 0.8917, "type": "Organization", "normalized_text": "Packers"}, {"start": 38, "end": 48, "probability": 0.7673, "type": "Person", "normalized_text": "Romeo Doubs"}], "urls": [{"start": 52, "end": 75, "url": "https://t.co/eUknbilLAH", "expanded_url": "https://twitter.com/timfenske/status/1586896324137476096/video/1", "display_url": "pic.twitter.com/eUknbilLAH", "media_key": "7_1586896258622431235"}]}, "source": "Twitter for iPhone", "text": "Amazing TD catch by Packers rookie WR Romeo Doubs ! https://t.co/eUknbilLAH", "id": "1586896324137476096", "lang": "en", "edit_history_tweet_ids": ["1586896324137476096"], "conversation_id": "1586896324137476096"}, {"created_at": "2022-10-29T20:04:10.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 74, "end": 79, "tag": "CART"}, {"start": 165, "end": 174, "tag": "lymphoma"}], "annotations": [{"start": 135, "end": 160, "probability": 0.5846, "type": "Other", "normalized_text": "American Educational Forum"}, {"start": 166, "end": 173, "probability": 0.4806, "type": "Other", "normalized_text": "lymphoma"}, {"start": 210, "end": 215, "probability": 0.7204, "type": "Other", "normalized_text": "Laurie"}, {"start": 223, "end": 230, "probability": 0.8237, "type": "Other", "normalized_text": "Kathleen"}], "mentions": [{"start": 35, "end": 45, "username": "DrLizBrem", "id": "4476878772"}, {"start": 52, "end": 65, "username": "LNastoupilMD", "id": "1491871658876944402"}, {"start": 123, "end": 132, "username": "lymphoma", "id": "43348496"}], "urls": [{"start": 291, "end": 314, "url": "https://t.co/dlbkLNGXFU", "expanded_url": "https://twitter.com/DrAEvens/status/1586448828466544640/photo/1", "display_url": "pic.twitter.com/dlbkLNGXFU", "media_key": "3_1586447978834837506"}]}, "source": "Twitter Web App", "text": "\ud83d\ude4c Great session today w/ co-chairs @DrLizBrem &amp; @LNastoupilMD for our #CART patient &amp; caregiver session @ the 2022 @lymphoma N.American Educational Forum on #lymphoma. \n\n\ud83d\ude4f V. inspiring stories from pts Laurie &amp; Kathleen (w/ her daughter) on their cancer journeys including CART. https://t.co/dlbkLNGXFU", "id": "1586448828466544640", "lang": "en", "edit_history_tweet_ids": ["1586448828466544640"], "conversation_id": "1586448828466544640"}, {"created_at": "2022-10-23T17:32:33.000Z", "author_id": "1697360292", "entities": {"hashtags": [{"start": 25, "end": 32, "tag": "ISHL12"}, {"start": 223, "end": 229, "tag": "lymsm"}, {"start": 230, "end": 239, "tag": "geriheme"}], "annotations": [{"start": 26, "end": 31, "probability": 0.4555, "type": "Other", "normalized_text": "ISHL12"}, {"start": 231, "end": 238, "probability": 0.5081, "type": "Other", "normalized_text": "geriheme"}], "mentions": [{"start": 0, "end": 9, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 10, "end": 24, "username": "RutgersCancer", "id": "2802993134"}, {"start": 197, "end": 206, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 207, "end": 222, "username": "BroeckelmannPJ", "id": "1209011263"}], "urls": [{"start": 240, "end": 263, "url": "https://t.co/UAaEMPXPz2", "expanded_url": "https://twitter.com/DrRaulCordoba/status/1584236348596457472/photo/1", "display_url": "pic.twitter.com/UAaEMPXPz2", "media_key": "3_1584236337477066753"}]}, "in_reply_to_user_id": "719175246050410496", "source": "Twitter for iPhone", "text": "@DrAEvens @RutgersCancer #ISHL12 That\u2019s the way to move forward with global \ud83c\udf0e collaborative efforts. I am very honored to co-chaired this very internationally session with you \ud83c\uddfa\ud83c\uddf8 \ud83c\uddea\ud83c\uddf8 \ud83c\uddf3\ud83c\uddf4 \ud83c\uddf8\ud83c\uddea \ud83c\udde7\ud83c\uddf7 \ud83c\uddee\ud83c\uddf9 \ud83c\udde9\ud83c\uddea @DrAEvens @BroeckelmannPJ #lymsm #geriheme https://t.co/UAaEMPXPz2", "id": "1584236348596457472", "lang": "en", "referenced_tweets": [{"type": "replied_to", "id": "1584231450236182529"}], "edit_history_tweet_ids": ["1584236348596457472"], "conversation_id": "1584231450236182529"}, {"created_at": "2022-10-24T09:59:36.000Z", "author_id": "2239893372", "entities": {"hashtags": [{"start": 230, "end": 237, "tag": "ISHL12"}], "annotations": [{"start": 16, "end": 17, "probability": 0.7123, "type": "Place", "normalized_text": "US"}, {"start": 71, "end": 80, "probability": 0.4495, "type": "Other", "normalized_text": "Serum TARC"}, {"start": 108, "end": 114, "probability": 0.707, "type": "Other", "normalized_text": "Hodgkin"}, {"start": 147, "end": 150, "probability": 0.4793, "type": "Other", "normalized_text": "TARC"}], "urls": [{"start": 238, "end": 261, "url": "https://t.co/1tztn10tJN", "expanded_url": "https://twitter.com/graham74GC/status/1584484745660223488/photo/1", "display_url": "pic.twitter.com/1tztn10tJN", "media_key": "3_1584484539367317504"}, {"start": 238, "end": 261, "url": "https://t.co/1tztn10tJN", "expanded_url": "https://twitter.com/graham74GC/status/1584484745660223488/photo/1", "display_url": "pic.twitter.com/1tztn10tJN", "media_key": "3_1584484539371556865"}, {"start": 238, "end": 261, "url": "https://t.co/1tztn10tJN", "expanded_url": "https://twitter.com/graham74GC/status/1584484745660223488/photo/1", "display_url": "pic.twitter.com/1tztn10tJN", "media_key": "3_1584484539371556864"}, {"start": 238, "end": 261, "url": "https://t.co/1tztn10tJN", "expanded_url": "https://twitter.com/graham74GC/status/1584484745660223488/photo/1", "display_url": "pic.twitter.com/1tztn10tJN", "media_key": "3_1584484539371511809"}]}, "source": "Twitter Web App", "text": "Diepstra et al: US dept of defence serum biobank\n- 101 Hodgkin cases\n- Serum TARC raised several yrs before Hodgkin diagnosis\nWe need to integrate TARC into diagnostic pathways to speed time to diagnosis of cHL\nFascinating data. \n#ISHL12 https://t.co/1tztn10tJN", "id": "1584484745660223488", "lang": "en", "edit_history_tweet_ids": ["1584484745660223488"], "conversation_id": "1584484745660223488"}, {"created_at": "2022-10-23T12:43:40.000Z", "author_id": "1697360292", "entities": {"hashtags": [{"start": 0, "end": 7, "tag": "ISHL12"}, {"start": 22, "end": 30, "tag": "Hodgkin"}, {"start": 31, "end": 40, "tag": "lymphoma"}, {"start": 139, "end": 145, "tag": "lymsm"}, {"start": 146, "end": 154, "tag": "frailty"}, {"start": 155, "end": 164, "tag": "geriheme"}], "annotations": [{"start": 23, "end": 29, "probability": 0.4613, "type": "Place", "normalized_text": "Hodgkin"}], "mentions": [{"start": 165, "end": 174, "username": "DrAEvens", "id": "719175246050410496"}], "urls": [{"start": 175, "end": 198, "url": "https://t.co/hGtWIuDLZ6", "expanded_url": "https://twitter.com/DrRaulCordoba/status/1584163647664058370/photo/1", "display_url": "pic.twitter.com/hGtWIuDLZ6", "media_key": "3_1584163635483607040"}]}, "source": "Twitter for iPhone", "text": "#ISHL12 Full house at #Hodgkin #lymphoma \u201cOlder &amp; Frail Patients\u201d session. Hot topic for a challenging high risk vulnerable population #lymsm #frailty #geriheme @DrAEvens https://t.co/hGtWIuDLZ6", "id": "1584163647664058370", "lang": "en", "edit_history_tweet_ids": ["1584163647664058370"], "conversation_id": "1584163647664058370"}, {"created_at": "2022-10-23T14:04:34.000Z", "author_id": "1697360292", "entities": {"hashtags": [{"start": 0, "end": 7, "tag": "ISHL12"}, {"start": 12, "end": 19, "tag": "selfie"}, {"start": 85, "end": 93, "tag": "Hodgkin"}, {"start": 94, "end": 103, "tag": "lymphoma"}, {"start": 104, "end": 110, "tag": "lymsm"}, {"start": 111, "end": 120, "tag": "geriheme"}], "annotations": [{"start": 1, "end": 6, "probability": 0.4452, "type": "Other", "normalized_text": "ISHL12"}, {"start": 86, "end": 92, "probability": 0.486, "type": "Other", "normalized_text": "Hodgkin"}, {"start": 95, "end": 102, "probability": 0.3592, "type": "Place", "normalized_text": "lymphoma"}, {"start": 105, "end": 109, "probability": 0.3777, "type": "Place", "normalized_text": "lymsm"}, {"start": 112, "end": 119, "probability": 0.5605, "type": "Other", "normalized_text": "geriheme"}], "mentions": [{"start": 25, "end": 34, "username": "DrAEvens", "id": "719175246050410496"}], "urls": [{"start": 121, "end": 144, "url": "https://t.co/r71SwMYf8f", "expanded_url": "https://twitter.com/DrRaulCordoba/status/1584184005993250818/photo/1", "display_url": "pic.twitter.com/r71SwMYf8f", "media_key": "3_1584183998628118529"}]}, "source": "Twitter for iPhone", "text": "#ISHL12 The #selfie with @DrAEvens before opening the session on older patients with #Hodgkin #lymphoma #lymsm #geriheme https://t.co/r71SwMYf8f", "id": "1584184005993250818", "lang": "en", "edit_history_tweet_ids": ["1584184005993250818"], "conversation_id": "1584184005993250818"}, {"created_at": "2022-10-23T12:56:06.000Z", "author_id": "1582593798", "entities": {"hashtags": [{"start": 9, "end": 18, "tag": "ISHL2022"}, {"start": 146, "end": 155, "tag": "lymphoma"}, {"start": 156, "end": 162, "tag": "lymsm"}, {"start": 163, "end": 179, "tag": "medicalcongress"}], "annotations": [{"start": 10, "end": 17, "probability": 0.5051, "type": "Other", "normalized_text": "ISHL2022"}, {"start": 99, "end": 114, "probability": 0.5618, "type": "Person", "normalized_text": "Hodgkin Lymphoma"}, {"start": 147, "end": 154, "probability": 0.4384, "type": "Place", "normalized_text": "lymphoma"}, {"start": 157, "end": 161, "probability": 0.5146, "type": "Place", "normalized_text": "lymsm"}], "mentions": [{"start": 20, "end": 29, "username": "draevans", "id": "18993076"}, {"start": 35, "end": 49, "username": "RutgersCancer", "id": "2802993134"}], "urls": [{"start": 180, "end": 203, "url": "https://t.co/oELaahDcvt", "expanded_url": "https://twitter.com/lymphomahub/status/1584166776967168005/photo/1", "display_url": "pic.twitter.com/oELaahDcvt", "media_key": "3_1584162103014952961"}, {"start": 180, "end": 203, "url": "https://t.co/oELaahDcvt", "expanded_url": "https://twitter.com/lymphomahub/status/1584166776967168005/photo/1", "display_url": "pic.twitter.com/oELaahDcvt", "media_key": "3_1584162103019061251"}, {"start": 180, "end": 203, "url": "https://t.co/oELaahDcvt", "expanded_url": "https://twitter.com/lymphomahub/status/1584166776967168005/photo/1", "display_url": "pic.twitter.com/oELaahDcvt", "media_key": "3_1584162103014866945"}, {"start": 180, "end": 203, "url": "https://t.co/oELaahDcvt", "expanded_url": "https://twitter.com/lymphomahub/status/1584166776967168005/photo/1", "display_url": "pic.twitter.com/oELaahDcvt", "media_key": "3_1584162103014952960"}]}, "source": "Twitter Web App", "text": "CONGRESS\u2502#ISHL2022\n\n@DrAEvans from @RutgersCancer discusses historical considerations and outcomes Hodgkin Lymphoma treatment in older patients\n \n#lymphoma #lymsm #medicalcongress https://t.co/oELaahDcvt", "id": "1584166776967168005", "lang": "en", "edit_history_tweet_ids": ["1584166776967168005"], "conversation_id": "1584166776967168005"}, {"created_at": "2022-10-23T03:44:26.000Z", "author_id": "1134857587348967425", "source": "Twitter for iPhone", "text": "Great paper by @DrAEvens !! Thanks for sharing https://t.co/HxtDxzjLpc", "entities": {"mentions": [{"start": 15, "end": 24, "username": "DrAEvens", "id": "719175246050410496"}], "urls": [{"start": 47, "end": 70, "url": "https://t.co/HxtDxzjLpc", "expanded_url": "https://twitter.com/majorajay/status/1583751995965308928", "display_url": "twitter.com/majorajay/stat\u2026"}]}, "id": "1584027942807478273", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1583751995965308928"}], "edit_history_tweet_ids": ["1584027942807478273"], "conversation_id": "1584027942807478273"}, {"created_at": "2022-10-22T13:51:28.000Z", "author_id": "2239893372", "entities": {"hashtags": [{"start": 268, "end": 275, "tag": "ISHL12"}, {"start": 276, "end": 283, "tag": "ISHL22"}], "annotations": [{"start": 277, "end": 282, "probability": 0.4244, "type": "Other", "normalized_text": "ISHL22"}], "mentions": [{"start": 50, "end": 60, "username": "becshakir", "id": "215677310"}], "urls": [{"start": 284, "end": 307, "url": "https://t.co/Gca5PgtXDF", "expanded_url": "https://twitter.com/graham74GC/status/1583818319781834754/photo/1", "display_url": "pic.twitter.com/Gca5PgtXDF", "media_key": "3_1583818314341617666"}, {"start": 284, "end": 307, "url": "https://t.co/Gca5PgtXDF", "expanded_url": "https://twitter.com/graham74GC/status/1583818319781834754/photo/1", "display_url": "pic.twitter.com/Gca5PgtXDF", "media_key": "3_1583818314375200774"}, {"start": 284, "end": 307, "url": "https://t.co/Gca5PgtXDF", "expanded_url": "https://twitter.com/graham74GC/status/1583818319781834754/photo/1", "display_url": "pic.twitter.com/Gca5PgtXDF", "media_key": "3_1583818314337361922"}, {"start": 284, "end": 307, "url": "https://t.co/Gca5PgtXDF", "expanded_url": "https://twitter.com/graham74GC/status/1583818319781834754/photo/1", "display_url": "pic.twitter.com/Gca5PgtXDF", "media_key": "3_1583818314337460226"}]}, "source": "Twitter for iPhone", "text": "Who should make a RT decision in early stage cHL? @becshakir presenting interesting study. Shows pts &amp; clinicians happy for clinicians to make final recommendation but pts need information &amp; clinicians need good info &amp; to take time to understand pt needs. #ISHL12 #ISHL22 https://t.co/Gca5PgtXDF", "id": "1583818319781834754", "lang": "en", "edit_history_tweet_ids": ["1583818319781834754"], "conversation_id": "1583818319781834754"}, {"created_at": "2022-10-22T11:10:40.000Z", "author_id": "865923978", "entities": {"hashtags": [{"start": 252, "end": 259, "tag": "ISHL12"}], "annotations": [{"start": 8, "end": 14, "probability": 0.5147, "type": "Other", "normalized_text": "Hodgkin"}, {"start": 61, "end": 69, "probability": 0.6409, "type": "Other", "normalized_text": "Bleomycin"}], "mentions": [{"start": 30, "end": 41, "username": "graham74GC", "id": "2239893372"}, {"start": 126, "end": 142, "username": "Ninja_Overgaard", "id": "1503644704751206401"}], "urls": [{"start": 260, "end": 283, "url": "https://t.co/DJUa2Xzg2h", "expanded_url": "https://twitter.com/Dr_Daniel_Molin/status/1583777853975384064/photo/1", "display_url": "pic.twitter.com/DJUa2Xzg2h", "media_key": "3_1583777846111133696"}]}, "source": "Twitter for iPhone", "text": "Elderly Hodgkin patients with @graham74GC Challenging group. Bleomycin problematic. Should mostly be excluded (listen also to @Ninja_Overgaard 14:51 tomorrow). BV can improve, chemo remain important. PD-1-i most promising, but not single. Remember RT.\n#ISHL12 https://t.co/DJUa2Xzg2h", "id": "1583777853975384064", "lang": "en", "edit_history_tweet_ids": ["1583777853975384064"], "conversation_id": "1583777853975384064"}, {"created_at": "2022-10-22T12:57:30.000Z", "author_id": "2239893372", "entities": {"hashtags": [{"start": 254, "end": 261, "tag": "ISHL12"}, {"start": 262, "end": 269, "tag": "ISHL22"}, {"start": 270, "end": 276, "tag": "lymsm"}], "annotations": [{"start": 10, "end": 14, "probability": 0.4591, "type": "Other", "normalized_text": "RAPID"}], "mentions": [{"start": 99, "end": 112, "username": "DavidJCutter", "id": "382175232"}], "urls": [{"start": 277, "end": 300, "url": "https://t.co/yPPZ2I0bt4", "expanded_url": "https://twitter.com/graham74GC/status/1583804739501760512/photo/1", "display_url": "pic.twitter.com/yPPZ2I0bt4", "media_key": "3_1583804551085363200"}, {"start": 277, "end": 300, "url": "https://t.co/yPPZ2I0bt4", "expanded_url": "https://twitter.com/graham74GC/status/1583804739501760512/photo/1", "display_url": "pic.twitter.com/yPPZ2I0bt4", "media_key": "3_1583804551081099274"}, {"start": 277, "end": 300, "url": "https://t.co/yPPZ2I0bt4", "expanded_url": "https://twitter.com/graham74GC/status/1583804739501760512/photo/1", "display_url": "pic.twitter.com/yPPZ2I0bt4", "media_key": "3_1583804551072780293"}]}, "source": "Twitter Web App", "text": "Hoppe: in RAPID, 54% pts predicted to have gtr heart disease risk from anthracycline than from RT (@DavidJCutter  et al). But techniques improved considerably since then. Increases suitability of RT for more pts partly as way of reducing chemo exposure. #ISHL12 #ISHL22 #lymsm https://t.co/yPPZ2I0bt4", "id": "1583804739501760512", "lang": "en", "edit_history_tweet_ids": ["1583804739501760512"], "conversation_id": "1583804739501760512"}, {"created_at": "2022-10-22T12:40:50.000Z", "author_id": "2239893372", "entities": {"hashtags": [{"start": 250, "end": 257, "tag": "ISHL12"}, {"start": 258, "end": 265, "tag": "ISHL22"}], "annotations": [{"start": 5, "end": 11, "probability": 0.4803, "type": "Person", "normalized_text": "Radford"}, {"start": 49, "end": 53, "probability": 0.4061, "type": "Organization", "normalized_text": "RADAR"}, {"start": 71, "end": 74, "probability": 0.507, "type": "Other", "normalized_text": "ABVD"}, {"start": 87, "end": 90, "probability": 0.4557, "type": "Other", "normalized_text": "AVD-"}], "urls": [{"start": 266, "end": 289, "url": "https://t.co/55BSAgTsrr", "expanded_url": "https://twitter.com/graham74GC/status/1583800544736337920/photo/1", "display_url": "pic.twitter.com/55BSAgTsrr", "media_key": "3_1583800384681906177"}]}, "source": "Twitter Web App", "text": "Prof Radford presenting the currently recruiting RADAR study comparing ABVD based with AVD-BV based therapy in 1L early stage cHL. RT allowed for &gt;60y and &gt;5cm bulk at baseline. Can the PFS increase even further in this good prognosis disease?\n#ISHL12 #ISHL22 https://t.co/55BSAgTsrr", "id": "1583800544736337920", "lang": "en", "edit_history_tweet_ids": ["1583800544736337920"], "conversation_id": "1583800544736337920"}, {"created_at": "2022-10-22T08:11:41.000Z", "author_id": "1697360292", "entities": {"hashtags": [{"start": 0, "end": 7, "tag": "ISHL12"}, {"start": 91, "end": 99, "tag": "Hodgkin"}, {"start": 100, "end": 109, "tag": "lymphoma"}, {"start": 110, "end": 119, "tag": "geriheme"}], "annotations": [{"start": 1, "end": 6, "probability": 0.4747, "type": "Other", "normalized_text": "ISHL12"}], "urls": [{"start": 120, "end": 143, "url": "https://t.co/YORvH8eM5t", "expanded_url": "https://twitter.com/DrRaulCordoba/status/1583732811877744640/photo/1", "display_url": "pic.twitter.com/YORvH8eM5t", "media_key": "3_1583732781330403328"}, {"start": 120, "end": 143, "url": "https://t.co/YORvH8eM5t", "expanded_url": "https://twitter.com/DrRaulCordoba/status/1583732811877744640/photo/1", "display_url": "pic.twitter.com/YORvH8eM5t", "media_key": "3_1583732781322043394"}]}, "source": "Twitter for iPhone", "text": "#ISHL12 Excellent discussion in the Q&amp;A session in the workshop of older patients with #Hodgkin #lymphoma #geriheme https://t.co/YORvH8eM5t", "id": "1583732811877744640", "lang": "en", "edit_history_tweet_ids": ["1583732811877744640"], "conversation_id": "1583732811877744640"}, {"created_at": "2022-10-21T19:30:04.000Z", "author_id": "1294745239656202240", "entities": {"hashtags": [{"start": 26, "end": 33, "tag": "ISHL12"}], "annotations": [{"start": 18, "end": 23, "probability": 0.4818, "type": "Other", "normalized_text": "jetlag"}, {"start": 27, "end": 32, "probability": 0.742, "type": "Other", "normalized_text": "ISHL12"}], "urls": [{"start": 34, "end": 57, "url": "https://t.co/tCLiXEo3RA", "expanded_url": "https://twitter.com/GuiperiniMD/status/1583541143492386817/photo/1", "display_url": "pic.twitter.com/tCLiXEo3RA", "media_key": "3_1583541125532581901"}]}, "source": "Twitter for Android", "text": "Best way to fight jetlag.\n#ISHL12 https://t.co/tCLiXEo3RA", "id": "1583541143492386817", "lang": "en", "edit_history_tweet_ids": ["1583541143492386817"], "conversation_id": "1583541143492386817"}, {"created_at": "2022-10-20T20:20:48.000Z", "author_id": "969879464128770048", "entities": {"annotations": [{"start": 37, "end": 40, "probability": 0.4817, "type": "Other", "normalized_text": "club"}], "urls": [{"start": 42, "end": 65, "url": "https://t.co/wtjXO0ctvK", "expanded_url": "https://twitter.com/malwrhunterteam/status/1581214412261982209/video/1", "display_url": "pic.twitter.com/wtjXO0ctvK", "media_key": "7_1581214233420828673"}]}, "source": "Twitter for iPhone", "text": "Reading article 1 min before journal club https://t.co/wtjXO0ctvK", "id": "1583191523805446144", "lang": "en", "edit_history_tweet_ids": ["1583191523805446144"], "conversation_id": "1583191523805446144"}, {"created_at": "2022-10-20T20:09:58.000Z", "author_id": "1209011263", "entities": {"hashtags": [{"start": 20, "end": 27, "tag": "ISHL12"}], "annotations": [{"start": 21, "end": 26, "probability": 0.4224, "type": "Other", "normalized_text": "ISHL12"}, {"start": 41, "end": 49, "probability": 0.7844, "type": "Place", "normalized_text": "G\u00fcrzenich"}], "mentions": [{"start": 279, "end": 285, "username": "Koeln", "id": "1171286929"}], "urls": [{"start": 195, "end": 218, "url": "https://t.co/AwQpIWroqW", "expanded_url": "http://hodgkinsymposium.org", "display_url": "hodgkinsymposium.org", "status": 200, "title": "12th International Symposium on Hodgkin Lymphoma", "description": "The 12th International Symposium on Hodgkin Lymphoma (ISHL12), will take place in Cologne, Germany, between October 22 and 24, 2022.", "unwound_url": "https://www.hodgkinsymposium.org/"}, {"start": 286, "end": 309, "url": "https://t.co/ACKzgPVsaV", "expanded_url": "https://twitter.com/BroeckelmannPJ/status/1583188799592747008/photo/1", "display_url": "pic.twitter.com/ACKzgPVsaV", "media_key": "3_1583184807743393820"}]}, "source": "Twitter Web App", "text": "Less than 48h until #ISHL12 kicks off at G\u00fcrzenich! With &gt;700 registered participants, &gt;100 abstract presentations, patient involvement and excellent faculty, this is going to be a blast \ud83d\udd1c https://t.co/AwQpIWroqW Safe travels to everyone - looking forward to welcoming you @Koeln https://t.co/ACKzgPVsaV", "id": "1583188799592747008", "lang": "en", "edit_history_tweet_ids": ["1583188799592747008"], "conversation_id": "1583188799592747008"}, {"created_at": "2022-10-20T16:28:20.000Z", "author_id": "719175246050410496", "entities": {"hashtags": [{"start": 167, "end": 176, "tag": "Lymphoma"}], "annotations": [{"start": 86, "end": 89, "probability": 0.3853, "type": "Other", "normalized_text": "Brem"}, {"start": 98, "end": 105, "probability": 0.382, "type": "Other", "normalized_text": "Nasoupil"}, {"start": 131, "end": 162, "probability": 0.7244, "type": "Other", "normalized_text": "North American Educational Forum"}, {"start": 168, "end": 175, "probability": 0.6034, "type": "Other", "normalized_text": "Lymphoma"}, {"start": 246, "end": 247, "probability": 0.7778, "type": "Place", "normalized_text": "US"}], "mentions": [{"start": 251, "end": 265, "username": "RutgersCancer", "id": "2802993134"}, {"start": 266, "end": 278, "username": "RWJBarnabas", "id": "45596617"}], "urls": [{"start": 279, "end": 302, "url": "https://t.co/bboC1bkUmI", "expanded_url": "https://twitter.com/DrLizBrem/status/1583120198789656577", "display_url": "twitter.com/DrLizBrem/stat\u2026"}]}, "source": "Twitter for iPhone", "text": "Very much looking to co-chairing this meeting/educational forum w/ 2 rising stars, Dr Brem and Dr Nasoupil.\ud83c\udf1f\ud83c\udf1f\n\nThis 2022 (virtual) North American Educational Forum on #Lymphoma will feature other top experts in the field.\n\nIt will be great; JOIN US!\n\n@RutgersCancer @RWJBarnabas https://t.co/bboC1bkUmI", "id": "1583133023092215809", "lang": "en", "referenced_tweets": [{"type": "quoted", "id": "1583120198789656577"}], "edit_history_tweet_ids": ["1583133023092215809"], "conversation_id": "1583133023092215809"}, {"created_at": "2022-10-20T15:37:22.000Z", "author_id": "4476878772", "entities": {"annotations": [{"start": 43, "end": 69, "probability": 0.6686, "type": "Other", "normalized_text": "N American Educational Form"}], "mentions": [{"start": 33, "end": 42, "username": "lymphoma", "id": "43348496"}, {"start": 130, "end": 139, "username": "DrAEvens", "id": "719175246050410496"}, {"start": 144, "end": 157, "username": "LNastoupilMD", "id": "1491871658876944402"}], "urls": [{"start": 178, "end": 201, "url": "https://t.co/E6cw7AouIZ", "expanded_url": "https://lymphoma.org/resources/educationresources/programs/edforum/", "display_url": "lymphoma.org/resources/educ\u2026", "images": [{"url": "https://pbs.twimg.com/news_img/1585675159574298625/-VHRZbRM?format=png&name=orig", "width": 524, "height": 287}, {"url": "https://pbs.twimg.com/news_img/1585675159574298625/-VHRZbRM?format=png&name=150x150", "width": 150, "height": 150}], "status": 200, "title": "North American Educational Forum on Lymphoma", "description": "The North American Educational Forum on Lymphoma is the most comprehensive lymphoma-specific educational conference in North America.", "unwound_url": "https://lymphoma.org/resources/educationresources/programs/edforum/"}]}, "source": "Twitter Web App", "text": "Working on presentations for the @lymphoma N American Educational Form, coming up soon, 10/28-30! Thrilled to be co-chairing with @DrAEvens and @LNastoupilMD!! Virtual and free! https://t.co/E6cw7AouIZ", "id": "1583120198789656577", "lang": "en", "edit_history_tweet_ids": ["1583120198789656577"], "conversation_id": "1583120198789656577"}, {"created_at": "2022-10-19T19:55:33.000Z", "author_id": "70984741", "entities": {"hashtags": [{"start": 96, "end": 107, "tag": "BillsMafia"}], "annotations": [{"start": 74, "end": 83, "probability": 0.8279, "type": "Other", "normalized_text": "Philm Room"}, {"start": 97, "end": 106, "probability": 0.8129, "type": "Organization", "normalized_text": "BillsMafia"}], "mentions": [{"start": 14, "end": 26, "username": "JoshAllenQB", "id": "197974180"}, {"start": 53, "end": 65, "username": "dawson_knox", "id": "3042083863"}, {"start": 89, "end": 95, "username": "Bills", "id": "222345032"}, {"start": 110, "end": 122, "username": "PhilSimmsQB", "id": "3401444831"}, {"start": 123, "end": 133, "username": "Edelman11", "id": "272250951"}, {"start": 134, "end": 144, "username": "BMarshall", "id": "256289743"}], "urls": [{"start": 145, "end": 168, "url": "https://t.co/EqRby0I0Dl", "expanded_url": "https://twitter.com/insidetheNFL/status/1582822782672416769/video/1", "display_url": "pic.twitter.com/EqRby0I0Dl", "media_key": "13_1582821108616597504"}]}, "source": "Twitter Media Studio", "text": "Breaking down @JoshAllenQB's game-winning TD pass to @dawson_knox in the 'Philm Room' \ud83d\udcdd\n\n@Bills #BillsMafia | @PhilSimmsQB @Edelman11 @BMarshall https://t.co/EqRby0I0Dl", "id": "1582822782672416769", "lang": "en", "edit_history_tweet_ids": ["1582822782672416769"], "conversation_id": "1582822782672416769"}]}, "meta": {"next_token": "7140dibdnow9c7btw423wyprl7nc4umci8jdgx7inyfjp", "result_count": 100, "newest_id": "1601350227625377792", "oldest_id": "1583078029391441925"}, "neighbors": ["2802993134", "45596617", "2239893372", "2212735524"]}